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The studies performed in this Ph.D. project were directed at evaluating 
the anticancer and cancer preventive properties of cinnamoyl-based 
compounds. Anticancer potential of naturally occurring cinnamaldehyde (CA) 
and its ortho-substituted analogs was evaluated by studying their growth-
inhibitory and cytotoxic efficacies against human colon carcinoma HCT 116 
and human mammary carcinoma MCF-7 cells. Due to their relatively greater 
antiproliferative activities, the CA analogs 2-benzoyloxy cinnamaldehyde 
(BCA), 5-fluoro-2-hydroxy cinnamaldehyde (PP1) and 5-fluoro-2-benzoyloxy 
cinnamaldehyde (GJ23) were subjected to further investigation. Studies 
involving cell cycle analysis of HCT 116 cells revealed that CA and its more 
potent analogs BCA, PP1 and GJ23 induced a G2 phase arrest which was 
accompanied by a loss of cell cycle regulatory proteins such as cdk1and 
cdc25C. Dysregulation of these cell cycle regulators occurred at doses that 
induced apoptosis in the cancer cells.  
In addition to their effects on the cell cycle regulatory proteins, lead 
CA analogs led to a collapse of the microtubular network and caused tubulin 
aggregation in HCT 116 and MCF-7 cells at pro-apoptotic doses. Direct 
interaction of the CA analogs and sulfhydryls of the tubulin protein was 
established in an in vitro cell-free system, suggesting that in addition to cell 
cycle interruption, targeting tubulin was another mechanism that might 
contribute to the induction of apoptosis by cinnamaldehydes.   
Cancer preventive properties of the CA analogs were investigated by 
examining their ability to induce the detoxifying phase 2 enzymes via 
stabilization of the transcription factor Nrf2 that activates expression of the 
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enzymes by binding to the consensus DNA sequence identified as the 
antioxidant response element (ARE). BCA exhibited greatest phase 2 enzyme-
inducing potency among the ortho-substituted CA analogs studied. In HEK-
293 cells, the ARE-dependent transcriptional activity observed upon BCA 
treatment was almost nine-fold as compared to that of untreated control. It was 
also found that protein levels of Nrf2 and the phase 2 enzymes were increased 
in BCA-treated cells. In addition to upregulation of the phase 2 cytoprotective 
enzymes, BCA also suppressed inflammatory responses through inhibition of 
the NF-κB signal transduction pathway. It was also observed that phase 2 
response activation was enhanced in presence of the protein p21, indicating its 
participation in induction of the Nrf2-mediated cytoprotective response.        
Chemopreventive properties of a series of novel supercinnamaldehyde 
analogs were also investigated. Supercinnamaldehydes, being 3-
oxoethylidiene-indolin-2-ones, were evaluated for their cytoprotective 
properties by studying their ability to increase ARE-dependent transcriptional 
activity. Ability of the compounds to inhibit release of nitric oxide (NO) upon 
stimulation by bacterial lipopolysaccharides (LPS) was studied to assess their 
anti-inflammatory potential. The cytoprotective and anti-inflammatory 
activities were found to be correlated and the analog HLO6 that bears a phenyl 
group at the 2’-oxoethylidene position, displayed highest potency for both 
activities.   
Together, findings of the studies presented in this Ph.D. project 
expanded the knowledge on the bioactivities of cinnamoyl-based compounds. 
In particular, studies on the anticancer and chemopreventive properties of 
these compounds indicated that the 'cinnamoyl' scaffold can be potentially 
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exploited for development of novel compounds as candidate therapeutics for 
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Cancer is possibly as old as human civilization. One of the oldest 
descriptions of cancerous tumors has been found in Egyptian manuscripts 
from 3000-1500 B.C., in which the disease is referred to as an untreatable 
“ulcer”. The term ‘cancer’ also has its roots in ancient medicine when the 
Greek physician Hippocrates likened a tumor surrounded by blood vessels to a 
crab and named the disease as ‘karkinos’ (crab in Greek) which was later 
translated to Latin as ‘cancer’ (David & Zimmerman, 2010).  
Although cancerous tumors or neoplasms (new and abnormal growth 
of tissues) have existed throughout recorded history, it was considered to be a 
rare disease in ancient times. Today, cancer is one of the leading causes of 
mortality and morbidity worldwide. The sharp increase in global burden of 
cancer can be chiefly attributed to two reasons. First, as cancer is primarily a 
disease of the elderly, increased life expectancy is a contributing factor to the 
increase in number of people with malignant tumors. Secondly, with 
modernization and industrialization, our exposure to carcinogens has greatly 
increased leading to an escalation in the incidence and prevalence of cancer 
(Cutter et al., 1999). As depicted in Fig. 1.1, 7.6 million people (13% of all 
deaths) died of cancer in 2008, and the number of deaths due to cancer is 
estimated to increase to 13 million in 2030 (Ferlay et al., 2010). Although the 
statistics seem ominous, significant advances have been made in the field of 
cancer biology and novel molecular targets have been identified in recent 
decades. Some of the significant successes in cancer treatment include 
targeted therapies such as imatinib (Gleevec), trastuzumab (Herceptin), and 




associated with cancer have considerably declined. However, cancer is still 
regarded as a formidable adversary due to complexities of the tumor 
microenvironment and extensive molecular alterations in a cancer cell (Hahn 
& Weinberg, 2002). Drug discovery against cancer therefore remains a 
challenging task. In lieu of the increasing incidences of cancer and limitations 
of available therapy regimes, there is an urgent need to discover novel 
chemical entities to combat complicated malignancies. Understanding the 
process of oncogenesis and identifying properties unique to cancer cells is of 
paramount importance in order to develop potential therapeutics against 







Figure 1.1 Increase in cancer-associated mortalities. According to the Globocan 
database, 7.6 million deaths were attributed to cancer in 2008, which are predicted to 
increase by a little less than two fold in 2030 (Ferlay et al., 2010).   
 
1.1.1 Multi-step carcinogenesis  
The fundamental characteristic of cancer cells is their ability to 
undergo uncontrolled proliferation. Normal cells have an intricate balance of 
growth and death signals controlled by cellular regulatory systems. In cancer 




and division such that these cells are able to evade growth inhibitory and death 
signals and divide in an uninhibited manner. This abnormal growth is often 
associated with alterations in the genes controlling the cell cycle (Ruddon, 
2007). Initiation of carcinogenesis occurs with a mutation in a single cell, 
which then divides to give rise to a clone of altered cells. These altered cells 
experience a series of mutations as they divide and eventually grow into a 
tumor of aggressively proliferating cells (Fig. 1.2a). These cells are not bound 
by the restraints of normal cell growth and division and are capable of 
growing in absence of growth signals as well as are able to evade growth 
inhibitors. In advanced stages, the cells from primary tumors may metastasize 
to other sites (Lodish et al., 2007). As shown in Fig. 1.2b, a multitude of 
mutations in the cells over time causes them to evolve into a destructive 
cancer phenotype characterized by six fundamental properties: self-sufficiency 
in proliferative signals, insensitivity to growth inhibitory signals, ability to 
undergo infinite cell divisions, induce formation of new blood vessels, defy 
apoptosis, and ability to invade and metastasize to other tissues (Hanahan & 





















Figure 1.2 Multi-step cancer development. (a) Cancer begins when a single cell 
experiences a mutation. This mutation causes the cell to divide more rapidly than a 
normal cell. As the mutated cell multiplies, the defect is transmitted to the daughter 
cells which multiply frequently leading to hyperplasia. As these cells divide 
excessively, they may experience more mutations and form a mass of abnormal or 
dysplastic cells. The in situ tumors are localized to the tissue of origin. Malignant 
tumors develop as a result of mutations that render them capable of invading 
neighboring tissues or metastasizing to distant tissues in the body. Figure adapted 
from (Chial, 2008). (b) The mutations that occur during carcinogenesis may alter six 
fundamental cellular properties (as shown in the figure) that lead to development of 








1.1.2 The cell cycle and its deregulation in cancer 
The cell cycle is a series of cellular events that result in cell growth and 
division into daughter cells. In non-cancerous cells, orderly progression of the 
cell cycle involves a sequence of intricately orchestrated events regulated by a 
number of cellular proteins. Cyclin-dependent kinases (cdk) are a group of 
serine/threonine kinases that function as key regulators of the cell cycle 
together with their regulatory subunits known as cyclins, named for their 
cyclical production and degradation during the cell cycle. Each phase of the 
cell cycle is regulated by specific cdk-cyclin complexes. Four isotypes of cdk 
(cdk1, cdk2, cdk4, and cdk6) and ten isotypes of cyclin (belonging to four 
classes A, B, D, and E) are directly involved in controlling the cell cycle 
(Malumbres & Barbacid, 2005; van den Heuvel & Harlow, 1993). Progression 
from one phase of the cell cycle to the next is controlled through ‘checkpoints’ 
that govern activity of the relevant cdk-cyclin complexes. In each phase of the 
cell cycle, these checkpoints verify accurate completion of cellular events as 
programmed before proceeding to the next phase. Defects detected by these 
checkpoints induce a “wait” signal in the form of a cell cycle arrest that allows 
time for repair of the defects. In normal cells, prolonged activation of the 
checkpoint or inability to repair these defects drives the cells into apoptosis to 
avert transmission of the defects into the daughter cells (Malumbres & 
Barbacid, 2009). The DNA damage checkpoint that guards G2 to mitosis 
transition to ensure fidelity of DNA replication, and the spindle assembly 
checkpoint that regulates chromosome separation and mitotic exit, are 





1.1.2.1 The G2 checkpoint 
Activation of the cdk1-cyclinB complex is a key event regulating 
transition from G2 phase to mitosis. During G2 phase, expression of cyclin B1 
gradually increases and cdk1-cyclin B1 complexes are formed. However, cdk1 
is maintained in its inactive state by phosphorylation at Thr14 and Tyr15 by 
Wee and Myt kinases. On progression into late G2, cdk1 undergoes 
dephosphorylation at Thr14 and Tyr15 catalyzed by cell division cycle 25 
(cdc25) phosphatases, thus activating the cdk1-cyclin B1 complex (Ferrari et 
al., 2006). Subsequently, cyclin B1 is phosphorylated at its cytoplasmic 
retention sequence causing nuclear translocation of the cdk1-cyclin B1 
complex that marks mitotic entry (Hagting et al., 1999; Li et al., 1997).  Once 
activated, the cdk1-cyclin B1 complex phosphorylates several key substrates 
in the mitotic machinery and is therefore known as the ‘master regulator of 
mitosis’ (Lindqvist et al., 2007). As shown in Fig.1.3, when DNA damage 
occurs, the protein kinases ataxia telangiectasia mutated (ATM) kinase or 
ATM and Rad3-related (ATR) kinase are activated, which in turn respond by 
phosphorylating and activating Checkpoint kinase (Chk) 1 and/or Chk2 
kinases (McGowan & Russell, 2004). Inhibitory phosphorylation of the 
cdc25C phosphatase by Chk1/Chk2 creates a binding site for the protein 14-3-
3, which sequesters and blocks the interaction of cdc25C with cdk1-cyclin B1 
(Chen et al., 2003; Dalal et al., 1999), thereby preventing mitotic entry. 
Cdc25C is maintained in its inactive state by Chk1/Chk2 till the DNA is 
repaired, resulting in a G2 arrest. If DNA repair is unsuccessful, the cells enter 















Figure 1.3 Activation of the G2 checkpoint in response to DNA damage. When DNA 
damage occurs, the ATM/ATR pathway is activated, leading to phosphorylation of 
Chk1/2 and subsequent phosphorylation of cdc25C by Chk1/2. The 14-3-3 proteins 
sequester phosphorylated cdc25C in the cytoplasm, resulting in inhibition of cdc25C-
mediated activation of cdk1-cyclin B1 complexes. Inability to activate cdk1-cyclin 
B1 complexes arrests the cells in G2 phase. Repair of DNA by cellular repair 
mechanisms liberates the cell from the arrest and a normal cell cycle is restored. 
Alternatively, DNA damage that is beyond repair or a prolonged arrest in the G2 
phase drives the cell into apoptosis.   
 
1.1.2.2 The spindle assembly checkpoint 
The mitotic microtubule spindle is responsible for faithful distribution 
of chromosomes into daughter cells. As the genetic composition of the 
daughter cells depends on the ability of the spindle to accurately segregate the 
chromosomes, a tightly regulated spindle assembly checkpoint ensures the 




and mitotic exit. The checkpoint comprises a complex assembly of proteins, 
which act together to evoke a mitotic arrest in the event of improper alignment 
of chromosomes to the spindle (Musacchio & Salmon, 2007). If the 
chromosomes are aligned appropriately to the spindle, the anaphase-promoting 
complex/cyclosome (APC/C) causes ubiquitination and proteasomal 
degradation of securin, a protein whose function is to inhibit the enzyme 
separase, which cleaves the cohesin complex that holds the two sister 
chromatids together. Once securin is degraded, the cohesin complex is cleaved 
and the two chromatids are pulled towards opposite ends of the spindle (Reed, 
2006). Cyclin B1 is also a substrate of the ubiquitin ligase APC/C, and 
proteolysis of cyclin B1 inactivates cdk1, thus promoting mitotic exit 
following bi-orientation of the chromosomes. In case of inaccurate attachment 
of the spindle, cdc20, a co-factor for APC/C, is inhibited by proteins such as 
mad2, BubR1 and Bub3, which constitute the mitotic checkpoint complex 
(MCC) (Fig. 1.4). Inhibition of cdc20 thus inactivates APC/C and halts mitotic 
progression by preventing separation of chromosomes  (Ge et al., 2009).  
The spindle assembly checkpoint protein survivin is a member of the 
inhibitor of apoptosis (IAP) family of proteins, and has dual roles in mitosis 
and apoptosis. Although survivin levels are undetectable in non-dividing cells, 
its expression increases in mitosis wherein it localizes at the centromeres and 
microtubules, and is involved in maintaining the integrity of the spindle that 
segregates the chromosomes (Li et al., 1998). Increased survivin expression 
has been correlated with aggressive phenotypes in cancer cells, and targeting 
survivin has been considered as a potential strategy for anticancer therapy 













Figure 1.4 Effect of the spindle assembly checkpoint on cell cycle. Progression into 
mitosis requires the activation of the cdk1-cyclin B1 complex. As the cell transits into 
metaphase, chromosomes are aligned and the kinetochores are attached to the bipolar 
mitotic spindle. If the kinetochores are not attached (shown in red) the MCC (mad2, 
BubR1, Bub3) inhibits cdc20, which acts a co-factor for the ubiquitin ligase APC/C. 
Upon attachment of the kinetochores and bi-orientation of the chromosomes, the 
inhibitory action of the MCC on cdc20 is withdrawn, and activity of the APC/C 
ubiquitin ligase leads to degradation of its substrates securin (SEC) and cyclin B1. 
Proteolysis of securin activates separase, which cleaves the cohesin complex that 
holds the sister chromatids together such that the two sets of chromosomes are 
directed towards opposite ends. Degradation of cyclin B1 inactivates cdk1, and the 
cell exits mitosis. Figure adapted from Musacchio & Salmon, 2007.  
 
1.1.2.3 Cell cycle deregulation as a therapeutic opportunity 
Deregulation of the cell cycle is a hallmark of cancer (Massagué, 
2004). Genetic and epigenetic factors frequently affect the cell cycle 
regulatory proteins in cancer cells causing an increase or decrease in their 




control mechanisms, resulting in an incompetent cellular damage response 
system (Kastan & Bartek, 2004). Under these circumstances, cancer cells 
override the checkpoint controls and the cell cycle continues, resulting in 
transmission of genomic defects to daughter cells. On this basis, proteins 
regulating the checkpoints of cell cycle are therefore rational targets for 
development of anticancer drugs (Shapiro, 2006). It is therefore unsurprising 
that several drugs currently in preclinical or clinical studies have been targeted 
against cell cycle regulatory proteins such as the cdks, DNA damage 
checkpoint proteins including ATM/ATR and Chk 1/2, cell cycle phosphatases 
such as cdc25C as well as mitotic kinases Aurora, Plk1 and Mps1 
(Malumbres, 2006).  
In particular, cdk inhibitors have been evaluated as potential 
chemotherapeutic agents due to their ability to restore cell cycle control. These 
inhibitors are classified as pan cdk inhibitors such as flavopiridol and 
roscovitine, or molecules targeting specific cdks such as P1446A-05 (cdk4), 
LEE011 (cdk4/6) and P276-00 (cdk1/4/9). However, first generation of cdk 
inhibitors have displayed modest activity in clinical trials, and it has been 
suggested that combination therapy regimes involving cdk inhibitors along 
with other chemotherapeutic agents that kill cancer cells by a different 
mechanism of action would be more advantageous. It is also being accepted 
that as each cdk has unique roles in the cell cycle, selection of cdk inhibitors 
based on the cell types and tumor-specific biomarkers may improve 





1.1.3 Tubulin and microtubules as therapeutic targets in cancer 
In addition to the cell cycle regulatory proteins, role of microtubules is 
central for uninterrupted progression through various phases of the cell cycle. 
Tubulin subunits comprise a family of ubiquitous globular proteins of 
approximately 50 kDa molecular weight. The α- and β-forms of tubulin exist 
as heterodimers and polymerize to form long, hollow, filamentous structures 
known as microtubules (Fig. 1.5). Microtubules are an essential part of the 
eukaryotic cytoskeleton and participate in vital functions such as maintenance 
of cell shape, cellular motility and signaling, intracellular transport, and cell 
division (Wade, 2009). Due to their crucial roles in formation of the mitotic 
spindle during cell division, compounds that target tubulin or microtubules 
have been successfully developed as anticancer agents. Validation of tubulin 
as a target is underscored by the fact that before the advent of targeted 
therapies, DNA-damaging agents and tubulin-binding agents comprised the 









Figure 1.5 Formation of microtubules. The soluble α- and β-tubulin heterodimers 
polymerize to form a microtubule nucleus. Dimers are further added onto the 
microtubule nucleus resulting in formation of highly dynamic microtubules. Figure 




The vinca alkaloids and taxanes, two of the earliest identified classes 
of microtubule targeting agents, are currently indicated in a range of solid 
tumors and haematological cancers. Vinca alkaloids have been indicated in 
lymphomas and solid tumors such as bladder and breast cancers, while major 
applications of taxanes include treatment of cancers of the ovary, breast, 
prostrate, and non-small cell lung cancer (NSCLC) (Jones et al., 2010; Müller-
Beissenhirtz, et al., 2005; Pajk et al., 2008; Scagliotti et al., 2012; Takakura et 
al., 2010). Despite the success of these classical microtubule-targeting agents, 
evolution of highly aggressive tumors and development of resistant tumors 
warrants continual search for novel tubulin-targeting agents (Morris & 
Fornier, 2008; Murray et al., 2012).  
1.1.3.1 Microtubule dynamics  
 Biological functions of microtubules are largely regulated by their 
polymerization dynamics, which refer to the addition or removal of tubulin 
subunits resulting in lengthening or shrinkage of the microtubule filaments 
(Williams et al., 1986). Microtubules chiefly exhibit two kinds of dynamic 
behaviors, ‘dynamic instability’ and ‘treadmilling’. In dynamic instability, the 
two ends of microtubules grow and shorten independently of each other. Of 
the two ends, the ‘plus’ end undergoes faster and more extensive growth and 
shrinkage than the ‘minus’ end. Treadmilling is the simultaneous removal of 
tubulin subunits at the plus end and addition at the minus end, resulting in a 
net shortening at one end and an equivalent net growth at the other end 
(Mitchinson & Kirschner, 1984). The dynamics of microtubules require tight 
spatial and temporal regulation, especially during mitosis in order to ensure 




Mechanisms that regulate microtubule dynamics include differential 
expression of tubulin isotypes and post-translational modifications (Luduena, 
1998; McKean et al., 2001), microtubule-associated proteins (MAPs) (Itoh & 
Hotani, 2004) and microtubule-interacting proteins (Komarova et al., 2009), 
which are discussed briefly in the following paragraphs. 
Post-translational modifications 
Detyrosination of tubulin is the reversible enzymatic removal of a 
tyrosine residue in results in more stable microtubules, as the microtubule-
depolymerizing kinesins selectively depolymerize tyrosinated microtubules 
(Kumar and Flavin, 1981; Peris et al., 2009). Acetylation of tubulin at Lys40 
of the α-tubulin stabilizes microtubules, although mechanism for this 
stabilization remains to be found (L’Hernault and Rosenbaum, 1985; Maruta 
et al., 1986). It has been hypothesized that acetylation may induce a 
conformational change in the α-, β-tubulin dimer that results in a change in the 
stability of microtubules. However, there is no definitive information on the 
mechanism of stabilization of microtubules by acetylation. Polyglutamylation 
has been found to attract microtubule-severing enzymes such as katanin and 
spastin that results in decreased stability of the microtubules and reduced 
microtubule mass (Sharma et al., 2007; Lacroix et al., 2010). During mitosis, 
there is an enhancement in the post translational modifications such as 
detyrosination, polyglutamylation and acetylation in the mitotic spindle 
(Gundersen and Bulinski, 1986; Piperno et al., 1987; Bobinnec et al., 1998). 
Polyglutamylase activity increases at the onset of mitosis, and it has been 
proposed that induction of microtubule severing due to polyglutamylation may 




severing (McNally et al., 2006), whereas it may be critical for ensuring timely 
cytokinesis by regulating spastin-mediated microtubule severing (Connell et 
al., 2009). The depolymerizing kinesin MCAK is vital for regulation of 
chromosome segregation during anaphase. Activity of MCAK is dependent on 
the tyrosination state of α-tubulin, and thus detyrosination may regulate 
separation of chromosomes during mitosis (Maney et al., 1998).   
Expression of tubulin isotypes 
The human genome has at least nine genes each for both α- and β-
tubulin, which code for the different tubulin isotypes (Khodiyar et al., 2007; 
Ferlini et al., 2007). Expression of the tubulin isotypes is often cell and tissue 
specific; for example βI and βV are expressed in most tissues, whereas the 
isotypes βII and βIVb are found in neurons, and βVI is found only in 
megakaryocytes and platelets. Isotype expression and composition of the 
microtubules determines their dynamics. For example, microtubules formed 
from βIII tubulin display higher dynamics than those composed of βII or βIV 
tubulin (Panda et al., 1994). On the other hand, overexpression of the isotypes 
βV or βVI tubulin suppresses microtubule dynamics and causes appearance of 
microtubule fragments (Bhattacharya and Cabral, 2009; Yang et. al., 2011).        
MAPs and microtubule-interacting proteins  
Microtubule dynamics are greatly regulated by a balance of 
microtubule-stabilizing and –destabilizing proteins that are described as MAPs 
or microtubule-interacting proteins. These proteins include the MAP family of 
proteins, tau, stathmin, survivin and others. MAPs such as MAP1, MAP2, 
MAP4 and tau stabilize microtubules (Takemura et al., 1992), whereas 




XKCM1, MCAK and XKIF2 destabilizes microtubules (Desai et al., 1999; 
Belmont and Mitchison, 1996). Other proteins such as survivin and Eg5 
regulate formation and stability of the bipolar mitotic spindle during cell 
division (Kapoor and Mitchison, 2001; Li et al., 1998).  
1.1.3.1.1 Microtubule dynamics during the cell cycle 
 Microtubule dynamics are cell cycle-dependent and exhibit a slow 
microtubule turnover during interphase. As depicted in Fig.1.6, microtubules 
undergo rapid changes at the onset of mitosis causing the interphase 
microtubule network to disassemble followed by formation of the mitotic 
spindle (Zhai et al., 1996). The microtubules that form the spindle are several-
fold (4-100) more dynamic than the interphase microtubules (Rusan et al., 
2001). At the onset of prometaphase, highly dynamic microtubules are formed 
that emanate from the two spindle poles. These microtubules undergo phases 
of rapid growth and shrinkage until they are successfully attached to the 
kinetochores (Hayden et al., 1990). Once microtubules from both poles are 
attached to the sister kinetochores, a bipolar spindle is oriented. In events of 
incomplete or inaccurate attachments, the spindle assembly checkpoint 
(discussed in section 1.1.2.2) is activated (Musacchio & Salmon, 2007). Upon 
correct attachment, the synchronous growth and shrinkage of microtubules 
aligns the chromosomes along the metaphase plate. During metaphase, the 
microtubules connecting the chromosomes to the poles are under high tension 
(Nicklas et al., 1995). This tension arises from the simultaneous growth of 
microtubules at the kinetochores and shrinkage at the poles known as the 
dynamic behavior treadmilling. As the cell progresses to anaphase, the protein 




are pulled towards opposite poles by rapid growth and shrinkage of 











Figure 1.6 Morphological changes in the microtubular structure during the cell cycle. 
Interphase microtubules display slow microtubule dynamics. At the onset of mitosis, 
microtubule dynamics increase drastically, and the bipolar spindle is formed. In 
metaphase, the chromosomes are attached to the spindle and aligned at the metaphase 
plate. As the cell progresses through anaphase, chromosomes are pulled towards 
opposite poles by the dynamic action of microtubules. During telophase, 
microtubules between the chromosomes have elongated and the two sets of 
chromosomes are near the poles. Cytokinesis ensues and the cell finally divides into 
two daughter cells. Microtubules are colored green and chromatin or chromosomes 
are colored blue. Figure adapted from Kavallaris, 2010. 
 
1.1.3.2 Microtubule-destabilizing and -stabilizing agents  
 Microtubule-targeting agents have been traditionally classified into the 
microtubule-destabilizing agents and microtubule-stabilizing agents. The 




therefore increase the tubulin dimer to microtubule ratio. The destabilizers 
bind to either the vinca-binding domain or the colchicine-binding site (Fig. 
1.7). Compounds that bind to the vinca-binding site include vinca alkaloids 
such as vincristine, vinblastine, vinflunine and vinorelbine, dolastatins and 
cryptophycins (Hamel, 1992; Smith & Zhang, 1996). Colchicine and its 
analogs, as well as agents such as podophyllotoxin, also bind to the colchicine 
site (Cortese et al., 1977; Wilson & Meza, 1973). 
Microtubule-stabilizing agents such as the taxanes (paclitaxel, 
docetaxel) enhance formation of polymerized microtubules and increase the 
polymer mass. Taxanes bind to the taxol-binding site on β-tubulin (Fig. 1.7). 
Examples of other stabilizing agents that bind to the taxol domain or an 
overlapping site include epitholines, discodermolide, ixabepilone, 
cyclostreptin and dictyostatin (Buey et al., 2005; Nogales et al., 1995). Some 
destabilizing agents such as estramustine and noscapine (Naik et al., 2011; 
Panda et al., 1997), and stabilizing agents such as lauliamide and peloruside A 
(Hamel et al., 2006) have been found to bind to novel sites on tubulin.  
Both categories of drugs – microtubule-stabilizers and –destabilizers, 
suppress microtubule dynamics at concentrations much lower than those 
required to affect the polymer mass (L. Wilson & Jordan, 1995). The dynamic 
properties of microtubules are central to cell division and therefore mitosis 
phase of the cell cycle is particularly vulnerable to tubulin-targeting agents. 
Several other compounds have also been found to arrest cells in mitosis by 










Figure 1.7 Binding sites of vinca alkaloids (vinblastine), colchicine and taxanes 
(paclitaxel). Vinca alkaloids binds to the microtubule ends, colchicine binds to 
soluble tubulin dimers, while paclitaxel binds along the interior surface of 
microtubules. Adapted from Dumontet & Jordan, 2010.   
 
In addition to the drug-binding domains, the tubulin dimer contains 20 
conserved cysteine residues, most of which, in spite of being ‘buried’ 
according to their electron diffraction structure, are accessible by reagents 
(Krauhs et al., 1981; Ponstingl et al., 1981; Lowe et al., 2001). Sulfhydryl 
groups in some of these cysteine residues are involved in regulation of 
polymerization and depolymerization of microtubules (Mellon & Rebhun, 
1976). It has been found that excluding one or two disulfide bonds required for 
optimal polymerization, oxidation of the cysteine residues results in loss of 
polymerization ability of the protein (Britto et al., 2002). Although the precise 
cysteine residues essential for assembly have not been identified, two pairs of 
cysteines in β-tubulin, Cys12-Cys201/211 and Cys239-Cys354, are cross-
linkable by N,N’-ethylene bis(iodoacetamide) and perhaps are susceptible to 
oxidation by other agents (Little & Luduena, 1987). Electrophilic compounds 
such as isothiocyanates and diallyl sulfides have been found to interact 
directly with tubulin via sulfhydryl groups. Diallyl trisulfide modifies Cys12 




et al., 2005), while benzyl isothiocyanate has been found to covalently modify 
Cys347 of α-tubulin in a cell-based study (Mi et al., 2008). Both diallyl 
trisulfide and benzyl isothiocyanate also inhibit growth and induce apoptosis 
in cancer cells, suggesting the potential of sulfhydryl groups in tubulin as a 
target for development of novel tubulin-targeting agents for anticancer 
therapy.  
1.1.3.3 Mechanisms of drug resistance against tubulin-binding agents 
 Understanding of mechanisms of resistance to therapies is the key to 
developing novel microtubule-targeting agents. A primary reason underlying 
development of resistance is the efflux of drugs by membrane efflux pumps. 
Among the ATP-binding cassette (ABC) proteins, the efflux transporter P-
glycoprotein, which efficiently effluxes taxanes and vinca alkaloids, is majorly 
responsible for emergence of the multidrug resistant phenotype (Fojo & 
Menefee, 2007). Efflux transporters belonging to the multidrug resistance-
associated protein family also participate in cellular export of vinca alkaloids, 
taxanes and epolithone B (Hopper-Borge et al., 2009). A second mechanism of 
resistance is mutations affecting tubulin isotypes or tubulin-regulatory proteins 
such as MAPs. Abnormally high levels of class-III β-tubulin (βIII-tubulin) 
have been associated with highly aggressive and resistant tumors (Seve & 
Dumontet, 2008). Altered expression of MAPs such as tau, MAP2 and MAP4 
have also been found to affect sensitivity of tumors to tubulin binding agents 
(Don et al., 2004). It is yet to be discovered how differential expression of 
tubulin and MAPs is regulated in cancers, and knowledge of this regulation 
may aid identification of biomarkers such that therapies can be accurately 




1.2 Cancer chemoprevention 
In 2008, there were an estimated 12.7 million new cancer cases 
worldwide, which are predicted to increase to more than 20 million by 2030 
(Ferlay et al., 2010). However, according to WHO, one-third of all cancers can 
be prevented. Smoking and alcohol consumption are associated with cancer 
types such as cancers of the lung, oral cavity, larynx, oesophagus, liver, 
colorectum. Similarly, obesity has been linked to cancers of the oesophagus, 
colorectum, breast, endometrium and kidney. Prevention of these cancers can 
be achieved by eliminating the associated risk factors; for example, avoiding 
smoking and alcohol consumption, adopting healthy diets and physical 
activity. Other prevention strategies include avoiding exposure to known 
carcinogens, some examples being protection from solar radiation to prevent 
skin cancer and vaccination against Hepatitis B to prevent liver cancer. In 
addition to lifestyle modifications and minimizing exposure to carcinogens, 
prevention of cancer by supplementation of chemopreventive agents has 
received much attention in recent years.  
The term cancer ‘chemoprevention’ was coined by Michael Sporn 
(Sporn et al., 1976), and is defined as, “the use of natural or synthetic agents to 
prevent, retard or reverse carcinogenic progression”. Synthetic 
chemopreventive agents are usually drugs already in clinical use for other 
pharmacological activities fortuitously found to possess chemopreventive 
properties. Examples include the anti-estrogen drug tamoxifen (Fisher et al., 
2005), anti-hyperlipidemic agent atorvastatin (Kapoor, 2008) and non-
steroidal anti-inflammatory agents (NSAIDs) such as aspirin. However, as 




use is always associated with risk of adverse effects. Apart from these drugs, a 
variety of dietary phytochemicals have also been reported to exhibit 
chemopreventive properties. Sulforaphane from broccoli, curcumin from 
turmeric, shogaols from ginger, allyl sulfides from garlic, epigallocatechin 
gallate from green tea, and genistein from soy being examples of such 
compounds. Notably, as shown in Fig. 1.8, amid their diversified chemical 
structures, these phytochemicals share in common electrophilic centers that 
may possibly contribute to their biological activites. As these compounds are 
derived from dietary sources, these compounds may be considered as 
pharmacologically more tolerable and acceptable for consumption by healthy 
















1.2.1 Mechanism of protection against cancer by chemopreventive agents 
Multicellular organisms are continually exposed to an abundance of 
electrophiles and oxidants. Some of these electrophiles and oxidants have 
biological functions such as participation in cellular signaling, enzymatic 
reactions, defense against microbial organisms, and inflammatory response. 
Although these biological functions are beneficial, some of these agents also 
have the potential to produce noxious effects on the cell by directly binding to 
nucleic acids, proteins and lipids and thereby impairing the normal functions 
of these cellular macromolecules. Accumulating scientific evidence suggests 
that these oxidants and electrophiles play a major role in the development of 
diseases such as cancer, chronic inflammation, neurodegeneration, and aging 
(Ma & He, 2012). The major threat from these carcinogens is their ability to 
bind to genetic material and induce mutations that may ultimately progress 
into malignant neoplasms.  
To combat insults from extrinsic and intrinsic agents, eukaryotic cells 
have evolutionarily developed multiple defense systems that detoxify or 
remove the stressor to maintain optimal cellular conditions. On encountering 
such agents, the strategies deployed by cells can be categorized as 1) Phase I 
enzymes. The phase I reactions such as oxidation, reduction or hydrolysis 
involve alteration of the functional groups of the molecules and generally lead 
to formation of more reactive intermediates. The cytochrome P450 enzymes 
are responsible for a majority of the phase I reactions.  2) Phase II enzymes. 
Reactions catalyzed by these enzymes usually render the molecules more polar 
in order to facilitate their excretion. Phase II reactions often involve 




glucuronic acid or sulfate. Examples of phase II enzymes include UDP-
glucuronsyltransferases, sulfotransferases and glutathione S-transferases. and 
3) Efflux transporters. These proteins serve to transport toxic entities outside 
the cell and thus together with phase II enzymes protect cells from 
carcinogens. Phase II enzymes are highly inducible and cytoprotection by 
selective induction of these enzymes is a promising approach to reduce the 
risk of cancer (Talalay, 2000). The extent of deleterious effects of a potential 
carcinogen depends on the balance of activities of phase I enzymes that 
produce reactive intermediates and phase IIenzymes that eliminate these 
metabolites (Dinkova-Kostova et al., 2005). Protection against carcinogens by 
induced expression of the cytoprotective enzymes in cells treated with 













Figure 1.9 Inhibition of oncogenesis by chemopreventive agents. Naturally occurring 
chemopreventive agents protect the cell by inducing the expression of the 
cytoprotective detoxifying phase 2 enzymes that act to inactivate the carcinogen or 





The nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) transcription 
factor, which regulates expression of phase 2 enzymes, has been demonstrated 
to be at the heart of the adaptive induction in response to stressors (Itoh et al., 
1997). Under constitutive unstressed conditions, Nrf2 is sequestered and 
directed for proteasome-dependent degradation by its repressor protein Kelch-
like erythroid cell-derived protein with CNC homology (ECH)-associated 
protein 1 (Keap1) (Itoh et al., 1999; Kang et al., 2004). However, in presence 
of electrophiles or oxidative stress, Nrf2 escapes Keap1-mediated degradation 
and binds to DNA enhancer consensus sequences identified as antioxidant 
response elements (ARE), finally resulting in transactivation of downstream 
genes (Prestera et al., 1995). Examples of Nrf2-target genes include those 
encoding enzymes such as NAD(P)H:quinone oxidoreductase 1 (NQO1), UDP 
glucuronosyltransferase (UGT), glutathione S-transferases (GSTs), 
thioredoxin reductase, heme oxygenase 1 (HO-1), electrophile-inactivating 
molecules such as glutathione and thioredoxin, as well as multidrug response 
transporters (Thimmulappa et al., 2002). Enzymes regulated by the ARE 
sequence may not always be the classical phase II conjugating enzymes. For 
example, ARE also regulates enzymes such as NQO1 and epoxide hydrolase, 
which are phase I enzymes that are cytoprotective. In this regard, 
cytoprotective genes that are inducible by electrophiles are referred to as 
“phase 2” enzymes (Talalay, 2000). Increased expression of these phase 2 
proteins thus provides an enhanced antioxidant and detoxifying defense 






1.2.2 The Nrf2-Keap1 pathway in cytoprotective response 
1.2.2.1 Negative regulation of Nrf2 by Keap1 
Nrf2 belongs to the Cap ‘n’ Collar (CNC) basic region-leucine zipper 
family of transcription factors. It forms heterodimers with small Mafs, and 
binds to the ARE motif located within promoter regions of its target genes 
(Itoh et al., 1997). ARE is a cis-acting DNA enhancer with the core sequence 
identified as 5’-TGACnnnGC-3’ (Nioi et al., 2003). Nrf2 exhibits strong 
affinity to this sequence, and upon binding initiates ARE-dependent 
transcription of downstream genes. Nrf2 contains six highly conserved 
functional domains (Fig. 1.10a): Nrf2-ECH homology 1-6 (Neh1-6), of which 
the Neh2 domain participates in binding to its repressor Keap1, Neh4 and 
Neh5 act as transactivation domains, and Neh1 mediates heterodimerization 







Figure 1.10 Domain structures of Nrf2 and Keap1. (a) Nrf2 contains six conserved 
domains, Neh1-Neh6. The Neh2 domain of Nrf2 binds to Keap1 through the DLG 
and ETGE motifs. Nrf2 is ubiquitinated by the E3 ubiquitin ligase Cullin3 (Cul3) at 
the lysine residues located within the Neh2 domain. Neh1 domain is the basic leucine 
zipper that is involved in dimerization with Mafs and DNA binding. Neh4 and Neh5 
domains participate in transactivation. (b) Keap1 structure is divided into five 
domains; NTR, BTB, IVR, DGR and CTR. BTB domain mediates homodimerization 








Under normal physiological conditions, Nrf2 is maintained in the 
cytoplasm by direct physical interaction with Keap1. Keap1 structure contains 
five domains, the N-terminal region (NTR), broad complex tram-track and 
bric-a-brac (BTB) domain, intervening region (IVR), the Kelch domain 
containing six Kelch repeats (DGR) and the C-terminal region (CTR) (Fig. 
1.10b). The Kelch repeats contained in the DGR domain interact with Neh2 
domain in Nrf2 (Itoh et al., 1999), while the BTB domain is involved in 
binding to the ubiquitin E3 ligase cullin 3 (Cul3) (Zipper & Mulcahy, 2002). 
Keap1 acts as a substrate adaptor for the Cul3-dependent ubiquitin E3 ligase 
complex such that when Nrf2 is tethered by Keap1, the ubiquitin ligase 
conjugates ubiquitin molecules onto the lysine residues located in the Neh2 
domain of Nrf2. Polyubiquitylated Nrf2 is directed for degradation by the 26S 
proteasome (Fig. 1.11) (Cullinan et al., 2004; Furukawa & Xiong, 2005; 
Kobayashi et al., 2004; Zhang et al., 2004). As a result, under basal conditions, 
the dynamics of constant production and degradation of Nrf2 results in a short 





















Figure 1.11 Activation of Nrf2 under conditions of oxidative and electrophilic stress. 
Activity of the transcription factor Nrf2 is central to the inducible expression of 
several cytoprotective genes. Under constitutive conditions, Nrf2 is sequestered by 
Keap1 in the cytoplasm. Keap1 also binds to the ubiquitin ligase Cul3 and facilitates 
ubiquitination of Nrf2, which is then degraded via the proteasomal pathway. When 
the cell experiences oxidative or electrophilic stress, Nrf2 escapes Cul3-mediated 
degradation, and free Nrf2 molecules translocate to the nucleus to bind to the ARE 
sequences that leads to upregulated expression of cytoprotective proteins such as the 
phase 2 enzymes.       
 
1.2.2.2 Cysteines in Keap1 protein as sensors of cellular redox status 
Chemically distinct classes of Nrf2-inducing molecules bear a common 
feature: all molecules contain electrophilic moieties capable of interacting 
with the nucleophilic sulfhydryl groups contained in the cysteine residues of 
Keap1 (Dinkova-Kostova et al., 2002). Keap1 contains an unusually high 
number of cysteine residues, which is approximately twice the average 
cysteine content of all human proteins (Miseta & Csutora, 2000). Human 




amino acids, and a number of these cysteines are highly reactive with low pKa 
values due to their proximity to basic residues (Snyder et al., 1981). 
Considering these key features, Keap1 was first proposed and later 
experimentally demonstrated to act as a sensor of cellular redox conditions; it 
responds to oxidative stress by withdrawing its repressive effect such that Nrf2 
escapes degradation and increased Nrf2 levels lead to upregulated 
transactivation of genes encoding for cytoprotective and detoxifying enzymes.    
Three cysteines, Cys151, Cys273, and Cys288 have been found to be 
critical for repression of Nrf2. Mutation of Cys151 abolishes the ability of 
Keap1 to react to cellular stress and therefore lead to Nrf2 induction (Zhang & 
Hannink, 2003; Zhang et al., 2004). On the other hand, mutation of either 
Cys273 or Cys288 or both results in an inability of Keap1 to repress Nrf2 and 
direct it for ubiquitination (Kobayashi et al., 2004; Wakabayashi et al., 2004; 
Zhang & Hannink, 2003). It has also been established that molecules from 
different chemical classes modify a unique set of cysteine residues as shown in 











Table 1.1 Cysteine residues of Keap1 modified by Nrf2 inducers 
Compound Cysteines modified in Keap1 Reference 
Dexamethasone 21-
mesylate 
257, 273,288,297,613 Dinkova-Kostova 
et al., 2002 
Biotinylated 
iodoacetamide 
151,257,273,288,297,319,613 Eggler et al., 2005 
IAB* 196,226,241,257,288,319 Hong et al., 2005 
Sulforaphane 151,489,583,624 Hong et al., 2005; 
Hu et al., 2011 
Xanthohumol 151,319, 613 Luo et al., 2007 
Isoliquiritigenin 151, 266 Luo et al., 2007 
10-Shogaol 151,257,368 Luo et al., 2007 
* IAB, N-iodoacetyl-N-biotinylhexylenediamine 
 
Moreover, different endogenous stressors have been found to induce 
Nrf2 by modification of distinct cysteines in Keap1 (McMahon et al., 2010). 
These reports thus led to the deduction that each class of electrophiles alters a 
unique group of cysteines or follows a ‘cysteine code’ to induce the 
antioxidant response by Nrf2 (Kobayashi et al., 2009; Takaya et al., 2012). 
Fig. 1.12 shows the cysteine modification profiles or ‘cysteine code’ of 
chemically diverse electrophiles. Although the cysteines in Keap1 have been 
known to play a pivotal role in facilitating the stabilization of Nrf2 by being 
targeted by electrophilic inducers, further mechanistic studies exploring how 
modification of cysteines leads to a loss of Keap1’s ability to repress Nrf2 are 











Figure 1.12 Cysteine residues of Keap1 modified by different electrophiles. Each 
group of chemically distinct electrophiles modifies a unique set of cysteines or 
follows a ‘cysteine code’. Cysteines in red have been proven to be biologically 
significant in vivo. Figure adapted from Taguchi et. al., 2011.  
 
1.2.2.3 Proposed mechanisms of Nrf2 stabilization 
Since the discovery of Keap1 as a negative regulator of Nrf2, models 
elucidating the reduction in Keap1-mediated Nrf2 repression by electrophiles 
have been proposed. At first it was surmised that interaction with electrophilic 
compounds leads to a change in Keap1 conformation such that it can no longer 
sequester Nrf2, and free Nrf2 translocates to the nucleus to bind to ARE. 
However, recent studies observed that although Keap1-Cul3 ligase activity is 
reduced upon electrophile treatment, Keap1-Nrf2 interaction is not affected 
(Kobayashi et al., 2006). Keap1 exists as a homodimer with a cherry-bob 
structure comprising two globular components connected by a cylindrical stem 
(Ogura et al., 2010). Stoichiometry of Keap1-Nrf2 interaction is 2:1 with the 
Kelch region of each Keap1 monomer interacting with two distinct binding 




identified as the low-affinity DLG motif and the high-affinity ETGE motif (Lo 
et al., 2006; McMahon et al., 2006; Tong et al., 2006a). Together, these 
observations have led to the inception of the ‘hinge and latch model’ wherein 
the higher affinity binding with the ETGE motif is described as the ‘hinge’ 
while the lower affinity DLG motif serves as the ‘latch’ (Fig. 1.13). 
Simultaneous interaction at both sites allows favorable alignment of lysine 
residues in the Neh2 domain of Nrf2 for ubiquitination by Cul3. In conditions 
of oxidative or electrophilic stress, Nrf2-Keap1 binding is disengaged at the 
latch, while still retaining interaction at the hinge, such that Nrf2 can no longer 
be ubiquitinated (Tong et al., 2006b). As existing Nrf2 is not degraded, Keap1 
binding sites remain occupied and de novo synthesized Nrf2 molecules are 
free to translocate into the nucleus to bind to ARE sequences (Kobayashi et 









Figure 1.13 The ‘hinge and latch’ model for Nrf2 stabilization. According to this 




affinities at the ETGE (hinge) and DLG (latch) motifs respectively. (b) Binding at 
both ETGE and DLG motifs positions the lysine residues of Nrf2 vulnerable to 
ubiquitination by Cul3, which is followed by proteasome-mediated degradation of 
Nrf2. (c) In conditions of oxidative and electrophilic stress or other inducers such as 
chemopreventive agents, binding at the low-affinity DLG motif, or latch, is severed 
and Nrf2 escapes ubiquitination by Cul3.    
  
An alternative model proposes that oxidative and electrophilic stress 
cause disruption of the Keap1-Nrf2-Cul3 binding that causes a switch in 
ubiquitination from Nrf2 to Keap1. This results in ubiquitination and 
subsequent degradation of Keap1, and stabilization of Nrf2 (Rachakonda et 
al., 2008).  
Although several models of Nrf2 regulation by Keap1 and its rescue by 
electrophiles have been proposed, the hinge and latch model provides the most 
plausible explanation for the repression of Nrf2 by Keap1. According to this 
model, Keap1 dimers tether a single molecule of Nrf2 such that its lysine 
residues are immobilized for ubiquitylation. The findings that Nrf2-Keap1 
interaction is not affected by inducers, and that de novo synthesized Nrf2 
binds to ARE and elicits the antioxidant response also support the hinge and 
latch model, which proposes that the Keap1-Nrf2 interaction is severed at only 
one of the two binding sites after treatment with inducers, and therefore does 
not entail the complete release of Nrf2 from Keap1. It may be noted, however, 
that the different models may not be mutually exclusive, and possibly operate 
in conjunction with each other or may be specific for the given physiological 
conditions.      
1.2.2.4 New and alternative insights in ARE-Nrf2-Keap1 signaling  
Recent studies suggest that the Nrf2-Keap1 pathway is more complex 




partners for Nrf2 and Keap1, as well as links indicating cross-talk with other 
signaling pathways have been discovered, some of which are discussed below. 
The cdk1 inhibitor p21 was found to compete with Keap1 for 
interaction with the DLG motif of Nrf2. Interaction of Nrf2 with p21 releases 
the ‘latch’ and protects Nrf2 from Keap1-mediated degradation (Chen et al., 
2009). In the absence of p21, Nrf2 stabilization and induction of the 
cytoprotective response is attenuated. It is known that in addition to its role in 
cell cycle and p53-mediated apoptosis, p21 functions to protect the cell against 
oxidative stress and promotes cell survival. Such findings by Chen et al. 
(2009) have thus indicated that cytoprotective effect of p21 is dependent on 
Nrf2, and activation of the cytoprotective genes by Nrf2 is potentiated in the 
presence of p21 (Chen et al., 2009).       
The transcription factor nuclear factor kappa light-chain enhancer of 
activated B cells (NF-κB) has multiple cellular roles such as regulating cell 
survival, proliferation, inflammatory responses, and maintenance of 
homeostasis. Recent reports have indicated existence of cross-talk between the 
NF-κB and Nrf2-Keap1 pathways. In a study by Liu et al. (2008), it was 
shown that binding of the p65 subunit of NF-κB to Keap1 led to a decrease in 
Nrf2 activity by increasing Nrf2 degradation and diminishing Nrf2’s ARE-
binding ability. In another study, Keap1 was found to interact with inhibitor of 
κB kinase β (IKKβ), resulting in degradation of IKKβ (Kim et al., 2010; Lee et 
al., 2009). Even as these studies shed light on the interplay between the NF-κB 
and Nrf2 pathways, how each pathway affects activity of the other during 




The polyubiquitin binding and autophagy inducing-protein p62 has 
also been identified to interact with Keap1. This interaction leads to inhibition 
of Nrf2 ubiquitination and subsequent induction of the phase 2 cytoprotective 
response (Copple et al., 2010; Jain et al., 2010; Komatsu et al., 2010; Lau et 
al., 2010).  
Phosphorylation of Nrf2 by mitogen-activated protein kinases 
(MAPKs), protein kinase C (PKC), and phosphatidylinositol 3-kinase (PI3K) 
has been proposed to regulate its activation (Niture et al., 2009; Niture et al., 
2010; Surh et al., 2008). However, the exact cellular consequences of 
phosphorylation of Nrf2 are yet to be fully elucidated.  
In addition to Nrf2, the nuclear factors Jun, Fos and Fra have been 
found to regulate ARE activity. It has been reported that Fos and Fra 
negatively regulate ARE transcriptional activity, possibly by binding to ARE 
and therefore inhibiting binding of Nrf2 (Venugopal and Jaiswal, 1996). On 
the other hand, the nuclear factor Jun has been found to dimerize with Nrf2 
and potentiate the antioxidant gene expression (Levy et al., 2009). 
Taken together, to date, reported studies have produced findings 
indicating the possibility of an integrated response system involving the Nrf2-
Keap1 pathway that is activated in times of cellular stress. Precise elucidation 
of the molecular mechanisms to fully map out the network of underlying 
pathways warrants further examination. 
1.2.2.5 The dark side of Nrf2: involvement in tumorigenesis 
As discussed in the previous sections, there is abundant evidence to 




antioxidant capacity, and thus reducing ROS levels and the amount of DNA 
damage. In contrast to these findings, it has recently been suggested that 
activity of Nrf2 may favor tumor survival. Keap1 and Nrf2 mutations have 
been discovered in lung, gall bladder and head and neck cancers that result in 
a hyperactivation of Nrf2 (Singh et al., 2006; Ohta et al., 2008; Shibata et al., 
2008; Stacy et al., 2006). These reports therefore suggest that the activity of 
Nrf2 that protects normal cells against carcinogenesis also maintains a 
favorable redox balance in tumor cells that promotes survival and growth. 
Further evidence for the “dark side” Nrf2 was provided by the finding that 
oncogenes such as K-Ras, B-Raf and Myc induce Nrf2 transcription that may 
contribute to tumorigenesis by causing detoxification of ROS and providing a 
more conducive cellular environment (DeNicola et al., 2011). Due to the role 
of Nrf2 in promoting cancer growth, Nrf2 inhibitors have been explored as a 
strategy in cancer therapy. It has been proposed that downregulation of the 
antioxidant enzymes in cancer cells would render them incompetent to combat 
oxidative damage and consequently result in cancer cell death. In addition, 
Nrf2 inhbition may sensitize tumors to anticancer drugs by suppression of the 
detoxifying enzymes and efflux transporters. In support of this hypothesis, 
recently an Nrf2-inhibiting compound brusatol has been found to sensitize 
tumor cells to cisplatin treatment (Ren et al., 2011). Although there is 
compelling evidence to support the role of Nrf2 in protection of normal cells 
against carcinogenesis, the paradoxical involvement of Nrf2 in promoting 
tumor growth raises a concern on the use of chemopreventive agents. These 




careful titration of doses and optimization of treatment regimes rather than 
long administration of doses eliciting maximum activity. 
1.2.3 Suppression of inflammation as a chemopreventive strategy  
 The relationship between inflammation and cancer was first reported 
as early as 1858 by Rudolf Virchow when he observed infiltrating leukocytes 
within neoplastic tissues. Based on this observation he hypothesized that 
cancer originated at sites of chronic inflammation (Virchow & Chance, 1858). 
Over the last few decades, understanding of the tumor microenvironment has 
revealed further links between inflammation and cancer that may have 
implications in the treatment and prevention of cancer. Although inflammation 
is a host defense strategy against injury or infection and is self-limiting, 
persistent inflammatory responses have been correlated to tissue pathologies 
such as cancer. In normal wound healing responses, immune cells are 
deployed transiently at the sites of tissue injury to enhance proliferation, and 
the response is disengaged once the injurious agent is removed or tissue repair 
is complete. In contrast, failure to inactivate the immune response in a timely 
manner may result in excessive changes in the tissue architecture, and cause 
damage to biological macromolecules (proteins, lipids and DNA) due to 
oxidative stress, which collectively increase the risk of carcinogenesis (Chen 
et al., 2007). In this sense, tumors have also been described as wounds that 
never heal (Dvorak, 1986).  
A growing body of evidence from preclinical and clinical studies 
suggests that chronic inflammation may potentially serve as a gateway to 




cancer is the strong association of colon cancer with chronic inflammatory 
bowel disorders such as Crohn’s disease and ulcerative colitis (Gelber et al., 
1955; Okayasu, 2012). Similarly, infection with papillomavirus or 
Helicobacter pylori increases the risk of cervical and gastric cancers 
respectively (Ernst & Gold, 2000; Loffeld et al., 1990; Zoler, 1983). Other 
examples include skin inflammation and melanoma (Green et al., 1985), 
Hepatitis B or C and liver cancer (Matsuzaki et al., 2007), cystitis and bladder 
carcinoma (Michaud, 2007), as well as ovarian endometriosis and epithelial 
ovarian cancer (Freedman et al., 2004).  
1.2.3.1 Inflammatory cells in tumors 
Infiltrating immune cells have been repeatedly observed in malignant 
tumors and these inflammatory cells are now accepted as one of the 
components constituting the complex tumor microenvironment (Fig. 1.14). 
Developing neoplasms often harbor an assorted population of inflammatory 
cells including lymphocytes and a diverse collection of leukocytes such as 
macrophages, dendritic cells, neutrophils, eosinophils and mast cells 
(Mantovani et al., 1992; Negus et al., 1997). These cells overexpress or secrete 
a myriad of inflammatory mediators including cytokines such as interleukins 
(IL) and tumor necrosis factor α (TNFα), enzymes such as cyclooxygenase-2 
(COX-2), inducible nitric oxide synthase (iNOS), proteases and matrix 
metalloproteinases (MMPs), prostaglandins such as prostaglandin E2 (PGE2), 
as well as cytotoxic mediators such as reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). The mechanisms by which these effectors 
may contribute to carcinogenesis include induction of genetic instability, 




membrane, as well as metastatic circulation and implantation of cancer cells 







Figure 1.14 Components of the tumor microenvironment. Tumor cells produce 
cytokines and chemokines that are mitogenic and serve as chemoattractants for 
inflammatory cells such as neutrophils, eosinophils, monocytes, macrophages, and 
mast cells, as well as fibroblasts and endothelial cells. These infiltrating cells secrete 
proteolytic enzymes, cytokines and chemokines, which facilitate cell proliferation, 
tumor growth, vascularization, invasion and metastatic spread of malignant cells. 
Figure adapted from Coussens & Werb, 2002. 
 
1.2.3.2 Biochemical mediators linking inflammation and cancer 
Cytokines  
Cytokines are intercellular signaling molecules that regulate several 
cellular processes such as growth, differentiation as well as inflammatory and 
immune responses. Cytokine signaling is effected by binding to cell-specific 
receptors followed by activation of kinases such as mitogen-activated protein 
kinases (MAPKs), inhibitor of NF-κB (IκB) kinases (IKKs), AKR mouse 
thymoma kinase (Akt), PI3K, Janus-activated kinase (JAK). This is in turn 
followed by activation of the downstream transcription factors such as NF-κB, 
activator protein-1 (AP-1), and signal transducer and activator of transcription 




TNFα is a cytokine with dual, antagonistic roles in carcinogenesis. 
While a high local concentration is selectively destructive to tumor 
vasculature, persistent production of TNFα induces angiogenesis and cell 
proliferation (Arnott et al., 2004; Morgan et al., 2008). Elevated levels of 
TNFα have been observed locally in several chronic inflammatory conditions 
such as inflammatory bowel disease and Helicobacter pylori infection, as well 
as in neoplasms of the breast, colorectum, bladder and prostrate (Leek et al., 
1998; Naylor et al., 1993). Its role as an endogenous tumor promoter is 
supported by the findings that mice deficient in TNFα or its receptor are less 
susceptible to development of skin cancer (Moore et al., 1999).  
 Interleukins such as IL-1 and IL-6 have also been implicated in 
inflammation-associated cancer (Suganuma et al., 2002). Biopsy samples of 
inflammation-associated gastric tumors revealed that levels of IL-1β and IL-6 
are higher in the neoplastic tissue than the surrounding normal tissue (Noach 
et al., 1994). The isoform IL-1α modulates genes involved in cell survival, 
proliferation and neovascularization, while IL-1β has been found to facilitate 
tumor invasiveness and metastasis. IL-6 alters the expression of genes 
involved in cell cycle and inhibition of apoptosis, and encourages anchorage-
independent growth of colon carcinoma cells (Kai et al., 2005). Studies have 
found that inhibition of IL-1β in mice results in reduced development of 
metastases, while Il-6-deficient mice are more resistant to development of 
melanoma, suggesting the involvement of these mediators in carcinogenesis 
(Vidal-Vanaclocha et al., 2000; von Felbert et al., 2005). 
Soluble chemotactic cytokines or ‘chemokines’ are involved in 




are also involved in proliferation, migration, invasion, systemic migration of 
tumor cells to distal organs and inhibition of apoptosis. 
COX-2 
Cellular levels of COX-2, the inducible form of cyclooxygenase, are 
elevated in response to diverse inflammatory stimuli such as cytokines, 
bacterial lipopolysaccharides (LPS), UV irradiation and ROS. The major 
biological function of COX-2 is the synthesis of prostaglandins, which bind to 
G-protein coupled receptors to produce a variety of effects depending on the 
cell type and tissue where they are synthesized.   
 Abnormally high levels of COX-2 at sites of chronic inflammation 
have been associated with increased risk of carcinogenesis. Overexpression of 
COX-2 in mice increases their susceptibility to develop malignant tumors, 
while mice deficient in Cox-2 are less prone to developing intestinal, breast or 
skin cancers (Muller-Decker et al., 2002; Tiano et al., 2002). Due to the 
association of increased COX-2 levels with the risk of tumorigenesis, 
administration of COX-2 inhibitors such as celecoxib has been evaluated as a 
cancer preventive strategy (Harris et al., 2000).  
iNOS and nitric oxide (NO) 
 NO is formed during the enzymatic conversion of L-arginine to 
citrulline by NOS isoforms. Expression of iNOS is increased in response to 
several external and endogenous stimuli, whereas the other two isoforms of 
NOS, endothelial NOS (eNOS) and neuronal NOS (nNOS), are constitutively 




cell-cell adhesion, cytokines, ROS, immune complexes, environmental pH, 
interferon-γ, and microbial products such as LPS (Bogdan, 2001). At low 
concentrations, NO acts as a signaling molecule usually through activation of 
guanylate cyclase and participates in biological functions such as vasodilation 
and neurotransmission. High concentrations of NO have been reported to exert 
growth inhibitory and cytotoxic effects on invading microbes and tumor cells. 
In contrast, a number of precancerous lesions and malignant tumors contain 
constitutively increased levels of iNOS (Aaltoma et al., 2001; Wilson et al., 
1998). Increased levels of NO and its highly reactive derivative peroxynitrite 
(ONOO
-
) have been found to promote inflammation-related carcinogenesis by 
inducing effects such as DNA damage, inhibition of DNA repair enzymes, 
promoting cell proliferation, resisting apoptosis, and enhancing angiogenesis 
and metastasis (Chen et al., 2006).  
1.2.3.3 The NF-κB signaling pathway in inflammation-linked 
carcinogenesis  
The NF-κB complex plays a central role in activation of immune and 
inflammatory responses. NF-κB family of transcription factors consist of 
protein dimers that bind to DNA sequences identified as the κB binding sites. 
NF-κB proteins are Rel homology domain containing proteins such as RelA 
(p65), RelB, c-Rel, p50, and p52.  Under normal conditions, the NF-κB 
proteins are sequestered in the cytoplasm by the inhibitory IκB proteins. The 
canonical pathway of NF-κB signaling (illustrated in Fig. 1.15) is triggered by 
a number of diverse stimuli including bacterial or viral products, oxidative 
stress and pro-inflammatory cytokines (Pahl, 1999), which leads to activation 




inhibitor via the ubiquitin-proteasome pathway. Degradation of IκB liberates 
the NF-κB proteins to translocate to the nucleus. The transcription factors are 
further phosphorylated in the nucleus that results in modulation of their 
transcriptional activities. Activated NF-κB induces expression of a broad panel 
of genes including genes regulating immune and inflammatory responses, 
apoptosis-inhibitory genes, genes promoting cell proliferation, and genes that 












Figure 1.15 Canonical pathway of NF-κB activation. Stimuli such as inflammatory 
cytokines, genotoxic stress and LPS activate the NF-κB signaling cascade by 
phosphorylation of IKKs, which in turn phosphorylate and direct IκB for proteasome-
mediated degradation. Loss of IκB proteins results in liberation and nuclear 
translocation of the NF-κB dimers that bind to the κB motifs and induce expression of 




There is ample evidence linking the activation of NF-κB in 
inflammation-associated cancer development. Activation of NF-κB is often 
observed in several cancers, including breast tumors, hepatocellular 
carcinoma, acute myelogenous leukemia, multiple myeloma, acute 
lymphoblastic leukemia and prostate cancer (Biswas et al., 2004; Feinman et 
al., 1999; Griffin, 2001; Kordes et al., 2000; Palayoor et al., 1999). Moreover, 
through upregulation of its target genes, NF-κB is able to induce several of the 
six essential cellular properties required for tumorigenesis as described by 
Hanahan and Weinberg (discussed in section 1.1.1). Hyperactivity of the NF-
κB family of transcription factors has been found to contribute to 
tumorigenesis by enhancing cell proliferation, inhibiting apoptosis and 
promoting angiogenesis, invasiveness and metastasis.  
Promoting tumor growth 
 Activation of the transcription factor NF-κB upregulates expression of 
cytokines such as IL-1, IL-6 and TNFα (Hiscott et al., 1993; Libermann & 
Baltimore, 1990; Shakhov et al., 1990), growth factors such as vascular 
endothelial growth factor (VEGF) (Chilov et al., 1997) and granulocyte 
macrophage-colony stimulating factor (GM-CSF) (Schreck & Baeuerle, 
1990), as well as chemokines such as IL-8, growth regulated oncogene α 
(GROα) (Anisowicz et al., 1991) and monocyte chemoattractant protein-1 
(MCP-1) (Ueda et al., 1994). These factors support development of neoplasms 
by promoting cell proliferation, neovascularization and tumor growth. 
Overproduction of proinflammatory mediators such as COX-2 and iNOS  
results in enhanced production of prostaglandins such as PGE2 and NO 




precancerous lesions and promote tumor growth (Hwang et al., 1997; Xie et 
al., 1994).   
Resisting apoptosis 
 Members of the IAP family such as IAP1, IAP-2, XIAP and survivin, 
as well as the B-cell lymphoma-2 (Bcl-2) family such as Bcl-xL are also 
regulated by NF-κB (Khoshnan et al., 2000; Stehlik et al., 1998; You et al., 
1997). The NF-κB signaling cascade acts as a pro-survival pathway by 
inducing expression of these anti-apoptotic proteins. In normal homeostatic 
tissues, cells that have undergone mutations or DNA damage would normally 
be eliminated by checkpoint control mechanisms. On the other hand, cells 
containing elevated levels of the apoptosis-inhibitory proteins are more likely 
to survive through such insults and may undergo carcinogenic transformation 
in the process. Induced expression of these proteins also renders the cells less 
sensitive to anticancer therapy, resulting in emergence of resistant tumors.   
Supporting invasion and metastasis 
 Increased expression of matrix metalloproteinases such as MMP-2 and 
MMP-9 coordinated by NF-κB (Yokoo & Kitamura, 1996) facilitates invasion 
through the stroma, whereas various chemokines assist in directing the tumor 
cells to remote sites. Upregulation of adhesion molecules such as intercellular 
adhesion molecule-1 (ICAM-1) (Van de Stolpe et al., 1994) and vascular cell 
adhesion molecule-1 (VCAM-1) (Iademarco et al., 1992) aid in relocation of 
the malignant cells in distal organs. Enhanced activation of NF-κB signaling in 





1.2.3.3.1 NF-κB-inhibition as a potential strategy in chemoprevention 
Owing to the role of chronic inflammation and NF-κB activation in 
emergence of neoplasms, therapies targeting inflammation by inhibition of the 
NF-κB signaling have been considered potential strategies for prevention and 
treatment of inflammation-related oncogenesis (Yamamoto & Gaynor, 2001). 
Inhibition of IKK activity, preventing IκB degradation and direct inhibition of 
NF-κB are possible approaches to inhibit the NF-κB pathway. Knockout of 
IKKβ in intestinal epithelial cells has been found to reduce the risk of 
carcinogenesis by 80% in a colitis-associated cancer mouse model (Greten et 
al., 2004). Inhibition of IKK and COX-2 by consumption of NSAIDs also 
decreases likelihood of developing rectal, gastric and colon cancers (Gupta & 
Dubois, 2001; Shishodia & Aggarwal, 2004; Yin et al., 1998). Other IKKβ 
inhibiting compounds include naturally occurring compounds such as 
flavonoids and curcuminoids (Bharti et al., 2003).  
Prevention of IκB degradation by treatment with proteasome inhibitors 
such as bortezomib has been found to inhibit proliferation of multiple 
myeloma cells and sensitize chemoresistant colorectal and lung cancer cell 
lines (Hideshima et al., 2002). Other strategies to prevent IκB degradation are 
inhibition of IκB phosphorylation by treatment with compounds such as 
BAY11-7082/7085, and inhibition of ubiquitin ligases specific for IκB 
ubiquitination (Dai et al., 2004). Direct inhibitors of NF-κB are not well 
studied. This class may include compounds that inhibit nuclear translocation 





1.3 Drug discovery from natural compounds 
Nature’s rich treasure of medicines has fascinated scientists and 
physicians since several centuries. Today, more than half of the drugs used 
clinically are derived from natural products (Cragg et al., 2009). Bioactive 
natural compounds are usually secondary metabolites that do not participate 
directly in growth and development of the plant. These chemicals are 
biosynthesized by the plant in response to environmental cues for specific 
functions such as cellular signaling, pollinator attraction, or as a defense 
strategy against insects and animals (Molinari, 2009). These natural 
compounds have undergone evolutionary selection to possess precise three-
dimensional structures containing functional groups in a well-defined spatial 
orientation that renders them suitable for binding to biological 
macromolecules (Paterson & Anderson, 2005). Additionally, these compounds 
are chemically adapted for compatibility with the aqueous milieu within the 
cellular microenvironment (Clardy & Walsh, 2004). Nevertheless, some of the 
reasons that prevent their application as therapeutic agents include lack of 
desirable potency, lack of selectivity for molecular targets, or undesirable 
pharmacokinetic profiles. A rational approach for discovering new drugs 
would be to use natural compounds as chemical scaffolds onto which 
functional groups can be added, removed or modified to obtain natural 
compound-like molecules that have been tailored to be used as therapeutics 






1.3.1 Trans-cinnamaldehyde (CA) 
CA occurs naturally in the 
bark of Cinnamomum zeylanicum and 
Cinnamomum cassia, commonly 
known as the spice cinnamon (Fig. 
1.16). CA is biosynthesized in plants 
by reduction of cinnamic acid, which 
is formed from phenylalanine through 
the shikkimic acid pathway (Wijesekera et al., 1974). CA constitutes 
approximately 75% of the volatile oil obtained from cinnamon bark and is 
considered to impart the aroma and flavor to cinnamon (Senanayake et al., 
1977). CA was first isolated from essential oil of cinnamon by Dumas and 
Peligot in 1834 while it was first synthesized in the laboratory by Chiozza in 
1854 (Swift, 1999).  
1.3.1.1 Biological properties of CA 
Health benefits of cinnamon have been identified since ancient times, 
and it was used as an herbal remedy in traditional medicine. In Ayurveda, 
cinnamon has been indicated for gastrointestinal, respiratory and 
gynecological disorders. Traditional Chinese medicine practitioners employed 
cinnamon as a warming herb to relieve wind chill and treat asthma caused due 
to cold (Barceloux, 2009). More recently, wide-ranging activities of cinnamon 
and its active component CA have been reported. These include anti-diabetic 
(Subash Babu et al., 2007), anti-bacterial (Shan et al., 2007), 
immunomodulatory (Koh et al., 1998), antiangiogenic (Kwon et al., 1997), 
Figure 1.16 Cinnamon bark. CA imparts 
the characteristic ‘cinnamon’ aroma and 
flavor to the spice. Image courtesy of 




CDK4/cyclinD1-inhibitory (Jeong et al., 2000), inhibitory effect against cell-
cell adhesion (Liao et al., 2008), cytotoxic (Moon & Pack, 1983), as well as 
cytoprotective properties (Moon et al., 2006). The biological activity of CA 
has been largely attributed to an α,β-unsaturated carbonyl group, also known 
as a Michael acceptor moiety (Fig. 1.17). Replacement of the carbonyl group 
or saturation of the side chain double bond results in loss of its biological 




Figure 1.17 Structure of CA. Circled region shows the Michael acceptor group.  
 
1.3.1.1.1 Anticancer potential of cinnamaldehydes  
Cytotoxic activity of CA was first reported by Moon and Pack (1983) 
against mouse leukemic cells. Lee et al. (1999) then reported that CA and its 
two analogs 2-hydroxycinnamaldehyde (HCA) and 2-
benzoyloxycinnamaldehyde (BCA) inhibited growth of twenty-nine human 
cancer cell lines. BCA is also shown to inhibit growth of human colon cancer 
cells in a mouse xenograft model without affecting proliferation of human 
smooth muscle cells as well as mouse fibroblasts, which underpins the 
selectivity of BCA towards cancer cells (Han et al., 2004). Subsequently, 
independent studies reporting the cytotoxic and growth inhibitory properties of 
CA and its analogs against cancer cells have attempted to unravel the 
molecular pathways and cellular events underlying their anti-proliferative 




induces apoptosis in human cervical cancer cells by a loss of mitochondrial 
membrane potential. In agreement with this study, Hong et al. (2007) found 
that apoptosis induced by analog HCA occurs through inhibition of 
proteasomal activity and subsequent mitochondrial perturbation. In another 
study by Lee et al. (2007), inhibition of AP-1 activity was proposed to be 
involved in apoptosis induction by HCA. Two independent studies have to 
date suggested that cinnamaldehydes exert their cytotoxic activities via ROS-
mediated apoptosis (Han et al., 2004; Ka et al., 2003). Inhibition of 
thioredoxin reductase was also reported as a mechanism underlying the 
antiproliferative properties of cinnamaldehydes (Chew et al., 2010).  
Some studies have reported inconsistent findings on the cellular events 
altered upon treatment with CA analogs. While Jeong et al. (2003) and Han et 
al. (2004) observed a G2/M phase arrest on treatment with cinnamaldehydes, 
Wu et al. (2005) and Cabello et al. (2009) observed S phase and G1 phase 
arrests respectively. Although the molecular and cellular events involved in 
apoptosis induction by cinnamaldehydes remain unclear and debatable, their 
pro-apoptotic activity has been consistently observed in vitro and in vivo 
against a wide array of cancer types. CA and its analogs therefore deserve 
investigation as potential anticancer agents.    
1.3.1.1.2 Chemopreventive potential of cinnamaldehydes  
In addition to the antitumor properties observed at pro-apoptotic doses, 
studies have also reported the cytoprotective and chemopreventive activities of 
cinnamaldehydes at sub-lethal concentrations. It has been found that long term 




developing hepatocellular carcinoma (Moon et al., 2006). CA and its analogs 
have also been found to increase Nrf2 levels in vitro in a range of cell lines, 
causing an upregulation of phase 2 enzymes (Huang et al., 2011; Wondrak et 
al., 2010). In another study, Wondrak et al. (2008) reported that treatment with 
CA protects skin fibroblasts from photooxidative stress by induction of phase 
2 enzymes via Nrf2. In addition to the cytoprotective activities, 
immunomodulatory effect of cinnamaldehydes has also been documented in 
recent studies that may contribute to its potential chemopreventive actions. CA 
inhibits LPS-induced proliferation of lymphocytes and modulates T-cell 
differentiation (Koh et al., 1998). Addtionally, CA has also been found to have 
a suppressive effect on TNF-α-induced NF-κB activation and LPS-induced 
secretion of pro-inflammatory cytokines through inhibition of MAP kinases 
(Liao et al., 2008).  
1.4 Aims of the Ph.D. project 
As highlighted in the previous section, CA exhibits a pleiotropic 
biological profile and its activities are majorly attributable to the side-chain 
propenal moiety that acts as a Michael acceptor. Despite its multiple activities, 
therapeutic potential of the naturally occurring CA is limited by its weak 
potency. To address this limitation, it was hypothesized that with respect to the 
antitumor and chemopreventive properties, analogs of CA and structurally 
related cinnamoyl-based compounds bearing substituents that potentiate 




Biological evaluation of the antitumor and chemopreventive properties 
of cinnamoyl-based compounds was performed. Cellular events and molecular 
mechanisms associated with these properties were also investigated.  
As such, aims set out for the project were: 
1) To evaluate a series of ortho-substitued CA analogs against cancer 
cells and identify lead compounds possessing potent antiproliferative 
and cytotoxic activities. 
2) To investigate cellular events and/or molecular mechanism(s) 
underlying the antitumor properties of lead cinnamaldehydes.  
3) To evaluate the chemopreventive potential of CA analogs by studying 
their ability to induce the Nrf2-mediated cytoprotective response and 
their anti-inflammatory properties.  
4) To evaluate a series of cinnamoyl-based compounds, conventionally 
called ‘supercinnamaldehydes’, for their cytoprotective and anti-
inflammatory properties and identify lead compounds possessing 
potent activities.  








CHAPTER 2  
 





Materials and antibodies with their suppliers are enlisted in Table 2.1 and 
Table 2.2 respectively. 




Sigma Aldrich (St. Louis, MO, USA)  
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 
Sigma Aldrich (St. Louis, MO, USA) 
5,5'-dithiobis-(2-nitrobenzoic 
acid) (DTNB) 
Sigma Aldrich (St. Louis, MO, USA) 
Acrylamide/bis-acrylamide 40% 
solution 37.1:1  
Bio-Rad Laboratories (Hercules, CA, USA)  
Agarose  Invitrogen (Carlsbad, CA, USA) 
Ammonium persulfate (APS) Sigma Aldrich (St. Louis, MO, USA) 
Ampicillin Sigma Aldrich (St. Louis, MO, USA) 
β-mercaptoethanol Bio-Rad Laboratories (Hercules, CA, USA) 
Bacto
TM
 agar BD (Franklin Lakes, NJ, USA) 
Bacto
TM 
tryptone BD (Franklin Lakes, NJ, USA) 
Bacto
TM
 yeast extract BD (Franklin Lakes, NJ, USA) 
Bicinchoninic acid protein assay kit Thermo Scientific (Rockford, IL, USA) 
Biotinylated iodoacetamide (BIAM) Sigma Aldrich (St. Louis, MO, USA) 
Bovine serum albumin (BSA) Thermo Scientific (Rockford, IL, USA) 
Bradford Dye Reagent Concentrate Bio-Rad Laboratories (Hercules, CA, USA) 
Calcium chloride  Sigma Aldrich (St. Louis, MO, USA) 
Cinnamic acid (CAC) Sigma Aldrich (St. Louis, MO, USA) 
CL-Xposure® X-ray films Thermo Scientific (Rockford, IL, USA) 
Commassie Brilliant blue R-250 Bio-Rad Laboratories (Hercules, CA, USA) 
Dimethylsulfoxide (DMSO) Fisher Scientific (Loughborough, UK),  
Sigma Aldrich (St. Louis, MO, USA) 
DMEM medium (high glucose) Sigma Aldrich (St. Louis, MO, USA) 
Doxorubicin hydrochloride Sigma Aldrich (St. Louis, MO, USA) 
Dual Luciferase® Reporter assay 
system  
Promega (Madison, WI, USA) 
DuoSet ELISA Development kit R&D systems (Minneapolis, MN, USA) 
Enhanced Chemilumenescence 
western blotting kit 
Perkin Elmer (Waltham, MA, USA) 
Thermo Scientific (Rockford, IL, USA) 
Ethylenediamine tetracetic acid 
(EDTA) 
Merck (Darmstadt, Germany) 
Ethylene glycol-bis(β-
aminoethylether)-N,N,N’,N’-
tetraacetic acid (EGTA) 
MP Biomedicals (Solon, OH,USA) 
Fetal Bovine Serum (FBS) HyClone Laboratories (Logan, UT, USA) 
GeneJuice® transfection reagent Novagen (Gibbstown, NJ, USA) 
Glycerol Fluka Biochemika (Buchs, Switzerland) 
Glycine 1
st
 Base (Singapore) 
Griess reagent  Fluka Biochemika (Buchs, Switzerland) 
Guanosine triphosphate (GTP) Sigma Aldrich (St. Louis, MO, USA) 






L-glutamine HyClone Laboratories (Logan, UT, USA) 
Laemmli sample buffer (2x) Bio-Rad Laboratories (Hercules, CA, USA) 
Lipopolysaccharides (LPS) from 
E.coli 
Sigma Aldrich (St. Louis, MO, USA) 
Low melting agarose Pronadisa (Madrid, Spain) 
Magnesium Chloride  Sigma Aldrich (St. Louis, MO, USA) 
Methanol Fisher Scientific (Loughborough, UK) 
N,N,N’,N’-tetramethylene 
ethyldiamine (TEMED) 
Calbiochem (Gibbstown, NJ, USA) 
Nitrocellulose membrane Bio-Rad Laboratories (Hercules, CA, USA) 
Paclitaxel Sigma Aldrich (St. Louis, MO, USA) 
Pageruler
TM 
prestained protein ladder  Fermentas (Glen Burnie, MD, USA) 
Paraformaldehyde Sigma Aldrich (St. Louis, MO, USA) 
Penicillin-Streptomycin PAN Biotech GmbH (Aidenbach, Germany) 
Phosphate buffered saline (PBS) 1
st
 Base (Singapore) 
Poly-L-lysine 1% w/v solution Sigma Aldrich (St. Louis, MO, USA) 
Porcine tubulin  Cytoskeleton (Denver, CO, USA) 
Propidium iodide Sigma Aldrich (St. Louis, MO, USA) 
Protease inhibitor cocktail tablets Roche Diagnostics (Manheim, Germany) 
Protein G Sepharose
TM
 beads  Amersham Biosciences (Uppsala, Sweden) 
Qiaprep miniprep spin kit Qiagen GmbH (Hilden, Germany) 
Ribonuclease A (RNAseA) Sigma Aldrich (St. Louis, MO, USA) 
RPMI 1640 medium GIBCO (Grand Island, NY, USA) 
Sodium β-glycerophosphate Sigma Aldrich (St. Louis, MO, USA) 
Sodium bicarbonate  MP Biomedicals (Solon, OH,USA) 
Sodium citrate BDH Chemicals (Poole, UK) 
Sodium chloride 1
st
 Base (Singapore) 
Sodium dodecyl sulfate (SDS) 1
st
 Base (Singapore) 
Sodium hydroxide Kanto Kagaku (Singapore) 
Sodium fluoride Sigma Aldrich (St. Louis, MO, USA) 
Sodium orthovanadate MP Biomedicals (Solon, OH, USA)  
Sodium pyrophosphate Sigma Aldrich (St. Louis, MO, USA) 
Sodium pyruvate GIBCO (Grand Island, NY, USA) 
Streptavidin-horseradish peroxidase 
(Streptavidin-HRP) 
Biosource International (Camarillo, TX,USA) 
Sucrose  Sigma Aldrich (St. Louis, MO, USA) 
Trans-cinnamaldehyde  Sigma Aldrich (St. Louis, MO, USA) 
Tris 1
st
 Base (Singapore) 
Triton X-100 USB (Cleveland, OH, USA) 
Trypsin/EDTA (1x) GIBCO (Grand Island, NY, USA) 
Tween 20 Sinopharm Chemical Reagent Co. Ltd 
(Shanghai, China) 
X-ray developer Konica Minolta Holdings (Tokyo, Japan) 
X-ray fixer Konica Minolta Holdings (Tokyo, Japan) 







Table 2.2 List of antibodies  
Antibody Supplier 
anti-β-actin Santa cruz biotechnology (Santa cruz, CA, USA) 
anti-β-tubulin Sigma Aldrich (St. Louis, MO, USA) 
anti-caspase-3 Cell signaling technology (Danvers, MA, USA) 
anti-cdc20 Cell signaling technology (Danvers, MA, USA) 
anti-cdc25C Cell signaling technology (Danvers, MA, USA) 
anti-cdk1 Cell signaling technology (Danvers, MA, USA) 
anti-cleaved caspase-3 Cell signaling technology (Danvers, MA, USA) 
anti-COX-2 Santa cruz biotechnology (Santa cruz, CA, USA) 
anti-cyclinB1 Cell signaling technology (Danvers, MA, USA) 
anti-Flag Sigma Aldrich (St. Louis, MO, USA) 
anti-GCLC Santa cruz biotechnology (Santa cruz, CA, USA) 
anti-γ-GCL Santa cruz biotechnology (Santa cruz, CA, USA) 
anti-GSTA1 obtained from Dr. John D. Hayes’ laboratory 
(Ninewells Hospital and Medical School, 
University of Dundee, Dundee, UK) 
anti-HA Roche Diagnostics (Manheim, Germany) 
anti-HO-1 Stressgen (San Diego, CA, USA) 
anti-IκBα Cell signaling technology (Danvers, MA, USA) 
anti-IKKα Cell signaling technology (Danvers, MA, USA) 
anti-IKKβ Cell signaling technology (Danvers, MA, USA) 
anti-iNOS Santa cruz biotechnology (Santa cruz, CA, USA) 
anti-mad2 Santa cruz biotechnology (Santa cruz, CA, USA) 
anti-MMP-9 R&D systems (Minneapolis, MN, USA) 
anti-NQO1 Santa cruz biotechnology (Santa cruz, CA, USA) 
anti-Nrf2 Santa cruz biotechnology (Santa cruz, CA, USA) 
anti-p21 BD biosciences (San Jose, CA, USA) 
anti-p65 Cell signaling technology (Danvers, MA, USA) 
anti-PARP Cell signaling technology (Danvers, MA, USA) 
anti-phospho-cdc25C (Ser216) Cell signaling technology (Danvers, MA, USA) 
anti-phospho-cdk1 (Tyr15) Cell signaling technology (Danvers, MA, USA) 
anti-phospho-cyclinB1 (Ser133) Cell signaling technology (Danvers, MA, USA) 
anti-phospho-histone H2AX Cell signaling technology (Danvers, MA, USA) 
anti-phospho-histone H3 Cell signaling technology (Danvers, MA, USA) 
anti-phospho-IKKα/β Cell signaling technology (Danvers, MA, USA) 
anti-phospho-p65 Cell signaling technology (Danvers, MA, USA) 
anti-survivin Epitomics (Burlingame, CA, USA) 
anti-TNFα Calbiochem (Gibbstown, NJ, USA) 
Alexa fluor 488 conjugated goat 
anti-mouse IgG 
Molecular Probes (Eugene, OR, USA) 
Alexa fluor 488 conjugated goat 
anti-rabbit IgG 
Molecular Probes (Eugene, OR, USA) 
Alexa flour 594 conjugated goat 
anti-rabbit IgG 
Molecular Probes (Eugene, OR, USA) 
HRP conjugated goat anti-mouse 
IgG 
Thermo Scientific (Rockford, IL, USA) 
HRP conjugated goat anti-rabbit 
IgG 







2.2.1 General cell culture 
Cell culture procedures were performed in a class II biological safety 
cabinet. The HCT 116 p21-/- cell line was obtained from Dr. Bert Vogelstein 
(Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA), whereas the 
wild-type (WT) and Keap1-/- mouse embryonic fibroblasts (MEFs) were 
acquired from Dr. John D. Hayes (Ninewells Hospital And Medical School, 
University of Dundee, Dundee, UK). HCT 116 WT, HCT 116 p21-/- and 
MCF-7 cells were maintained in RPMI 1640 medium (containing 2 g/L 
sodium bicarbonate). HEK-293 cells and RAW 264.7 cells were maintained in 
DMEM medium (containing 4500 mg/L glucose and 3.7 g/L sodium 
bicarbonate). DMEM medium for HEK-293 cells was supplemented with 100 
mg/L sodium pyruvate. WT and Keap1-/- MEFs were maintained in IMDM 
medium (containing 2 g/L sodium bicarbonate). For WT and Keap1-/- MEFs, 
tissue culture plates were coated with 1% w/v gelatin solution overnight prior 
to culturing. MRC-5 cells were maintained in MEM medium (containing 2.2 
g/L sodium bicarbonate). All media were supplemented with 100 units/ml 
penicillin, 1 μg/ml streptomycin, 0.3 g/L L-glutamine and 10% v/v heat-
inactivated fetal bovine serum (FBS). For heat inactivation, FBS was 
incubated in a water bath at 56 ºC for 1 h. Cells were sub-cultured once they 
were 80-90% confluent. HCT 116 WT, HCT 116 p21-/-, MCF-7, HEK-293, 
MRC-5 cells were grown in T75 tissue culture flasks while WT and Keap1-/- 
MEFs were cultured in 100-mm plates. For sub-culturing, spent culture 
medium in the flask/plate was discarded and the cell monolayer was rinsed 




trypsin/EDTA 1x solution was applied onto the cell monolayer and the 
flask/plate was incubated at 37 ºC for 3-5 min until the cells had detached. 
Cells were resuspended in 10 ml of medium and 1-3 ml of this cell suspension 
was transferred to a T75 flask/100-mm plate containing 10-13 ml of culture 
medium. RAW 264.7 cells were maintained in 100 mm plates. To sub-culture 
RAW 264.7 cells, culture medium from the plate was discarded and cells were 
detached from the surface using a cell scraper. Detached cells were re-
suspended in 3 ml of culture medium and 1 ml of this medium was transferred 
to a new 100-mm plate containing 10 ml of culture medium. All cells were 
maintained at 37 ºC in a humidified atmosphere of 95 % air and 5 % CO2. To 
minimize phenotypic alterations, cells were not cultured for more than 3 
months. Frozen cells were revived from stocks in liquid nitrogen by rapid 
thawing at 37 ºC in a water bath and culturing in a T25 flask containing 7 ml 
of culture medium. For long-term storage, cells from maintenance cultures 
were pelleted and re-suspended in vials with 90% culture medium and 10% 
DMSO. Vials were placed in freezing container (for 1 ºC cooling per min) and 
stored at –80 ºC for 1 week and then transferred to a liquid nitrogen tank.           
2.2.2 Preparation of drug stocks 
All compounds except cinnamaldehyde (CA) were weighed accurately 
and dissolved in DMSO to prepare 200 µl of 50 mM solutions. Drug stocks 
were divided into 4-5 aliquots (to avoid repeated freeze thawing) and stored at 
–20 ºC for up to 1 year. CA stocks were prepared fresh each time to make 100 





2.2.3 MTT cell viability assay  
The effect of compounds on cell viability was assessed by viable cell-
mediated reduction of MTT to purple formazan. Cells harvested from T75 
flasks were syringed through a 23G needle to obtain a single cell suspension. 
Cells were counted using a haemocytometer and diluted with culture medium 
to achieve required cell densities (HCT 116: 3000 cells per well, MCF-7: 4000 
cells per well, MRC-5: 6000 cells per well, HEK-293: 12000 cells per well). 
Cell suspensions were added to 96-well plates (180 µl per well) and allowed to 
grow for 24 to 48 h until they reached approximately 60-70% confluence. A 
separate time zero (T0) plate seeded with two columns each of all cell lines 
was also cultured along with other plates. Drugs were serially diluted in 
culture medium from DMSO stocks immediately before treatment and 20 µl 
aliquots of these diluted solutions were added to the wells to achieve the 
desired concentrations. To control wells and T0 plates, 20 µl of medium was 
added to each well. The drug-treated plates were incubated at 37 ºC for 72 h 
following which 50 µl of MTT solution (2 mg/ml, final concentration 0.4 
mg/ml) was added to each well. To the T0 plate, 50 µl of MTT was added at 
the time of drug addition. After MTT addition, the plates were incubated at 37 
ºC for 4 h. The medium was aspirated and the purple formazan crystals formed 
from MTT were solubilized in 150 µl of DMSO:glycine buffer pH 10.5 (4:1). 
Plates were shaken for 15 min to ensure complete solubilization and 
absorbance was measured at 550 nm. To calculate concentrations required for 
50% growth inhibition (GI50) and 50% lethal concentration (LC50) a dose-




550 nm versus drug concentration (µM). The GI50 and LC50 values were 
computed using the following equations: 
GI50 (µM) =     (OD1 – OD at GI50) (C2 – C1)   +   C1 
       OD1 – OD2  
Where, 
OD at GI50 = (ODControl – OD at T0) + OD at T0 
                            2 
C1, C2 = concentrations of drug such that C2 > GI50 > C1 and  
OD1, OD2 = absorbance at C1 and C2 respectively such that OD1 > OD 
at GI50 > OD2 
                 
LC50 (µM) =    (OD3 – OD at LC50) (C4 – C3)   +   C3 
            OD3 – OD4  
Where, 
OD at LC50 =  OD at T0 
                     2 
C3, C4 = concentrations of drug such that C4 > GI50 > C3 and  
OD3, OD4 = absorbance at C3 and C4 respectively such that OD3 > OD 
at LC50 > OD4 
2.2.4 Soft agar assay 
Soft agar assay was performed to evaluate whether CA analogs were 
able to retard colony formation of cancer cells in anchorage-independent 
cultures. A semi-solid top layer containing cell suspension was layered on to a 
pre-solidified bottom layer which prevented cells from attaching to the surface 
of the plate. The bottom layer was prepared by mixing 9 ml of 2x RPMI 1640 
medium, 8 ml agarose solution (1.25 % w/v, final concentration 0.5 % w/v), 2 




this mixture was added to each well of a 6-well plate and allowed to solidify 
for about 10 min. HCT 116 and MCF-7 cells were harvested from T75 flasks 
and single-cell suspensions were obtained by syringing through a 23 G needle. 
Cells counts were determined and cells were suspended in RPMI 1640 
medium at densities of 3104 and 5104 cells per 0.6 ml suspension for HCT 
116 and MCF-7 cells respectively. Appropriate volumes of drug stocks (to 
achieve desired final concentrations in 1.8 ml of top layer) or DMSO were 
also added to the cell suspension. The semi-solid medium for top layer was 
prepared by mixing 2.5 ml of 2x RPMI 1640 medium, 4 ml low melting 
agarose (1.25% w/v, final concentration 0.5% w/v), 1 ml FBS and 0.5 ml 
sterile water. Top layer was prepared by combining 2 parts of this semi-solid 
medium with 1 part of cell suspension (1.2 ml semi-solid medium plus 0.6 ml 
cell suspension per well) and layered onto the bottom layer (1.8 ml per well). 
The plates were incubated at 37 °C in a humidified atmosphere containing 5% 
CO2 for two weeks without addition of fresh medium. Edges of the plates were 
loosely wrapped with parafilm to minimize evaporation. Cell colonies of size 
bigger than or equal to 0.1 mm were enumerated at 10x magnification using a 
Nikon Eclipse TE2000-U microscope (Tokyo, Japan). Representative 
photomicrographs were taken using a Nikon Digital Camera DXM1200 
connected to the microscope.   
2.2.5 Cell cycle analysis 
Cell cycle distribution profiles of HCT 116 cells were studied by 
analysing the cellular DNA content using flow cytometry. HCT 116 cells were 
harvested from T75 flasks and the cell count of the single cell suspension was 




seeded in 6-well plates at a density of 5105 cells per well in 2 ml culture 
medium. Cells were incubated at 37 °C for 24 h to 36 h before drug treatment 
to allow attachment and exponential growth. Following drug treatment, 
medium containing floating cells was collected in a tube and attached cells 
were washed with ice-cold PBS. Attached cells were dislodged by adding 0.2 
ml trypsin/EDTA 1x solution per well followed by incubating the plates at 37 
ºC for 3-5 min. After detachment, cells were resuspended in the medium 
containing floating cells. The samples were centrifuged at 1200 rpm for 5 min 
at 4 ºC. Pelleted cells were washed with PBS and resuspended in 500 µl of 
hypotonic fluorochrome solution (50 µg/ml propidium iodide (PI), 0.1% 
sodium citrate, 0.1% Triton X-100, and 0.1 mg/ml RNase A). The cells were 
incubated overnight at 4 C protected from light. Samples were analyzed on a 
Beckman Coulter (Dako) CyAn ADP flow cytometer and data analysis was 
performed using Summit Software v4.3. 
2.2.6 Immunocytochemistry 
To plate HCT 116 WT or HCT 116 p21-/- cells on coverslips, sterile 
coverslips were placed in wells of 6-well plates and incubated with 0.01% w/v 
poly-L-lysine solution for 10 min. The poly-L-lysine solution was then 
removed and coverslips were allowed to air-dry inside the biosafety cabinet. 
Single cell suspensions of HCT 116 WT or p21-/- cells were then seeded in 
the 6-well plates containing coverslips at a density of 5105 cells per well. The 
plates were incubated at 37 °C for 24 h to 36 h until cells were 60-70% 
confluent for experiments carried out to detect phospho-histone H3 and 




experiments. Drug treatment was performed once the required cellular 
confluence was achieved. Following treatment, the culture medium was 
discarded and cells were fixed by incubating with 4% paraformaldehyde for 
10 min with gentle shaking. Fixed cells were washed once with ice-cold PBS 
and stored in PBS at 4 °C (for up to 1 week). For immunolabeling, cells were 
washed 3 x 5 min with PBS-T (PBS with 0.05 % Tween 20) and 
permeabilized using 0.2% Triton X-100 in PBS for 10 min followed by 3 x 5 
min washes with PBS-T. To minimize non-specific binding, permeabilized 
cells were blocked with 5% horse serum in PBS-T for 1 h and washed 3 x 5 
min with PBS-T. Cells were then incubated with primary antibody against 
protein of interest (anti-phospho-histone H3, anti-β-tubulin or anti-γ-H2AX 
antibody) followed by incubation with Alexa Fluor 594-conjugated anti-rabbit 
IgG (for anti-phospho-histone H3) or Alexa Fluor 488-conjugated anti-mouse 
IgG (for anti-β-tubulin and anti-γ-H2AX). Both primary and secondary 
antibodies were used at a dilution of 1:1000 in PBS-T containing 1% horse 
serum, and the cells were washed 3 x 5 min between probing with primary and 
secondary antibodies to minimize non-specific binding. The plates were gently 
shaken during incubation to allow even distribution of the antibodies on the 
coverslips. Immunolabeled coverslips were mounted on glass slides using 
Vectashield mounting medium containing 4',6-diamidino-2-phenylindole 
(DAPI) to counterstain the nuclei. Edges of the coverslips were sealed onto the 
slide using clear nail polish. Microscopic images were obtained using a Nikon 
Eclipse Ti-S epifluorescence microscope connected to a Nikon DS-Ri1 camera 
at 40x magnification for cells labelled by antibodies against phospho-histone 




quantify cells stained by anti-phospho-histone H3 antibody, results were 
expressed as a percentage of cells co-labelled with DAPI and Alexa Fluor 594 
over cells stained with only DAPI in a total of six microscopic images taken 
from random spots on the immunolabelled coverslips. Results were 
representative of three independent experiments. 
2.2.7 Treatment with test compounds and cell lysate collection 
2.2.7.1 Analysis of cell cycle proteins in HCT 116 cells 
HCT 116 cells were cultured in 100-mm tissue culture plates at a 
seeding density of 1.5×10
6
 cells per plate and incubated for 24 h to 36 h to 
allow for exponential growth before treatment with cinnamaldehydes. To 
study the dose-dependent effect of the compounds, four concentrations and 
two timepoints (12 h and 24 h) were investigated, whereas for the time-
dependent studies, one concentration of each drug and seven timepoints (0 h, 3 
h, 6 h, 10 h, 16 h, 24 h and 36 h) were employed. To study the effect of GJ23 
on cells in the presence of a pan caspase inhibitor, cells were pre-treated with 
50 µM Z-VAD-FMK for 1 h and then treated with 10-40 µM of GJ23 for 16 h. 
Following drug treatment, adherent and floating cells were pelleted, washed 
with ice-cold PBS and lysed in 200-400 µl Triton X-100 lysis buffer (25 mM 
Tris-HCl pH 7.5, 100 mM NaCl, 2.5 mM EGTA, 2.5 mM EDTA, 20 mM 
NaF, 1 mM Na3VO4, 10 mM sodium pyrophosphate, 20 mM sodium β-
glycerophosphate, 0.5% Triton X-100, containing freshly added protease 





2.2.7.2 Analysis of soluble and insoluble tubulin fractions in HCT 116 
cells 
HCT 116 cells were plated in 60-mm tissue culture plates at a seeding 
density of 7×10
5
 cells per plate, and incubated at 37 °C for 24 h. Following 
drug treatment for 16 h, medium containing floating cells was collected into a 
tube while attached cells were trypsinized. Floating and attached cells were 
pooled and pelleted by centrifuging at 1200 rpm, 5 min, 4 °C. Cell pellet was 
washed in ice-cold PBS and cells were lysed in 250-300 µl Triton X-100 lysis 
buffer To separate the soluble and insoluble tubulin fractions, lysates were 
centrifuged at 13000 rpm for 10 min at 4 °C. Supernatant containing the 
soluble tubulin fraction was collected in a separate microtube and the pellet 
containing the insoluble tubulin fraction was solubilized in 50-100 µl SDS 
lysis buffer (65 mM Tris-HCl pH 7.5, 150 mM NaCl, 2% SDS). The insoluble 
tubulin fraction was sonicated 2 x 5 sec pulses using a probe sonicator. Protein 
contents of the soluble tubulin fractions were determined using Bradford assay 
while that of the insoluble tubulin fractions were analyzed using bicinchoninic 
acid assay kit according to manufacturer’s instructions. 
2.2.7.3 Analysis of total tubulin in HCT 116 cells 
HCT 116 cells (7×10
5
) were seeded in 60-mm tissue culture dishes and 
incubated at 37 °C for 24 h before drug treatment. Cycloheximide (CHX) was 
added as a protein synthesis inhibitor along with the drugs to investigate the 
effect of BCA on tubulin degradation. Cells were treated with 40 µM CHX 
and 30 µM BCA for 4 h, 8 h, 12 h, 16 h and 24 h. After treatment, medium 




and pooled together with the floating cells. Cells were pelleted by centrifuging 
at 1200 rpm, 5 min, 4 °C. Cell pellet was washed in ice-cold PBS and lysed in 
SDS lysis buffer (150 µl). Protein content of the lysates was analyzed using 
bicinchoninic acid assay kit.   
2.2.7.4 Analysis of Nrf2 and phase 2 enzymes induction in HEK-293, HCT 
116 WT and HCT 116 p21-/- cells  
HEK-293, HCT 116 WT or p21-/- cells were cultured in 6-well plates 
and allowed to grow to 90-100% confluence. Drugs to be tested were added to 
the cells and plates were incubated at 37 °C. For experiments involving Nrf2 
analysis, HEK-293 cells were treated for 3 h, while HCT 116 WT and p21-/- 
cells were treated for 3 h and 6 h. For phase 2 enzymes, HEK-293, HCT 116 
WT and p21-/- cells were incubated with test compounds for 14 h. The culture 
medium was aspirated from the plates, and the cells were rinsed with ice-cold 
PBS. Triton X-100 lysis buffer (150-300 µl) was added to the cells and the 
collected lysates were stored at –20 °C until further analysis.  
2.2.7.5 Analysis of protection against doxorubicin in HEK-293, HCT 116 
WT and HCT 116 p21-/- cells  
HEK-293, HCT 116 WT and HCT 116 p21-/- cells were cultured in 6-
well plates and allowed to grow to 90-95 % confluence. Cells were treated 
with 5 µM and 10 µM concentrations of BCA or with vehicle DMSO for 12 h. 
Each treatment was performed in duplicates. After 12 h, one of the two wells 
for each treatment was challenged with doxorubicin (2 µg/ml) to induce DNA 
damage and incubated for another 12 h. The culture medium was then 




PBS. Triton X-100 lysis buffer (250-300 µl) was added to the cells and the 
lysates collected were stored at –20 °C until further analysis. 
2.2.7.6 Analysis of Nrf2 and phase 2 enzymes induction in WT and 
Keap1-/- MEFs  
WT and Keap1-/- MEFs were harvested from their cultures, seeded in 
6-well plates and incubated at 37 °C until approximately 90% confluent. 
Culture medium was aspirated and cells were replenished with fresh medium 6 
to 8 h before treatment. Cells were treated with drugs for 3 h (for Nrf2) or 16 h 
(for downstream enzymes). For cell lysis, the medium was aspirated and cells 
were washed once with ice-cold PBS followed by addition of Triton X-100 
lysis buffer (150-200 µl). Cells were scraped using a cell scraper and lysates 
were stored at –20 °C until further analysis. 
2.2.7.7 Analysis of iNOS, COX-2 and protein components of the NF-κB 
pathway in RAW 264.7 cells 
RAW 264.7 cells were seeded in 6-well plates and allowed to grow for 
24 h to 36 h until 80% confluence was achieved. The medium in the culture 
plates was replaced with serum-free medium 12 h prior to treatment. The cells 
were pre-treated with drugs for 1 h prior to induction of inflammatory 
conditions by adding 500 ng/ml LPS. Cells were lysed at 30 min (for NF-κB 
pathway) or 20 h (for iNOS, COX-2) post-treatment with LPS. Medium from 
the cells was aspirated, and cells were washed with ice-cold PBS. Triton X-
100 lysis buffer (180-200 µl) was added and the cell monolayer was scraped 
using a cell scraper to aid cell lysis. Lysates were collected in microtubes and 




2.2.8 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting 
Cell lysates frozen at –20 °C were thawed at 4 °C and pre-cleared by 
centrifugation at 13000 rpm, 10 min, 4 °C to remove cell debris and other 
insoluble components. Protein content of all lysates was determined using the 
Bradford protein assay except for insoluble and total tubulin lysates, which 
were analysed by bicinchoninic acid protein assay as the lysis buffer 
containing SDS was incompatible with Bradford reagent. 
2.2.8.1 Bradford assay 
The 5x Bradford reagent was diluted to 1x with distilled water. In a 
cuvette, 1 to 2 µl of cell lysate was added to 1 ml of 1x Bradford reagent and 
absorbance was measured at 595 nm using an Ultrospec 2100 pro UV/Vis 
spectrophotometer (Amersham Biosciences). Readings were measured in 
duplicates for each sample and mean absorbance was determined. A standard 
plot was obtained for a range of BSA concentrations (0.5-4 µg/ml). Protein 
concentrations in cell lysates were then calculated based on the linear equation 
derived from the standard plot.  
2.2.8.2 Bicinchoninic acid protein assay 
The protein content of insoluble tubulin fraction and total tubulin were 
determined using the bicinchoninic acid assay kit as per the manufacturer’s 
instructions. Working reagent for the assay was prepared by mixing 50 parts 
of Reagent A with 1 part of Reagent B. 200 µl of working reagent was added 




lysates or 25 µg/ml to 2 mg/ml of BSA solutions were added and the plate was 
incubated at 37 °C for 30 min. The plate was shaken constantly during 
incubation to ensure thorough mixing. After incubation, absorbance was 
measured at 562 nm and protein concentrations in lysates were calculated 
from the standard plot obtained from absorbance readings of BSA standard 
solutions.   
2.2.8.3 SDS-PAGE 
Proteins contained in the cell lysates were resolved using SDS-PAGE. 
Resolving gels containing 10, 12 or 15% w/v acrylamide and stacking gels 
containing 4% acrylamide were prepared by using the following formulae: 
Table 2.3 Formulae for resolving and stacking gel solutions 
Ingredient 
Resolving gel solution 
Stacking gel 
solution 
10% 12% 15% 4% 
40% acrylamide:bisacrylamide 
(37.1:1) 
2.5 ml 3 ml 3.75 ml 0.5 ml 
Resolving gel buffer (1.5 M 
Tris, 0.4% w/v SDS, pH 8.8) 
2.5 ml 2.5 ml 2.5 ml - 
Stacking gel buffer (0.5 M 
Tris, 0.4% w/v SDS, pH 6.8) 
- - - 1.25 ml 
Distilled water 5 ml 4.5 ml 3.75 ml 3.25 ml 
10% w/v APS 50 µl 50 µl 50 µl 30 µl 
TEMED 7.5 µl 7.5 µl 7.5 µl 4 µl 
 
All reagents required for resolving gel were mixed and approximately 
8 ml of the resolving gel solution was quickly poured into the casting cassette. 
An overlay of distilled water was applied onto the surface of the gel solution. 
The gel was allowed to polymerize for about 20 min after which the layer of 
distilled water was discarded. Stacking gel solution was then poured over the 
resolving gel contained in the casting cassette. A 10- or 15-well comb was 




samples and allowed to polymerize for 20 min. For both resolving and 
stacking gels, APS and TEMED were added immediately before pouring the 
solution in the casting assembly to avoid premature polymerization. Once the 
stacking gel had polymerized, the comb was removed and the gel along with 
the casting cassette was placed in an electrophoresis tank containing running 
buffer. 
Cell lysates containing equal amounts of proteins (30-50 µg) were 
diluted 1:1 with 2x Laemmli sample buffer (62.5 mM Tris HCl, 25% glycerol, 
2% SDS, and 0.02% bromophenol blue, pH 6.8) containing β-mercaptoethanol 
(final concentration 5% v/v) and boiled for 10 min at 95 °C. The samples were 
cooled to room temperature and quick spun for 5 sec before loading into the 
wells in the stacking gel.  
Proteins were separated according to their molecular weights at a 
constant voltage of 100-120 V in a running buffer containing 25 mM Tris HCl, 
192 mM glycine and 0.1% SDS. After separation, the proteins were 
transferred overnight onto nitrocellulose membranes under constant voltage of 
25 V in an ice-cold transfer buffer containing 25 mM Tris HCl, 192 mM 
glycine and 20% v/v methanol. 
2.2.8.4 Western blotting 
The transblotted membrane was blocked with 10% w/v non-fat dry 
milk in TBS-T (137 mM NaCl, 3 mM KCl, 25 mM Tris HCl pH 7.4 
containing 0.05% v/v Tween 20) for 1 h at room temperature, washed 3 x 5 
min with TBS-T followed by incubation with primary antibody (at dilutions of 
1:2000 to 1:7500 in TBS-T) for 2-3 h at room temperature or up to overnight 




membrane was incubated with secondary antibody conjugated to HRP at a 
1:10000 dilution in TBS-T containing 5% non-fat dry milk for 1-2 h at room 
temperature. The membrane was again washed 3 x 5 min with TBS-T to 
remove any unbound antibody. All membranes were also probed with anti-β-
actin antibody along with proteins of interest to ensure equal protein loading. 
2.2.8.5 Enhanced Chemiluminescence (ECL) reaction 
The transblotted proteins of interest were detected by applying equal 
volumes of reagent 1 and 2 of the ECL system (total volume 600-800 µl) to 
the membrane, capturing the emitted chemiluminescence onto CL-Xposure® 
X-ray films and developing the films using a Konica Minolta film developer.  
2.2.9 Biotinylated iodoacetamide (BIAM) assay  
To investigate the interaction of tubulin with cinnamaldehydes, 
sulfhydryl groups of tubulin were labeled with BIAM after incubation with 
drugs. 1 mg purified porcine tubulin (lyophilized) was reconstituted with 100 
µl of ice-cold PIPES-MgCl2 buffer (0.1 M PIPES, 0.5 mM MgCl2) pH 7.5 to 
make a stock solution of 10 mg/ml. Stock solution was further diluted with 
PIPES-MgCl2 buffer and 4 µM tubulin was incubated with either DMSO, 
CAC (100 µM), or cinnamaldehydes (50 µM and 100 µM) at 37 C for 30 
min. After incubation, 5 µl aliquots were withdrawn from the samples and 
incubated with 25 µl of freshly prepared 20 µM BIAM solution in PIPES-
MgCl2 buffer pH 6.5 at 37 C for 15 min. The reaction was quenched by 
adding freshly prepared iodoacetamide solution (final concentration 50 mM). 




Streptavidin-HRP to detect BIAM levels. The membrane was also probed with 
anti-β-tubulin antibody to ensure equal protein loading. 
2.2.10 DTNB assay  
The DTNB assay was employed to assess the interaction of 
cinnamaldehydes with sulfhydryl groups in tubulin protein. Purified porcine 
tubulin (1 mg) was reconstituted in 100 µl of PIPES-MgCl2 buffer (0.1 M 
PIPES, 0.5 mM MgCl2, pH 7.5) to achieve a concentration of 10 mg/ml. The 
tubulin stock solution was further diluted with PIPES-MgCl2 buffer and 100 µl 
aliquots of 4 µM tubulin solution were incubated with either DMSO or 
cinnamaldehydes for 30 min at 37 C in a 96-well plate. Following incubation, 
50 µl PIPES-MgCl2 buffer containing 1.5 mM DTNB and 5 mM Guanidine 
HCl was added to each sample and absorbance was measured at 412 nm using 
VERSAmax microplate reader (Molecular Devices) after an additional 
incubation for 5 min. Number of free sulfhydryl groups in tubulin samples in 
presence or absence of cinnamaldehydes were calculated from the absorbance 




2.2.11 In vitro tubulin polymerization assay 
The in vitro tubulin polymerization assay was performed to investigate 
any drug-induced changes in tubulin polymerization kinetics in a cell-free 
system using purified porcine tubulin. In individual wells of a 96-well plate, 3 
mg/ml tubulin in GPEM buffer (80 mM PIPES, 1 mM MgCl2, 1 mM EGTA, 1 
mM GTP, pH 6.8) containing 10% glycerol was mixed with either DMSO or 




using VERSAmax microplate reader pre-warmed to 37 C. Readings were 
measured until there was no difference in three consecutive readings. At this 
point, CaCl2 (final concentration 3 mM) was added to initiate 
depolymerization and absorbance readings were determined every 15 sec until 
there was no change in three consecutive readings. 
2.2.12 Amplification of plasmid DNA 
DH5α competent E.coli cells were used for transformation with 
plasmid DNA. The competent cells were thawed from –80 °C and an aliquot 
of 20 µl was mixed with 0.5 µl of plasmid DNA in a microtube pre-chilled on 
ice. The bacteria-plasmid mixture was incubated on ice for 10 min. To heat-
shock the competent cells, the microtube was incubated at 42 °C for 1 min in a 
water bath and then immediately returned on ice for 1 min. SOC medium (280 
µl) was added and the tube was incubated at 37 °C for 1 h in a shaking 
incubator. The bacterial suspension (200 µl) was spread onto a LB agar plate 
containing 100 µg/ml ampicillin and incubated overnight at 37 °C. Bacterial 
colonies were picked from the plate and inoculated into 12 ml of LB medium 
containing 100 µg/ml ampicillin. Tubes containing the cultures were incubated 
at 37 °C in a shaking incubator for about 14 h. Bacterial pellets were collected 
by centrifuging at 3500 rpm for 5 min and plasmid DNA was extracted using 
the QIAprep® spin miniprep kit according to the manufacturer’s protocol. 
Concentration of the plasmid DNA in EB buffer (10 mM Tris HCl, pH 8.5) 






2.2.13 Transient transfection 
For transfection, cells were allowed to grow until 50-60% confluence.  
GeneJuice® was used as the transfection reagent at a ratio of 2.7 µl 
GeneJuice: 1 µg plasmid DNA. Volume of GeneJuice® calculated was added 
to serum-free medium and incubated for 5 min at room temperature. Volume 
of DNA solution containing the required amount of plasmid was added slowly 
to the transfection reagent mixture and the resulting mixture was allowed to 
stand for 20-40 min at room temperature to achieve formation of liposome-
DNA complexes. The mixture was then added dropwise over random spots on 
the plate. The plate was then gently rocked to ensure even distribution and 
incubated at 37 °C.  
2.2.14 Immunoprecipitation 
HCT 116 cells plated in 60-mm diameter tissue culture dishes were 
transfected with 2 µg of plasmid pcDNA3.1-Nrf2-HA as described in section 
2.2.13. Transfected cells were were allowed to grow to 80-90% confluence 
and treated with 20 µM BCA for 6 h followed by lysis in 300 µl of Triton X-
100 lysis buffer. Lysates were centrifuged at 13000 rpm, 10 min, 4 °C. 
Immunoprecipitation reaction was set up by combining lysates containing 1 
mg protein with 25 µl of protein G-coupled sepharose beads and 1.5 µl of anti-
p21 antibody. The total volume in each sample was adjusted to 1 ml using 
lysis buffer. The samples were incubated for 2-3 h at 4 °C with gentle rocking 
and beads were collected by centrifuging the samples at 2000 rpm for 1 min. 
Protein-bound beads were then washed 1x with ice-cold washing buffer 1 (0.5 




(0.4 M NaCl, 20 mM Tris HCl, 1 mM EGTA, pH 7.4) and finally 1x with ice-
cold 50 mM Tris HCl. Washed beads were boiled with 50 µl of 2x Laemmli 
sample buffer containing 10% β-mercaptoethanol for 10 min at 95 °C to elute 
the bound proteins. Beads in the sample buffer were settled by centrifuging at 
13000 rpm for 1 min. Supernatants (30 µl) containing immunoprecipitated 
proteins as well as lysates (containing 30 µg proteins) were separated by SDS-
PAGE and immunoblotted using anti-HA and anti-p21 antibodies. 
2.2.15 Measurement of NO release by Griess reaction 
The formation of NO was investigated by measuring accumulation of 
nitrite (NO2
-
), which is a stable product of NO. RAW 264.7 cells were 
cultured in 24-well plates until approximately 80% confluent. Cells were 
serum starved by replacing FBS-containing culture medium with serum-free 
medium for 12 h. To induce inflammatory conditions, LPS (500 ng/ml) was 
then added 1 h after pre-treatment with drugs and the cells were further 
incubated for 20 h. Medium was collected and cleared by centrifuging at 1200 
rpm for 5 min. Equal volumes (100 µl) of the medium and Griess reagent (1% 
sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, and 2.5% 
phosphoric acid) were added to wells of a 96-well plate and the plate was 
shaken for 15 min protected from light. Absorbance was read at 540 nm using 
VERSAmax microplate reader. Standard plot was obtained from absorbance 
readings of of nitrite derived from a range of concentrations of sodium nitrite. 
Concentrations of nitrite in the samples were determined from the standard 
plot and concentration of the test drugs required to inhibit LPS-induced NO 




2.2.16 Luciferase gene reporter assay 
HEK-293 cells cultured in 24-well plates were transiently transfected 
with 0.1 µg of pGL3-ARE-dependent firefly luciferase reporter plasmid and 1 
ng of pCMV renilla luciferase plasmid as described in section 2.2.13. About 
24 h after transfection, cells were treated with drugs for 12 h. Firefly and 
renilla luciferase enzyme activities were determined using the Dual-
Luciferase® reporter assay kit (Promega) according to the manufacturer’s 
protocol. To determine firefly luciferase activity, 20 µl of cell lysate was 
mixed with 100 µl Luciferase Assay Reagent II and the luminescence emitted 
was measured using Infinite 200 microplate reader (Tecan). For renilla 
luciferase activity, 100 µl of Stop & Glo® reagent was subsequently added to 
the samples to simultaneously quench the firefly luciferase activity and initiate 
the renilla luciferase reaction. A second luminescence from the renilla 
luciferase was then measured. Luminescence readings from the firefly 
luciferase activity were normalized to those from renilla luciferase activity to 
minimize experimental variability caused due to differences in cell numbers 
and transfection efficiency across samples. Increase in ARE-dependent 
luciferase activity by test compounds was expressed as fold induction relative 
to DMSO control. From the fold inductions of a range of concentrations, 
concentration required to double (CD) ARE-activity was calculated for each 
compound studied.  
2.2.17 Enzyme-linked immunosorbent assay (ELISA) 
  Isolated human monocytes (CD14-positive) were obtained from Dr. 




Science, Technology and Research, Singapore), and seeded in 24-well plates 
(2×10
6
 cells/well) in RPMI 1640 medium. Drugs were added immediately to 
the cells and LPS (100 ng/well) was added 1 h after drug treatment. Medium 
from the treated wells was collected 20 h after addition of LPS and stored at –
80 ºC until further analysis. Secretion of the inflammatory mediators IL-6, IL-
1β and TNF-α in the cell culture medium was studied using DuoSet ELISA 
Development kit (R&D Systems) according to manufacturer’s protocol. In 96-
well half-well ELISA plates, antibodies were added and the plates were 
incubated at room temperature overnight to allow antibody adsorption. 
Following incubation, unbound antibodies were discarded and wells in the 
plates were washed three times with washing buffer (0.05% Tween 20 in 
PBS). To block the plates, reagent diluent (1% BSA in PBS) was added to the 
wells and the plates were incubated for 1 h at room temperature. Wells were 
thoroughly washed thrice. Samples (diluted 4x with reagent diluent) or a range 
of standards at optimized dilutions were applied to the wells (50 µl). Plates 
were incubated for 2 h at room temperature followed by washing 3x with 
washing buffer. Biotinylated antibodies were then added and plates were 
incubated at room temperature for another 2 h. Following three washes, 
streptavidin-HRP was added to the wells and allowed to incubate for 20 min. 
Plates were washed 3x and the substrate tetramethylbenzidine (TMB) was 
added, which lead to development of blue color. The reaction was terminated 
by adding 2N H2SO4 that turned the solution color to yellow. Absorbance was 
read at 450 nm using VERSAmax microplate reader and data was analyzed by 





2.2.18 Statistical analysis 
Numerical data points were presented as means ± SD. Samples treated 
with test compounds were compared against control using Student’s t-test and 










CHAPTER 3  
 






The flavor imparting component of cinnamon, CA, has been found to 
exhibit an array of biological activities including growth inhibitory properties 
against cancer cells (Cabello et al., 2009; Chuang et al., 2012; Kwon et al., 
1998; Lee et al., 1999; Moon & Pack, 1983; Zhang et al., 2010). Chemically, 
CA contains an α,β-unsaturated carbonyl moiety, also known as the Michael 
acceptor group, which has been found to be accountable for the biological 
effects of CA (Kwon et al., 1998). Although CA shows anti-cancer properties 
in cell culture and in vivo models, it lacks the potency required of a potential 
clinical agent. Therefore there lies ample scope in developing novel chemical 
derivatives based on the cinnamaldehyde scaffold with enhanced antitumor 
properties.  
Structural analogs of CA bearing substituents that would augment or 
attenuate its activity, were designed and synthesized in Dr. Andrew 
Westwell’s laboratory (School of Pharmacy and Pharmaceutical Sciences, 
Cardiff University, Cardiff, UK). The analog GJ23 was synthesized in Dr. 
Geoffery Wells’ laboratory (Department of Pharmaceutical and Biological 
Chemistry, University College London School of Pharmacy, London, UK). In 
this Chapter, these CA analogs were studied for their antiproliferative and 
cytotoxic effects against cancer cells. In addition, cellular events associated 








3.2.1 Growth inhibition and cytotoxicity of cinnamaldehydes against HCT 
116 and MCF-7 cell lines 
Reduction of MTT to purple formazan by viable cells was used to 
evaluate cinnamaldehydes for their cytotoxic effects against human colon 
carcinoma HCT 116 cells and mammary carcinoma MCF-7 cells. Based on the 
absorbance readings of the formazan solution, concentrations for 50% growth 
inhibition (GI50) and concentrations required to kill 50% cells (LC50) were 
calculated.  
The chemical structures of CA and its analogs are shown in Fig. 3.1 
along with the negative control cinnamic acid (CAC). From the MTT assays, 
as compared to CA, all synthetic analogs except SSP1 were observed to 
display enhanced growth-inhibitory and cytotoxic activities against cancer 
cells (Table 3.1). The 5-fluoro substituted analog PP1 and its 2-benzoyloxy 
substituted derivative GJ23 exhibited the strongest activities among the 
compounds. GJ23 showed mean LC50 values of 2.9 µM in HCT 116 cells and 
9.1 µM in MCF-7 cells, while LC50 values of PP1 were 3.2 µM and 21.7 µM 
in HCT 116 and MCF-7 cells respectively. The 2-benzoyloxy substituent in 
CA, which gives rise to BCA, also elicited enhanced activity and LC50 values 
of BCA were three-fold lower than that of CA in both cell lines. The 2-
hydroxy analog of CA (HCA) displayed marginally weaker activity than BCA. 
SSP2, the 2-pentoxy derivative, was equipotent to HCA, while 2-benzyloxy 
substituted SSP3 exhibited a weaker activity than HCA. CAC, which lacks the 




GJ23, PP1 and BCA, which emerged as the compounds exhibiting the most 










Figure 3.1 Structures of cinnamaldehyde analogs and cinnamic acid (CAC).  
 
Table 3.1 Antiproliferative and cytotoxic activities of cinnamaldehyde analogs 
against HCT 116 and MCF-7 cells 
Compounds HCT 116 MCF-7 
 
GI50 (µM) LC50 (µM) GI50 (µM) LC50 (µM) 
CA 9.2 ± 1.4 35.0 ± 11.2 8.2 ± 1.3 62.3 ± 22.8 
HCA 5.2 ± 1.5 9.4 ± 0.5 5.1 ± 0.4 58.8 ± 4.7 
BCA 3.5 ± 1.5 12.1 ± 4.1 4.2 ± 0.9 20.7 ± 0.4 
PP1 1.6 ± 0.3 3.2 ± 0.5 1.9 ± 0.2 21.7 ± 3.1 
GJ23 1.2 ± 0.3 2.9 ± 0.1 1.9 ± 0.8 9.1 ± 0.6 
SSP1 13.7 ± 2.8 64.3 ± 5.3 17.2 ± 1.8 95.9 ± 3.8 
SSP2 5.0 ± 1.5 10.0 ± 0.6 6.1 ± 1.0 23.5 ± 1.5 
SSP3 7.5 ± 0.8 25.6 ± 2.2 7.4 ± 2.0 29.4 ± 3.3 




The effects of lead analogs GJ23, PP1 and BCA on the viability of 
normal lung fibroblasts (MRC-5) were next tested. Notably, cinnamaldehydes 
displayed LC50 values two- to ten-fold greater in MRC-5 cells than that 
obtained for HCT 116 cells, while they were equipotent or up to three times 
more cytotoxic in MCF-7 cells as compared to MRC-5 cells (Table 3.2). 
Table 3.2 Antiproliferative and cytotoxic activities of cinnamaldehyde analogs 
against MRC-5 cells 
Compounds  MRC-5 
 
GI50 (µM) LC50 (µM) 
CA 40.4 ± 5.9 86.4 ± 1.7 
BCA 14.3 ± 3.8 25.7 ± 3.8 
PP1 15.2 ± 1.4 27.5 ± 1.9 
GJ23 12.7 ± 1.2 24.2 ± 0.8 
 
Anchorage-independent growth is a hallmark of cancer cells. Unlike 
normal adherent cells that undergo apoptosis upon detachment from the 
substratum, cancerous cells continue to proliferate in absence of anchorage to 
the extracellular matrix or neighboring cells (Thullberg & Stromblad, 2008). 
Effect of cinnamaldehydes on the ability of cancer cells to survive and 
proliferate spatially in an anchorage-independent environment was studied 
using the soft agar assay. HCT 116 and MCF-7 cells cultured in semi-solid 
growth media containing the CA analogs were allowed to grow for two weeks, 
and the number of cell colonies formed were enumerated. It was observed that 
cinnamaldehyde-treated wells displayed a significantly lower number of 
colonies as compared to DMSO control (Fig. 3.2). The lead analogs BCA, PP1 
and GJ23 inhibited colony formation at much lower concentrations than 
naturally occurring CA. CAC failed to show any significant reduction in the 





























Figure 3.2 Effect of cinnamaldehydes on growth of HCT 116 and MCF-7 cells in 
anchorage-independent cultures. Cells were suspended in RPMI 1640 medium 
containing DMSO, CAC or CA analogs and layered onto pre-solidified agarose-
containing medium in 6-well plates. Cells were incubated at 37 ºC for two weeks and 
colonies of size greater than 0.1 mm were enumerated manually using a light 
microscope. Upper panel: Photomicrographs (10x magnification) of HCT 116 and 
MCF-7 cells treated with DMSO, CAC, CA, BCA, PP1 or GJ23. Lower panel: 
Reduction in number of cell colonies presented as bar graphs. n = 3,* p < 0.05, ** p < 






3.2.2 Induction of cell cycle arrest in G2 phase by cinnamaldehydes 
To investigate the effect of cinnamaldehydes on cell cycle progression, 
HCT 116 cells treated with parent compound CA or the selected lead CA 
analogs BCA, PP1 and GJ23 were stained with the DNA-binding fluorescent 
dye propidium iodide and subjected to flow cytometric analyses. Based on 
their cellular DNA content, histograms displaying percentage of cells in G1, S, 
G2/M or sub G1 phases were obtained. Representative histograms were 
presented in Fig. 3.3a while the average percentages of cells in sub G1 and 
G2/M phases obtained from at least three independent experiments were 
presented in Fig. 3b. At 12 h and 24 h timepoints, cinnamaldehyde-treated 
cells showed a profound accumulation of cells in the G2/M phase (Fig. 3.3a 
and b). DNA histograms of cells treated with cytotoxic doses of 
cinnamaldehydes showed an appearance of cells in the sub-G1 phase at 24 h 
and 36 h, which was accompanied with a decrease in the percentage of cells in 
the G2/M phase. It was also observed that although non-lethal doses of 
cinnamaldehydes were also able to increase the percentage of cells in the 
G2/M phase, there was no appearance of the cells in sub-G1 phase, and at 36 h 
the DNA histograms were restored to normal cell cycle distributions 
resembling those of DMSO control. DNA histograms of cells treated with the 



























































Figure 3.3 Effect of cinnamaldehydes on cell cycle progression of HCT 116 cells. (a) 
HCT 116 cells were treated with specified concentrations of CA, BCA, PP1 and GJ23 
at indicated time points. Following treatment, cells were incubated in a buffer 
containing propidium iodide, which binds to DNA, and samples were subjected to 
flow cytometric analyses. DNA histograms showing number of events plotted against 
DNA content per event were obtained from flow cytometric analyses. (b) Percentages 
of cells in sub G1 and G2/M phases of the cell cycle after treatment with CA, BCA, 
PP1 and GJ23. Percentages were obtained from flow cytometric analyses of three 




As cells in both G2 and M phases contain 4N DNA content, the flow 
cytometric results did not distinguish whether CA analogs arrested the cells in 
G2 and inhibited mitotic entry or arrested cells in mitosis and prevented 
mitotic exit. To identify the precise phase of cell cycle arrest, lysates of 
cinnamaldehyde-treated cells were analyzed by immunoblotting using an 
antibody against the mitosis specific marker phospho-histone H3. Paclitaxel-
treated cells were used as a positive control for cells arrested in mitosis. While 
an obvious increase in levels of phospho-histone H3 was observed for 
paclitaxel-treated cells, no significant difference was observed in cells treated 
with CA analogs as compared to DMSO control (Fig. 3.4a). To determine any 
difference in number of cells undergoing mitosis upon cinnamaldehyde 
treatment, cells were immunolabeled by anti-phospho-histone H3 antibody 
followed by Alexa fluor 594-tagged secondary antibody, and visualized using 
fluorescence microscopy (Fig. 3.4b). Number of cells labeled with the mitotic 
marker were counted and presented as percentage of cells with phospho-
histone H3 per total number of cells. Similar to observations made using 
western blotting, the lead CA analogs failed to increase number of cells 
stained positive for phospho-histone H3, while paclitaxel showed a significant 
increase in mitotic cells (Fig. 3.4c). Together with flow cytometric analyses, 
these results indicate that CA and the lead analogs arrested cells in G2 phase 

















































Figure 3.4 Arrest of cells in G2 phase by cinnamaldehydes. (a) HCT 116 cells were 
treated with cinnamaldehydes for 12 h, and the cell lysates were subjected to western 
blot analyses using anti-phospho-histone H3 (p-histone H3) antibody. (b) 
Representative immunofluorescence microscopic images (40 x) of cells cultured on 
coverslips and treated with cinnamaldehydes or paclitaxel for 12 h. Drug-treated cells 
were fixed and probed with anti-phospho-histone H3 antibody followed by secondary 
antibody tagged to Alexa fluor 594, and counterstained with DAPI. Blue colour 
shows nucleus and red colour represents phospho-histone H3. (c) Percentage of cells 
stained positive for phospho-histone H3 per total number of cells, counted from six 
microscopic images taken from random spots on the coverslips. n = 3, * p < 0.05 
versus DMSO control. 
 
3.2.3 Dysregulation of cell cycle proteins by cinnamaldehydes 
One of the key events controlling transition of cells from G2 phase to 
mitosis is the multi-step activation of cdk1-cyclin B1 complex. The cdk1 
kinase has been described as one of the master regulators of mitosis and the 
cdk1-cyclin B1 complex is involved in phosphorylation of several components 
of the mitotic machinery (Lindqvist et al., 2007). As CA and the lead analogs 
were found to induce a G2 arrest followed by cell death, we pursued to 
investigate whether cinnamaldehydes had any effects on cdk1 that were 




lethal concentrations of cinnamaldehydes and the cell lysates collected at 
predetermined timepoints were subjected to western blot analyses to study the 
levels of total and phospho-cdk1. As shown in Fig. 3.5, it was observed that 
total and phospho-cdk1 (Tyr15) levels decreased in a time-dependent manner. 
Decrease in the levels of cdk1 occurred concurrently with emergence of the 
apoptotic markers cleaved caspase 3 and cleaved poly (ADP-ribose) 
polymerase (PARP). Densitometric analysis of the western blots was 
performed and decline in cdk1 levels appeared to be associated with the onset 
of apoptosis. Appearance of cleaved caspase 3 and cleaved PARP occurred at 
16 h for the more potent PP1 and GJ23, while for BCA and CA, it occurred at 
16 h to 24 h of drug treatment (Fig. 3.5). At a later timepoint of 36 h, a 
decrease in cleaved caspase-3 and cleaved PARP was observed. This decline 
could be attributed to the proteolysis occurring in apoptosis such that cleaved 
forms were further broken down into smaller fragments that were undetectable 
by the antibodies. 
Effects of cinnamaldehydes on levels of cyclin B1, the binding partner 
of cdk1, were also evaluated. The levels of total and phospho-cyclin B1 
(Ser133) increased 3 h after treatment and remained elevated up to 24 h, and 
showed a slight decline at 36 h. Levels of the phospho-histone H3 remained 



































































Figure 3.5 Time-dependent effects of (a) CA, (b) BCA, (c) PP1 and (d) GJ23 on 
cdk1, cyclin B1, phospho-histone H3 and apoptosis induction. HCT 116 cells treated 
with an apoptosis-inducing dose of the CA analogs were harvested at indicated 
timepoints and cell lysates were subjected to western blotting using antibodies against 
total cdk1, phospho-cdk1, total cyclin B1, phospho-cyclin B1, phospho-histone H3, 
full length and cleaved caspase 3, as well as full length and cleaved PARP. Right 
panels of the western blot analyses for each compound show densitometric analyses 
of band intensities obtained in western blots normalized to β-actin. Data points within 






In addition to the time-dependent effects, the dose-dependent effects of 
CA, BCA, PP1 and GJ23 on cycle regulatory proteins were next examined at 
two selected timepoints 12 h and 24 h. As shown in Fig. 3.6, proapoptotic 
doses of cinnamaldehydes led to a decrease in the total and phospho-cdk1 
(Tyr15) levels. At these lethal doses, levels of total and phospho-cdc25C 
(Ser216) also declined, while an accumulation of total and phospho-cyclin B1 
(Ser133) was observed. Generally, levels of cyclin B1 were higher at 12 h than 
24 h, possibly due to exponentially growing cells used for drug treatments. As 
cyclin B1 is expressed in dividing cells, higher levels of the protein were 
observed at 12 h when the cells might still be actively dividing, but dropped as 
their growth slowed at 24 h. Furthermore, spindle assembly checkpoint 
proteins mad2, cdc20 and survivin, which control alignment of chromatids to 
































































Figure 3.6 Dose-dependent effects of (a) CA, (b) BCA, (c) PP1, and (d) GJ23 on cell 
cycle regulatory proteins. HCT 116 cells were treated with indicated concentrations 
of cinnamaldehydes for 12 h and 24 h. Levels of proteins controlling G2 to M 
transition (cdk1, phospho-cdk1, cdc25C, phospho-cdc25C, cyclin B1, phospho-cyclin 
B1), those regulating spindle assembly (mad2, cdc20, survivin) and apoptotic markers 
(full length and cleaved caspase 3, full length and cleaved PARP) in the 
cinnamaldehyde-treated cell lysates were studied using western blotting. Blots were 





As the decrease in protein levels of cdk1 and cdc25C occurred 
concurrently with the onset of apoptosis, ruling out of the possibility that 
decline in the protein levels was due to proteolysis occurring in apoptosis was 
warranted. To this end, an experiment involving pre-treatment of HCT 116 
cells with 50 μM pan caspase inhibitor Z-VAD-FMK for 1 h prior to 
cinnamaldehydes treatment for 12 h was designed. Analog GJ23 possessing 
the strongest antiproliferative activity was selected for experimental 
investigation. Decline in levels of total and phospho-cdk1, as well as total and 
phospho-cdc25C was apparent even when apoptosis was blocked as indicated 
by absence of cleaved forms of caspase 3 and PARP (Fig. 3.7). These results 
thus suggested that reduction in levels of these proteins was an effect of the 









Figure 3.7 Effect of GJ23 on cell cycle regulatory proteins in cells pre-treated with 
pan caspase inhibitor Z-VAD-FMK. HCT 116 cells with or without 1 h pre-treatment 
with 50 μM Z-VAD-FMK were treated with GJ23 for 12 h. Cell lysates were 
analyzed by western blotting for proteins controlling G2 to M transition (cdk1, 
phospho-cdk1, cdc25C, phospho-cdc25C, cyclin B1, phospho-cyclin B1) and 
apoptotic markers (full length and cleaved caspase 3, full length and cleaved PARP). 






Accumulating evidence suggests that CA and its analogs suppress 
proliferation of cancer cells in culture as well as in mouse xenograft models 
(Cabello et al., 2009; Chuang et al., 2012; Kwon et al., 1998; Lee et al., 1999; 
Moon & Pack, 1983; Zhang et al., 2010). Synthetic derivatives of CA bearing 
substituents at the ortho-position were evaluated for their ability to elicit an 
enhancement in growth-inhibitory and cytotoxic activities against HCT 116 
and MCF-7 cells. It was observed that conjugation of electron-withdrawing 
substituents at the ortho-position on the Michael acceptor-bearing 
pharmacophore augmented their antitumor properties. The benzoyloxy and 
hydroxy substituents in BCA and HCA, respectively, rendered them more 
potent against cancer cells than CA. Strongest activities were exhibited by 
GJ23 and PP1 containing benzoyloxy and hydroxy groups at the ortho-
position in addition to an electron-withdrawing fluorine group. The electron-
withdrawing effect of benzoyloxy and hydroxy groups at the ortho position 
possibly increased the electrophilicity of the β-carbon of the side chain 
propenal group. In GJ23 and PP1, the inductively electron-withdrawing 
fluorine group at 5 position on the phenyl ring might have led to a further 
increase in the electrophilicity of the β-carbon resulting in a enhancement in 
the activity. In contrast, an electron-donating methoxy substitution in SSP1 
decreased its activity. Although SSP2 and SSP3 bearing electron-donating 
pentoxy and benzyloxy substituents respectively, displayed higher cell-killing 
activities than CA, their cytotoxicities were possibly attributable to presence 




values of SSP2 and SSP3 were 3.62 and 3.27 respectively, as compared to a 
clogP value of 1.67 for CA).  
The lead CA analogs BCA, PP1 and GJ23 were also studied in 
anchorage-independent cultures, and it was observed that growth of HCT 116 
and MCF-7 cells was stalled when treated with the compounds. Results from 
MTT and soft agar assays therefore validated the growth-inhibitory and 
cytotoxic abilities of these analogs and established their superiority over the 
naturally occurring CA.  
Cdk1 functions as the catalytic subunit of the cdk1-cyclin B1 kinase 
that catalyzes phosphorylation of several important substrates involved in 
mitosis. Activation of the cdk1-cyclin B1 complex is highly regulated and is 
one of the key events guarding G2 to mitosis transition (Lindqvist et al., 2007). 
During G2 phase, levels of cyclin B1 rise and cdk1-cyclin B1 complexes are 
formed. The inactive form of cdk1 is dephosphorylated by cdc25C 
phosphatase at Thr14 and Tyr15 for activation. Cdc25C also needs to be in its 
active dephosphorylated form to activate cdk1 (Malumbres & Barbacid, 
2009). Dephosphorylation of cdk1 is followed by phosphorylation of cyclin 
B1 at Ser133 to complete activation and allow nuclear translocation (Hagting 
et al., 1999). Failure to activate the cdk1-cyclin B1 complex inhibits 
progression of the cell cycle and is observed as a cell cycle arrest in the G2 
phase (Boutros et al., 2006). Investigation of the cell cycle regulatory proteins 
indicated that treatment with cinnamaldehydes led to a loss of cdk1 as well as 
cdc25C, while cyclin B1 was accumulated. In the time-dependent studies, loss 
of cdk1 correlated with the onset of apoptosis, as suggested by the concurrent 




levels showed a sharper decline than phospho-cdk1, indicating that the cells 
might contain a net increase in the levels of inactive phospho-cdk1. Levels of 
total and phospho-cdc25C had decreased upon cinnamaldehyde treatment. 
Decline in cdc25C, which is upstream of cdk1 in the activation cascade, might 
explain the net higher levels of phospho-cdk1. During a normal cell cycle, 
levels of cyclin B1 rise through the G2 phase wherein it couples with cdk1 to 
form the cdk1-cyclin B1 complex, which is activated at the onset of mitosis. 
Cyclin B1 levels are expected to increase through the G2 phase and it is likely 
that due to the cell cycle arrest, continued production of cyclin B1, which was 
not coupled with activation of cdk1 and subsequent progression into mitosis, 
resulted in its accumulation. It was deduced that as the cdk1-cyclin B1 
complex is an essential component for mitotic entry, loss of cdk1, and 
therefore absence of active cdk1-cyclin B1 complexes would lead to a block in 
transition from G2 phase to mitosis. Inability of the cells to surmount this 
block in the cell cycle potentially triggered apoptosis. Similar findings have 
been previously reported for the isothiocyanates sulforaphane and phenylethyl 
isothiocyanate (PEITC). Treatment of cancer cells with PEITC led to 
degradation of cdc25C and cdk1 (Xiao et. al., 2004), whereas treatment with 
sulforaphane led to a loss of cdc25C, altered cdk1 activity and caused 
accumulation of cyclin B1 (Jackson and Singletary, 2004), suggesting that the 
observations may not be unique to cinnamaldehydes.  
The investigated cinnamaldehyde analogs also caused depletion of 
spindle assembly checkpoint proteins cdc20, mad2 and survivin. However, as 
the cells were arrested in G2 phase, it would be unlikely that loss of these 




Since cinnamaldehydes brought about apoptosis in cancer cells by 
dysregulation of cell cycle proteins guarding transition from G2 to mitosis, 
their potential toxicities on normal proliferative cells were also evaluated. 
While CA and the lead analogs showed two to ten times lower 
antiproliferative and cytotoxic potencies in normal lung fibroblast MRC-5 
cells as compared to HCT 116 cells, their cytotoxicity in MRC-5 cells was 
comparable or marginally lower than MCF-7 cells. The presence of a Michael 
acceptor moiety in these compounds poses a concern for development of 
analogs with enhanced selectivity towards cancer cells. However, novel 
shogaol and curcumin analogs, which also bear a Michael acceptor group, 
have been developed such that they selectively kill cancer cells while sparing 
normal cells (Zhu et al., 2013; Pisano et al., 2010). Therefore, development of 
analogs that show higher selectivity against tumor cells is warranted for 
potential clinical application of cinnamaldehyde-based compounds as 
anticancer agents.   
To conclude, an arrest in the G2 phase prior to cell death was evident 
based on the accumulation of cells in the G2/M area of DNA histograms and 
absence of the mitotic marker phospho-histone H3 in cells treated with CA 
analogs. Taken together, the results suggested that cinnamaldehyde-induced 
loss of cdk1 and cdc25C, the cell cycle regulatory proteins which are critical 
for cell cycle progression, was associated with the observed G2 arrest  and 
subsequent induction of apoptosis. A summary of the effects of 
cinnamaldehydes on cell cycle progression and apoptosis induction is 
















Figure 3.8 Schematic summary of the effect of cinnamaldehydes on cell cycle 
progression and subsequent induction of apoptosis. Treatment with CA or its analogs 
caused a G2 phase arrest associated with depletion of cdk1 and cdc25C, thereby 







CHAPTER 4  
 





Some of the clinically most successful anticancer agents target tubulin 
to inhibit proliferation of cancer cells and thereby restrict tumor growth; well-
known examples include vincristine (Oncovin) and paclitaxel (Taxol) (Jordan 
& Wilson, 2004). A number of chemically diverse compounds have been 
found to bind to tubulin. These compounds affect the polymerization 
dynamics of microtubules and thereby inhibit cell proliferation. 
Conventionally, tubulin-interacting agents have been classified as microtubule 
stabilizers and destabilizers. Stabilizers promote assembly of tubulin 
heterodimers into microtubule polymers and include compounds such as 
paclitaxel and its synthetic analog docetaxel, epitholines, laulimalide, and 
discodermolide. Microtubule destabilizers inhibit tubulin polymerization into 
microtubules. Examples of such drugs include the Vinca alkaloids, 
colchicines, combretastatins and estramustine (Altmann & Gertsch, 2007). 
The Vinca alkaloids, originally isolated from periwinkle leaves, are the earliest 
class of microtubule-inhibiting drugs discovered. They bind to the β-subunit at 
the vinca-binding domain and inhibit tubulin polymerization (Safa et al., 
1987). Colchicine and combretastatins inhibit microtubule assembly by 
binding to the colchicine-binding site of β-tubulin while paclitaxel, docetaxel, 
epitholines and discodermolide promote tubulin polymerization by binding to 
the taxol domain (Rao et al., 1999). Apart from these sites, the α,β-tubulin 
dimer together contains 20 cysteine residues; 8 in α-tubulin and 12 in β-
tubulin (Ponstingl et al., 1981; Krauhs et al., 1981). Sulfhydryl groups 
contained in some of these cysteine residues have been implicated in tubulin 




sulfhydryls’ (Kuriyama & Sakai, 1974; Britto et al., 2005). Recently, a number 
of sulfhydryl-reactive compounds have been found to cause microtubule 
damage by direct binding to tubulin (Hosono et al., 2005; Mi et al., 2008). 
These agents are proposed to interfere with regulatory functions of the 
assembly-critical sulfhydryls and thereby cause microtubule disruption. 
Hence, compounds with the ability to interact with tubulin sulfhydryls may 
serve as potential candidates for targeting tubulin. These findings thus provide 
a more streamlined approach in the search for novel and more potent anti-
tubulin agents as compared to the previous fortuitous discoveries of anti-
tubulin agents.  
CA and its analogs contain an α,β-unsaturated carbonyl group that can 
potentially interact with nucleophiles such as sulfhydryl groups of tubulin. 
Binding of CA and its more potent analogs BCA, PP1 and GJ23 (identified in 
Chapter 3) to tubulin sulfhydryls was investigated and the subsequent effects 
on tubulin and microtubule structure were studied.  
 
4.2 Results 
4.2.1 Investigation of the possible interaction between cinnamaldehydes 
and tubulin 
With the knowledge that tubulin targeting agents are known to stabilize 
or destabilize microtubules through affecting the rate of tubulin 
polymerization, investigation of the polymerization kinetics of purified 
porcine tubulin in the presence of BCA was attempted. Tubulin was incubated 




nm to study tubulin polymerization. However, under the experimental 
conditions used, tubulin polymerization was sub-optimal as increase in 
absorbance values of untreated control was very gentle. Moreover, tubulin 
polymerization enhanced by positive control paclitaxel was not statistically 
significant as compared to control. BCA-treated samples also showed no 









Figure 4.1 Effect of BCA on in vitro tubulin polymerization. In wells of a 96-well 
plate, 20 μM BCA, 5 μM paclitaxel or DMSO was added to 3 mg/ml tubulin in 
GPEM buffer (80 mM PIPES, 1 mM MgCl2, 1 mM EGTA, 1 mM GTP, pH 6.8) and 
absorbance values were measured at 340 nm every 15 sec to monitor tubulin 
polymerization. n = 3, no statistical significance was observed between the three 
samples (error bars not shown in graph for clarity). 
 
As findings of the in vitro polymerization experiment were 
inconclusive and it could not be determined whether BCA altered the 
polymerization kinetics of tubulin, we postulated that if cinnamaldehydes 




protein. Given that cinnamaldehydes contain an α,β-unsaturated carbonyl 
moiety that has the propensity to interact with sulfhydryl groups, interaction of 
CA and the lead analogs with tubulin was therefore investigated. Purified 
porcine tubuiln was first incubated with CA, BCA, PP1 and GJ23 and then 
with BIAM. Free sulfhydryl groups in the protein would be labeled by BIAM, 
while sulfhydryl groups interacting with cinnamaldehydes would be 
unavailable for BIAM labeling. Increased interaction of cinnamaldehydes with 
tubulin would result in decreased BIAM labeling, observed as a reduction in 
band intensities of the western blot probed with streptavidin-HRP. A dose-
dependent decrease in band intensities of cinnamaldehyde-treated samples was 
observed (Fig. 4.2). The negative control CAC showed similar band intensity 
as that of the untreated protein sample, whereas CA displayed a mild decrease 
in intensity. The more potent analogs BCA, PP1, and GJ23 produced a marked 
decline in the band intensities.  
Interaction of cinnamaldehydes with tubulin cysteines was also 
evaluated by reacting cinnamaldehyde-treated tubulin with DTNB. DTNB is 
reduced by free sulfhydryl groups to form a disulfide and TNB. Free 
sulfhydryls contained per one α,β-tubulin dimer were calculated from 
absorbance of TNB. For the untreated control, number of sulfhydryls 
calculated per tubulin dimer was 19.72, which reconciled with the theoretical 
value of 20 cysteines per tubulin dimer (Ponstingl et al., 1981; Krauhs et al., 
1981). CA exhibited a weaker interaction with tubulin and modified one 
cysteine per tubulin dimer as compared to two cysteines modified by BCA and 
PP1, while more than four cysteines per tubulin dimer were modified by GJ23 











Figure 4.2 Possible interaction of cinnamaldehydes with sulfhydryl groups in tubulin 
protein. Purified tubulin was first incubated with cinnamaldehydes for 30 min at 37 
ºC and next incubated with BIAM. BIAM labeling of tubulin sulfhydryls was 
detected by western blotting with HRP-streptavidin. Equal protein loading was 




Table 4.1 Number of sulfhydryl groups modified per tubulin dimer upon 
cinnamaldehydes treatment.  
 
Control CA BCA PP1 GJ23 
Number of sulfhydryl 













In an attempt to identify the cysteines modified by cinnamaldehydes, 
purified porcine tubulin treated with 50 µM BCA was processed and subjected 
to mass spectrometric analysis using MALDI/TOF. However, due to 
interference from the MALDI matrix that resulted in significant signal 
suppression, results obtained were inconclusive (Fig. 4.3). Hence, though 
results obtained provided experimental evidence that CA and its analogs 
interacted with tubulin, possibly through the sulfhydryl groups, technical 
constraints prevented identification of the exact residues that interacted with 
cinnamaldehydes. More work would need to be conducted to optimize the 


























Figure 4.3 Mass spectrum of tubulin treated with BCA. Purified tubulin was 
incubated with DMSO or 50 µM BCA at 37 ºC for 30 min. Samples were cleared of 
small molecules such as drug and buffer components using a spin desalting column 
before being subjected to MALDI/TOF analysis. 
 
4.2.2 Induction of tubulin aggregation by cinnamaldehydes 
The possible effects of cinnamaldehydes on cellular tubulin were next 
studied. HCT 116 cells were treated with cinnamaldehydes and cellular 




microscopic images revealed collapse of the microtubular network and marked 
aggregation of tubulin in cinnamaldehyde-treated samples (Fig. 4.4a).  
To further probe the aggregation of tubulin, lysates of HCT 116 cells 
treated with CA or its analogs were segregated into soluble and insoluble 
fractions. The soluble fraction contained the dimeric α,β-tubulin, while tubulin 
polymers and aggregates comprised the insoluble fraction. In agreement with 
the immunofluorescence microscopic results, it was found from the western 
blot analyses that cinnamaldehydes caused a dose-dependent accumulation of 
tubulin in the insoluble fraction and a corresponding decline in tubulin content 
of the soluble fraction (Fig. 4.4b). Accumulation of tubulin was also tested in 
MCF-7 cells, and it was observed that similar to the findings in HCT 116 cells, 
CA analogs caused an increase in the tubulin content of the insoluble fraction 
together with a decrease in the soluble tubulin content (Fig. 4.4c).  
The possible effect of cinnamaldehydes on tubulin degradation was 
next assessed using BCA as the selected analog. HCT 116 cells were co-
treated with BCA and the protein synthesis inhibitor cycloheximide (CHX), 
and tubulin content at multiple timepoints was studied. No changes in total 
tubulin content over time were observed in the BCA plus CHX-treated cells 
and CHX-only treated cells, indicating that cinnamaldehydes did not affect 




























































































Figure 4.4 Induction of tubulin aggregation by cinnamaldehydes. (a) 
Immunofluorescence microscopic images of HCT 116 cells treated with DMSO (i & 
ii), BCA (iii & iv), PP1 (v & vi), and GJ23 (vii & viii). Cells cultured on coverslips 
were treated with DMSO or cinnamaldehydes for 8 h, fixed, and immunostained with 
anti-β-tubulin antibody followed by anti-mouse IgG conjugated to Alexa fluor 488, 
and counterstained with DAPI. Images were obtained at 100 x magnification. (b) 
HCT 116 or (c) MCF-7 cells were treated with indicated concentrations of 
cinnamaldehydes for 16 and 24 h respectively. Following cell lysis, the lysates 
containing soluble (left panel) and insoluble tubulin (right panel) fractions were 
separated and probed for tubulin levels using western blot analyses. (d) HCT 116 
cells were treated with either 30 μM BCA plus 40 μM cycloheximide (CHX) or only 
CHX and cell lysates containing total tubulin were analyzed by western blotting by 






The α and β tubulin subunits polymerize to form microtubules that 
comprise a vital part of the mammalian cytoskeleton. Characteristic 
polymerization dynamics of tubulin and microtubules are crucial for precise 
execution of their biological functions. Due to their involvement in 
fundamental functions such as formation of the mitotic spindle, agents that 
target tubulin dynamics are potentially capable of driving the cells into 
apoptosis.  
Ishiguro et al. (2008) had previously reported that sulfhydryl groups of 
tubulin were susceptible to attack by compounds bearing an α,β-unsaturated 
carbonyl pharmacophore. Indeed, it was found that Michael acceptor-bearing 
cinnamaldehydes targeted cysteine residues of tubulin in vitro, and GJ23, 
found to be the most potent among the cinnamaldehyde analogs studied in 
Chapter 3, modified the most number of cysteines per tubulin dimer. Potency 
of cysteine modification in tubulin was of the same order of cytotoxicity in 
HCT 116 and MCF-7 cells; rank of potencies:  CA < BCA < PP1 < GJ23. A 
correlation analysis between tubulin binding ability and cytotoxic potency 
revealed a correlation coefficient of about 0.69 for HCT 116 cells and 0.74 for 
MCF-7 cells, suggesting the likely involvement of tubulin modification in 
apoptosis induction. In a cellular system, cinnamaldehydes binding appeared 
to result in tubulin aggregation and accumulation in the insoluble cell-lysate 
fractions. Microtubule disruption has been previously reported for 
isothiocyanates (Jackson and Singletary, 2004), and formation of tubulin 




2009). In contrast, unlike isothiocyanates, cinnamaldehydes did not increase 
degradation of the tubulin aggregates.  
While the classic tubulin-targeting agents arrest cells in the mitotic 
phase, our results established a cell cycle arrest in the G2 phase (as discussed 
in Chapter 3). Interestingly, such biological activities were not unique to 
cinnamaldehydes. The semisynthetic triterpenoid CDDO (2-cyano-3,12-
dioxooleana-1,9(11)-diene-28-oic acid) has been reported to disrupt 
microtubules and decrease the mitotic index (Couch et al., 2006). Diallyl 
disulfide has also been found to interfere with polymerization of microtubules 
while inhibiting G2 to M transition (Knowles & Milner, 1998). A plausible 
explanation for the concurrent observation of tubulin aggregation and cell 
cycle arrest in G2 phase could be that cinnamaldehydes simultaneously 
attacked multiple cellular targets, which contributed towards manifestation of 
apoptosis in cancer cells.  
In summary, cinnamaldehydes targeted cysteine residues in tubulin and 
caused conspicuous tubulin aggregation, which was followed by apoptotic cell 
death (Fig. 4.5). Results presented in this Chapter suggested that together with 
the alteration of cell cycle proteins by cinnamaldehydes (data presented in 
Chapter 3), tubulin aggregation was associated with cinnamaldehyde-mediated 





















Figure 4.5 Schematic representation of cinnamaldehydes-induced tubulin aggregation 
and subsequent apoptosis. Results presented in this chapter suggest that 
cinnamaldehydes attack sulfhydryl groups of tubulin, which results in aggregation of 








CHAPTER 5  
 






A rationale approach to prevent cancer is to counter the threat from 
potential carcinogens by fortifying cellular defense systems. The phase 2 
antioxidant and detoxifying enzymes form a key part of the cell’s defense 
strategies. Presence of oxidative or electrophilic stress acts as a cue for the cell 
to deploy these enzymes and thereby prevent any deleterious cellular effects. 
Induction of the phase 2 response is coordinated by the transcription factor 
Nrf2 by binding to consensus DNA sequence identified as ARE found in the 
5’ promoter region of genes coding for these enzymes (Itoh et al., 1997).  
Under quiescent conditions, Nrf2 experiences a short half-life and exhibits 
basal activity due to its repression by Keap1, which sequesters Nrf2 in the 
cytoplasm and directs it for degradation. However, activity of Nrf2 is 
amplified in presence of oxidative or electrophilic stimuli, wherein it escapes 
degradation and induces expression of its downstream target genes (Prestera et 
al., 1995). 
Acute inflammation is a host defense strategy to remove injurious 
agents, however, it has been established that persistent or chronic 
inflammation often precedes oncogenesis (Coussens & Werb, 2002). Signal 
transduction pathways activated during inflammation promote cell survival 
and proliferation, which consequently increases the risk of carcinogenesis. 
Curbing inflammatory responses together with activation of the Nrf2-
dependent phase 2 enzyme induction has therefore been regarded as a holistic 




Cancer-preventive properties of the Michael acceptor-bearing 
cinnamaldehydes were investigated by evaluating their ability to offer Nrf2-
mediated cytoprotection and inhibit inflammatory responses. In addition, the 
role of the protein p21 in Nrf2-induced cellular protective responses was also 
studied.    
5.2 Results 
5.2.1 Nrf2-dependent phase 2 enzymes induction and cellular protection 
by BCA 
Possible effect of the lead CA analogs on ARE-dependent phase 2 
enzyme activation was investigated by studying their ability to induce ARE-
mediated gene transcription. The non-cancerous HEK-293 cells were 
transiently transfected with an ARE luciferase gene reporter plasmid wherein 
expression of a firefly luciferase gene was transactivated by the ARE 
promoter. Activation of ARE-dependent transcription would lead to increased 
expression of the firefly luciferase enzyme, which was estimated by measuring 
luminescence units emitted upon enzymatic conversion of substrate luciferin. 
Ratio of the luminescence measured in cinnamaldehyde-treated samples to 
untreated control was expressed as fold induction in ARE-dependent activity. 
As shown in Fig. 5.1a, BCA outperformed CA, PP1 and GJ23, and induced 
ARE transactivation by almost nine-fold at a concentration of 20 µM. CA (40 
µM), PP1 (20 µM) and GJ23 (20 µM) exhibited mean fold induction of 
approximately five-, four-, and seven-fold, respectively against control (Fig. 
5.1a). According to results of the MTT assays presented in Chapter 3, BCA 




and GJ23. Moreover, using cell viability assays, BCA was found to display 
more than 90% viability in HEK-293 cells upto a concentration of 20 μM. 
Based on its superior ARE-inducing activity, and relatively lower cytotoxicity, 
BCA was chosen for further studies to investigate its cytoprotective properties.   
As ARE activity is regulated by binding of the transcription factor 
Nrf2, BCA’s ability to stabilize Nrf2 was next evaluated in HEK-293 cells and 
WT MEFs. A marked increase in the protein levels of Nrf2 in both HEK-293 
cells as well as WT MEFs was observed upon BCA treatment (Fig. 5.1b).  
Expression of the ARE-dependent downstream targets of Nrf2 such as 
HO-1, NQO1, γ-glutamate-cysteine ligase (γ-GCL) and GSTA1 was next 
studied. An increase in the expression of these phase 2 enzymes was observed 
in presence of BCA in the two cell lines studied (Fig. 5.1c). The known Nrf2 
inducer tert-butyl hydroquinone (tBHQ) also stabilized Nrf2 and induced 
expression of the phase 2 enzymes. It was noted that CA also upregulated the 
phase 2 enzymes and stabilized Nrf2, albeit at higher concentrations, and 






























































































Figure 5.1 Induction of ARE-dependent phase 2 enzymes via stabilization of Nrf2 by 
cinnamaldehydes. (a) Fold induction in ARE-dependent transcriptional activity upon 
treatment with cinnamaldehydes. HEK-293 cells transfected with pGL3-ARE-
dependent firefly luciferase reporter and pCMV renilla luciferase plasmids were 
treated with the test compounds for 12 h. Luciferase enzyme activity was evaluated 
by measuring luminescence of the enzymatic reaction product. Firefly luciferase 
activity was normalized to renilla luciferase and increase in ARE-dependent firefly 
luciferase activity was presented as fold induction against DMSO (n = 3, columns 
indicate mean fold induction, SD presented as error bars. * p < 0.05 versus DMSO 
control). (b) HEK-293 cells or WT MEFs treated with CA or BCA were analyzed for 
levels of Nrf2 using western blot analyses. (c) HEK-293 cells or (d) WT MEFs 
treated with CA or BCA were analyzed for levels of phase 2 enzymes using western 
blotting. Lower panels of the western blot analyses for (c) and (d) show densitometric 




Following the observation of phase 2 response activation by BCA, 
investigation of whether induction of the phase 2 response indeed offered 
cellular protection against external stressors was next carried out. Doxorubicin 
is an anthracycline antibiotic commonly used against cancer, which is capable 
of inducing DNA damage by intercalating between nucleotide base pairs and 
through its involvement in iron-mediated production of free radicals 
(Momparler et al., 1976). Cellular protection conferred by BCA against 
doxorubicin-induced DNA damage was studied by western blot analyses of 
phosphorylated histone H2AX (γ-H2AX) in HEK-293 cells pre-treated with 
BCA (12 h) and challenged with doxorubicin (2 µg/ml, 12 h). A dose of 2 
µg/ml doxorubicin had previously been tested in the laboratory to induce 
DNA-double strand breaks without causing cytotoxicity. Histone H2AX is 
rapidly phosphorylated at sites of nascent DNA double strand breaks, and is 
essential for recognition and restoration of intact double stranded DNA (Paull 
et al., 2000). Phospho-histone H2AX, also known as γ-H2AX, was therefore 
employed as a marker for DNA damage. As shown in Fig. 5.2, level of γ-
H2AX was found to be conspicuously higher in doxorubicin-treated cells than 
in the untreated control. In addition, it was observed that cells treated with 
BCA prior to doxorubicin challenge expressed lower γ-H2AX levels than that 
of cells treated with doxorubicin alone. Cells treated with 10 µM BCA had 
levels of the DNA-damage marker protein similar to untreated control, 












Figure 5.2 Cytoprotection against doxorubicin-induced DNA damage by BCA pre-
treatment. HEK-293 cells were pre-treated with BCA (12 h) followed by treatment 
with doxorubicin for 12 h. Cell lysates were analyzed for γ-H2AX levels by western 
blotting.  
 
5.2.2 Inhibition of LPS-mediated stimulation of inflammatory conditions 
by BCA 
With the knowledge that curbing inflammation together with 
conferring cytoprotection has been considered as a holistic approach to inhibit 
carcinogenesis, anti-inflammatory properties of BCA were tested in the 
murine macrophage-like RAW 264.7 cells. Inflammatory conditions were 
induced in the cells using LPS. NO is generated by cells of the immune system 
in response to inflammatory stimuli, and amount of NO produced was thus 
measured to study possible inhibition of the inflammatory response by BCA. 
Secretion of NO was quantified by measuring concentration of its more stable 
product, the nitrite ion, in the culture media of cells pre-treated with CA or 
BCA and exposed to LPS. A marked increase in nitrite levels was observed in 
LPS-stimulated cells as compared to DMSO control, which suggested 
induction of an inflammatory response. (Fig. 5.3a). In addition, it was found 
that BCA treatment dose-dependently inhibited LPS-stimulated NO 
generation. CA also displayed modest reduction in nitrite levels.  
Having found that BCA and CA inhibited NO formation, effects on 




blot analyses. Effect on COX-2, which is responsible for production of the 
pro-inflammatory prostaglandins, was also studied. It was observed that levels 
of the inflammatory mediators iNOS and COX-2 were undetectable in control 
cells, whereas a marked upregulation was seen in LPS-treated cells. BCA 
treatment caused reduction in the levels of these enzymes, indicating effective 














Figure 5.3 Inhibition of LPS-induced inflammatory responses by BCA. (a) Inhibition 
of NO production by BCA in LPS-stimulated RAW 264.7 cells. Concentration of 
nitrite was measured in media of RAW 264.7 cells treated with CA or BCA 1 h prior 
to LPS challenge (500 ng/ml, 20 h) using Griess reaction. Concentrations of nitrite 
obtained were presented as percentage nitrite content in each sample to that in LPS-
only sample (n = 3, columns indicate mean nitrite percentage, SD presented as error 
bars. * p < 0.05 versus LPS-only treated cells, # p > 0.05 versus DMSO control). (b) 
Inhibitory effects of BCA on iNOS and COX-2 expression. RAW 264.7 cells treated 
with CA or BCA for 1 h were stimulated with LPS for 20 h, and cell lysates were 
analyzed by western blotting for iNOS and COX-2 levels. 
 
The bacterial endotoxin LPS has been known to stimulate 




transduction pathways such as the NF-κB signaling cascade. The downstream 
transcriptional targets of the NF-κB pathway include inflammatory mediators 
such as the enzymes iNOS and COX-2.  In addition to its role in inflammatory 
responses, the NF-κB pathway has also been implicated in tumorigenesis. 
Activation of the pathway is signified by phosphorylation of IκB kinases 
IKKα and IKKβ, and subsequent degradation of the inhibitory IκB proteins, 
which results in nuclear translocation and phosphorylation of the p65 subunit 
of transcription factor NF-κB. Through binding to its promoter sequence, p65 
activates the expression of several pro-inflammatory and pro-survival genes.   
Given the finding that BCA inhibited the LPS-mediated upregulation 
of iNOS and COX-2, effect of BCA on activation of NF-κB pathway by LPS 
was next studied in RAW264.7 cells. In LPS-stimulated cells, phospho-p65 
and phospho-IKKα/β bands were markedly increased, and levels of IκBα had 
declined, which indicated activation of NF-κB signaling (Fig. 5.4). Cells that 
received BCA prior to LPS treatment displayed reduced levels of phospho-p65 
and phospho-IKKα/β as compared to LPS only-treated cells. Total p65 and 
IKKα/β protein levels remained unchanged across all samples. Levels of the 
NF-κB inhibitory protein IκBα in BCA-treated cells showed an increasing 
trend, and at 20 μM BCA, the levels were similar to that of untreated control 
(Fig. 5.4). These results thus provided evidence that LPS-mediated induction 
of NF-κB signaling was inhibited by BCA. It was also observed that the parent 











Figure 5.4 Inhibition of LPS-induced NF-κB activation by BCA. RAW 264.7 cells 
treated with CA or BCA for 1 h were challenged with LPS for 30 min, and cell 
lysates were analyzed by western blotting using antibodies against NF-κB signaling 
proteins such as p65, phospho-p65, IκBα, IKKα, IKKβ, and phospho-IKKα/β. 
 
5.2.3 Repressed activation of the Nrf2-mediated phase 2 response and 
reduced cytoprotection by BCA in the absence of p21  
 In addition to its role as a cyclin-dependent kinase inhibitor, p21 also 
acts as a regulator of cellular redox conditions (Esposito et al., 1998). It has 
been recently reported that p21 competed with Keap1 for binding at the DLG 
site of Nrf2, that led to enhancement in Nrf2 activity (Chen et al., 2009). It has 
also been found that while binding of p21 disrupted Nrf2-Keap1 binding at the 
DLG site, the Nrf2-Keap1 interaction was preserved at the ETGE site in the 
Neh2 domain of Nrf2. Involvement of p21 in the induction of Nrf2-directed 
phase 2 antioxidant response was investigated by studying the effect of BCA 
on Nrf2 and phase 2 enzymes in HCT 116 WT and p21-/- cells. In both the 
WT and p21-null cells, Nrf2 induction was observed upon BCA treatment. 
However, induction of Nrf2 was higher in the WT cells as compared to that in 
the p21-null cells (Fig. 5.5a). Moreover, a dose-dependent increase in p21 




expression of the phase 2 enzymes HO-1, NQO1, and γ-GCL was next studied 
in HCT 116 WT and p21-/- cells. Induced expression of the enzymes was 
observed in both cell lines (Fig. 5.5b). Using densitometric analyses of the 
western blots, induction in enzyme levels of BCA-treated samples versus 
untreated control were calculated and expressed as fold induction (Fig. 5.5c). 
Generally, BCA-mediated induction of enzyme expression was observed to be 
milder in p21-/- cells as compared to that in the WT cells. In summary, the 
experimental findings revealed that BCA treatment increased p21 levels, and 
induction of the Nrf2-mediated antioxidant response was weaker in the 
absence of p21. This led to the proposed hypothesis that p21 was involved in 




































Figure 5.5 Nrf2 and phase 2 enzyme induction in BCA-treated HCT 116 WT and 
p21-/- cells. (a) Western blot analyses of Nrf2 and p21 levels in HCT 116 WT and 
p21-/- cells at 3 h and 6 h after BCA treatment. (b) Western blot analyses of the levels 
of phase 2 enzymes in HCT 116 WT and p21-/- cells treated with BCA (14 h). (c) 
Densitometric analyses of the western blots for phase 2 enzymes were performed. 
Fold induction was calculated as ratio of the enzymes’ band intensities (normalized to 
β-actin) in BCA-treated samples to that of untreated control. Each column represents 
the mean value of two independent experiments, SD denoted by error bars.  
     
 To study whether the observed difference in induced Nrf2 levels and 
induction of the phase 2 response between the WT and p21-null cells 
contributed to a difference in cytoprotection, the cells were treated with BCA 
prior to doxorubicin exposure (2 μg/ml, 12 h). DNA damage inflicted by 
doxorubicin treatment was determined by studying levels of γ-H2AX, the 




concentration effectively attenuated doxorubicin-induced genotoxicity, such 
that γ-H2AX levels were similar to that of the untreated control (Fig. 5.6a). 
However, in the p21-null cells, this BCA-mediated attenuation in γ-H2AX 
levels was diminished; only a marginal decline in levels of the DNA damage 
marker was brought about by BCA treatment to cells challenged with 
doxorubicin (lanes 4 and 6 versus lane 2 in Fig. 5.6a). The p21-/- cells treated 
with BCA-only also displayed a marginal increase in γ-H2AX levels, likely 
because the cells were devoid of a complete cytoprotective mechanism, and 
BCA as a xenobiotic itself was able to induce certain genotoxicity. This 
further lent support to the postulation that p21 was essential in facilitating the 
cytoprotective response. For a clearer illustration of the observation described 
above, densitometric analyses of the bands in western blots were carried out. 
As shown in Fig. 5.6b, BCA markedly reduced the increase in γ-H2AX levels 
in WT cells, while a less marked reduction was observed in the p21-/- cells.  
The cytoprotective effects brought about by BCA against the genotoxic 
effects of doxorubicin were also studied using immunocytochemistry. 
Following treatment with BCA and doxorubicin, cells were immunolabeled 
for γ-H2AX, and images were obtained using an epifluorescence microsope. 
In agreement with the western blot results, the fluorescence images showed 
that BCA was more effective in reducing the number of cells stained for γ-
H2AX in HCT 116 WT cells as compared to p21-/- cells (Fig. 5.6c). It was 
thus concluded that absence of p21 retarded BCA’s ability to inhibit DNA 
























































Figure 5.6 Cytoprotection against doxorubicin-induced DNA damage in HCT 116 
WT and HCT 116 p21-/- cells by BCA. (a) Upper panel: HCT 116 WT and p21-/- 
cells pre-treated with BCA (12 h) were exposed to doxorubicin (12 h) and cell lysates 
were analyzed for levels of γ-H2AX using western blot analyses. Lower panel: 
Percentage of γ-H2AX levels against doxorubicin (100%) were calculated from band 
intensities of western blots obtained from densitometric analyses. Each column 
represents the mean value of two independent experiments, SD denoted by error bars. 
(b) HCT 116 WT and p21 -/- cells were pre-treated with BCA (12 h) and challenged 
with doxorubicin (12 h). Cells were then fixed with paraformaldehyde, 
immunolabeled with anti-γ-H2AX antibody followed by secondary antibody 
conjugated to Alexa Fluor 488 (green), and counterstained with DAPI (blue). Images 
were obtained using Nikon Eclipse Ti-S epifluorescence microscope connected to a 




5.2.4 Investigation of the possible effect of BCA on Nrf2-p21 interaction 
 Following observations of a diminished cytoprotective response in 
HCT 116 p21-/- cells, it appeared that p21 was involved in induction of Nrf2 
and phase 2 enzymes. On this basis, it was hypothesized that BCA addition 
had increased interaction between Nrf2 and p21, which in turn led to increased 
stabilization of Nrf2 and its steady state levels. HCT 116 cells transiently 
transfected with Nrf2-HA plasmid were treated with BCA 20 μM and cell 
lysates were immunoprecipitated using anti-p21 antibody. Levels of Nrf2-HA 
in the immunoprecipitated (IP) samples were studied using western blotting. 
Nrf2 was found to interact directly with p21 as the IP samples displayed bands 
corresponding to Nrf2-HA in the untreated and BCA-treated samples when 
probed using anti-HA antibody. Chen et al. (2009) reported that interaction of 
Nrf2-p21 was enhanced in presence of inducers that led to augmentation of the 
Nrf2-dependent phase 2 activation. However, in this experimental setup, 
intensity of the band corresponding to Nrf2-HA in the BCA-treated IP sample 
was similar to that of the untreated control, indicating that BCA treatment did 
































Figure 5.7 Effect of BCA on interaction between p21 and Nrf2-HA in HCT 116 cells. 
HCT 116 WT cells transiently transfected with Nrf2-HA plasmid were left untreated 
or treated with 20 μM BCA for 6 h. The cell lysates were subjected to 
immunoprecipitation reaction using anti-p21 antibody, followed by immunoblotting 
with anti-HA and anti-p21 antibodies. The cell lysates used for immunoprecipiation 
were also analyzed by western blotting for protein levels of Nrf2-HA, p21 and β-
actin.     
 
5.3 Discussion 
Under basal conditions, Nrf2 is continually directed for degradation 
through the ubiquitin-proteasomal pathway by its negative regulator Keap1. 
The cysteine-rich Keap1 acts as a sensor of cellular redox conditions, and 
maintains homeostasis in times of oxidative or electrophilic stress by reducing 
its repressor activity such that Nrf2 can translocate to the nucleus and activate 
expression of the ARE-dependent cytoprotective genes (Prestera et al., 1995). 
Activity of the transcription factor Nrf2 is central to expression of the phase 2 
detoxifying enzymes, and contribution of Nrf2-dependent cytoprotective 
response in evading cancer is underscored by the fact that Nrf2-deficient mice 
display increased susceptibility to tumorigenesis (Ramos-Gomez et al., 2001). 
Sulfhydryl groups in Keap1 cysteines such as Cys151, Cys273 and Cys288 are 




levels for induction of the cytoprotective response (Dinkova-Kostova et al., 
2002). Owing to the nucleophilic nature of the Keap1 cysteines, Nrf2 
induction by electrophilic compounds belonging to chemically diverse classes 
such as compounds bearing Michael acceptor moieties has been considered as 
a potential preventive strategy for cancer (Magesh et al., 2012).       
Cancer preventive potential of the CA analogs was investigated by 
testing their ability to activate Nrf2-mediated induction of the phase 2 
enzymes. Among the analogs studied, BCA exhibited greatest stimulation of 
the ARE-dependent transcriptional activity. Enhanced protection against 
chemically-induced genotoxicity was observed as a cellular outcome of the 
phase 2 response activation. In addition to Nrf2 induction, BCA was also 
found to suppress LPS-mediated inflammatory response via inhibition of the 
NF-κB signal transduction pathway. Due to its role in inflammatory and cell 
survival mechanisms, the NF-κB signaling pathway is known to act as a 
mediator of tumor promotion. Activation of the cytoprotective Nrf2 signaling 
and inhibition of the pro-carcinogenic NF-κB pathway by BCA may therefore 
offer advanced protection and decrease susceptibility of cells against 
carcinogenic transformation. 
p21 is a small 164 amino-acid protein that regulates multiple cellular 
processes. It was initially found to act as a p53-dependent cell cycle regulator 
through inhibiton of cdks (el-Deiry et al., 1993; Gu et al., 1993; Harper et al., 
1993; Xiong et al., 1993). More recently, cellular roles of p21 other than 
imposition of cell cycle arrest have been identified. These include promotion 
of cell differentiation and proliferation, DNA replication and repair, apoptosis 




1994). Moreover, p21 is upregulated through p53-dependent and -independent 
mechanisms in response to oxidative stress to promote cell survival (Esposito 
et al., 1998; Russo et al., 1995). The findings that p21-null mice display 
increased sensitivity to hyperoxic (O’Reilly et al., 2001) and inflammatory 
stimuli (Lloberas & Celada, 2009), as well as being more vulnerable to 
spontaneous (Martin-Caballero et al., 2001) and chemically-induced 
carcinogenesis (Gartel & Tyner, 2002), have highlighted the protective roles 
of p21 against oxidative and electrophilic stress.  
According to the hinge and latch model of Nrf2-Keap1 binding, two 
molecules of Keap1 bind to a single Nrf2 molecule at the DLG and ETGE 
motifs contained in the Neh2 domain of Nrf2. The DLG site or the ‘latch’ 
binds to Keap1 with a lower affinity than the ETGE motif or ‘hinge’. A study 
had previously reported that antioxidant properties of p21 were mediated via 
direct binding to the DLG motif of Nrf2 (Chen et al., 2009). It was also 
reported that upon treatment with Nrf2 inducers such as tBHQ, p21 competed 
with Keap1 for binding to Nrf2 at the DLG site, however, interaction of Nrf2 
and Keap1 at the stronger affinity ETGE motif remained unaffected even in 
presence of inducers (Chen et al., 2009). To further investigate the 
mechanisms of activation of phase 2 response by BCA, we examined whether 
p21 had a role in BCA-induced cytoprotective response. The experiments 
conducted in this Chapter that involved p21-knockout cells revealed that 
BCA-mediated Nrf2 and phase 2 enzyme activation was suppressed in the 
absence of p21. In addition, in p21-null cells, the ability of BCA to confer 
cellular protection against genotoxicity was diminished. However, contrary to 




not altered upon BCA treatment. Therefore, although experimental evidence 
indicated that p21 potentiated the phase 2 enzyme response coordinated by 
Nrf2, it would be likely that this augmentation in the presence of BCA was 
mediated through alternative mechanisms instead of enhancement in Nrf2-p21 
interaction. In light of the recent finding that p53 regulates Nrf2 via p21 (Chen 
et al., 2012); further studies investigating mechanisms of p21-mediated 
amplification of Nrf2-activation as well as the role of p53 in Nrf2-dependent 
enzyme activation by BCA are warranted.  
Studies have reported that although the Nrf2-Keap1 interaction is 
severed at the DLG binding-site, Keap1 binding at the ETGE motif of Nrf2 is 
retained even upon treatment with Nrf2 inducers. However, due to dissociation 
at the DLG motif, Keap1 is unable to target Nrf2 for degradation, which 
results in saturation of Keap1 binding sites. As Keap1 sites are already 
occupied with Nrf2, de novo synthesized Nrf2 molecules are free to 
translocate to the nucleus and activate ARE-dependent transcription of the 
phase 2 genes (Li & Kong, 2009). We surmised that Nrf2-Keap1 binding 
would remain unaltered upon BCA treatment and therefore co-
immunoprecipiation experiments to test changes in Nrf2-Keap1 interaction 
were not performed.  
In summary, the cancer-preventive properties of BCA were 
investigated in this Chapter. BCA effectively induced expression of 
antioxidant and detoxifying enzymes through stabilization of Nrf2; the 
response offered cytoprotection against genotoxic damage induced by 
doxorubicin. It was also observed that the Nrf2-mediated cytoprotective 




protein p21 as compared to cells devoid of p21. A summary of these findings 













Figure 5.8 Graphic summary of the effect of BCA on Nrf2 stabilization and phase 2 
enzyme activation. Treatment with BCA led to stabilization of Nrf2 and upregulation 
of phase 2 enzymes, which was found to be amplified in the presence of p21. 












CHAPTER 6  
 
Evaluation of the cinnamoyl-based 






Pioneering studies by Talalay and co-workers established that the 
Michael acceptor motif is a common structural feature linking chemically 
diverse compounds possessing chemopreventive properties (Talalay et al., 
1995). A few examples include triterpenoids, curcuminoids, chalcones and 
shogaols (Surh et al, 2008). Based on the studies as described in Chapter 5, 
CA and its ortho-substituted lead analogs were also found to induce the phase 
2 antioxidant response through Nrf2.  
The rationale to study supercinnamaldehyde analogs was based on a 
study reporting activation of transient receptor potential channel subtype A1 
(TRPA1) receptor, a member of the TRP family of ion channels expressed in 
nociceptive neurons. It has been reported that TRPA1 can be activated by 
covalent binding of electrophiles to reactive cysteines in the ion channel 
(Macpherson et al., 2007). Interestingly, we observed that several of the 
electrophilic compounds found to activate TRPA1 in the study had also been 
reported to be inducers of Nrf2 in literature. In addition, the study established 
that supercinnamaldehyde was more potent than CA in activating TRPA1. 
Based on these findings, and given that Michael acceptors are potential Nrf2 
inducers, we hypothesized that the supercinnamaldehyde scaffold was a likely 
candidate to exert chemopreventive effects. 
 Studies presented in this Chapter were focused on evaluation of the 
potential chemopreventive potencies of a series of novel compounds 
‘supercinnamaldehydes’ by assessing their potencies for phase 2 enzyme 




investigated in this Chapter were designed and synthesized in the laboratory of 
Dr. Geoffrey Wells (Department of Pharmaceutical and Biological Chemistry, 
University College London School of Pharmacy, London, UK). 
6.2 Results 
6.2.1 Supercinnamaldehyde analogs induce transcriptional activity of 
ARE and suppress NO production 
The parent supercinnamaldehyde compound (HLO4) contains an 
indolin-2-one scaffold conjugated to an oxopropylidene group at position 3 
and a methyl substitution at N-1 position (Fig. 6.1). Novel 
supercinnamaldehyde analogs (chemical structures shown in Fig. 6.2) bearing 







Figure 6.1 Structure of supercinnamaldehyde. The parent supercinnamaldehyde 
HLO4 structure comprises an indolin-2-one ring conjugated to a 3-oxopropylidene 





























In order to investigate the chemopreventive potential of 
supercinnamaldehyde analogs, the ARE-dependent luciferase gene reporter 
assay testing the ability to induce phase 2 enzymes and the NO release assay 
assessing the ability to inhibit inflammatory responses were conducted. To 
select non-toxic concentrations of the compounds to be employed in the 
former assay, cell viabilities of HEK-293 cells upon treatment with 
supercinnamaldehyde analogs over a range of concentrations 5 to 30 μM were 
assessed. It was observed that for concentrations up to 20 μM, more than 80% 
viability was maintained for most compounds whereas a concentration of 30 
μM displayed mild toxicities (Appendix 1). Concentrations of up to 20 μM 
were therefore employed for the ARE-dependent luciferase reporter gene 
assay. Similar concentrations of the analogs were found to exert minimal 
cytotoxicities on RAW 264.7 cells (data not shown) and were hence used for 
the NO release assay. 
For the ARE-dependent luciferase gene reporter assay, fold inductions 
in ARE-dependent luciferase activity for the series of supercinnamaldehyde 
analogs versus DMSO control were calculated and presented in Fig. 6.3. The 
analog HLO6 showed the greatest induction of almost nine-fold, closely 
followed by the compounds HT65 and HT59 that displayed inductions of 
about seven- and six-fold respectively at concentrations of 20 µM. The parent 
compound HLO4 was found to increase ARE transcriptional activity by 
almost four-fold. Activities of the supercinnamaldehydes were also compared 
against the naturally occurring CA, which displayed a five-fold induction in 




activity by HLO6 was similar to that of BCA, which also displayed an 
induction of about nine-fold (results shown in Chapter 5).   
Supercinnamaldehydes effectively inhibited LPS-induced secretion of 
NO as shown in Fig. 6.4. The percentage of nitrite levels measured in cells 
pre-treated with 20 µM HLO6 over that produced in LPS-only treated cells 
were similar to that obtained for DMSO (LPS-untreated) control (p > 0.05 
versus DMSO). Nitrite levels in the samples treated with HT65 (20 µM) and 
HT59 (20 µM) were also found to be reduced to less than 10% of the LPS-
only treated cells. It was also noted that HLO4 and the more potent analogs 
HLO6, HT59 and HT65 exhibited stronger ARE-activating and NO-inhibiting 
properties as compared to CA, whereas NO-inhibitory properties of BCA 































































































































































































































































































































































































































































































































































































































































































































































6.2.2 Investigation of the possible correlation between the cytoprotective 
and anti-inflammatory potencies and of supercinnamaldehyde analogs 
The order of potencies of ARE-inducing and NO-inhibiting abilities of 
the studied supercinnamaldehyde analogs appeared to be matching, which 
warranted further investigation. For further analysis of the relationship 
between the activities, the concentration required to double ARE-dependent 
luciferase activity (CD) and the concentration required for 50% inhibition 
(IC50) of NO release were calculated. The CD and IC50 values for each 
compound were presented in Table 6.1. Statistical evaluation of the CD and 
IC50 values was performed and it was revealed that the two bioactivities were 
correlated. A linear correlation coefficient of 0.85 was obtained, indicative of 
an association between the phase 2 inducing and anti-inflammatory activities 
of the supercinnamaldehyde analogs (Fig. 6.5).  
Structure activity correlations for the analogs were established based 
on their CD and IC50 values (Table 6.1). A phenyl substitution at the 2’ 
position of the oxopropylidene group in the parent analog HLO4 yielded 
HLO6, which showed the greatest enhancement in activity among all analogs 
studied (CD 2.98 µM, IC50 5.01 µM). It was also observed that alkyl 
substitutions on the 2’-phenyl group generally elicited higher activities than 
the parent supercinnamaldehyde HLO4. Substitution of a methyl group at the 
ortho, meta or para positions of the 2’-phenyl group yielded HT64, HB310 
and HB309 respectively. In comparison to HLO4 (CD 10.95 µM, IC50 14.09 
µM), HB309 and HB310 displayed slight enhancement in activity (HB309: 




their potencies were weaker than that of HLO6. In contrast, cross comparison 
of the CD and IC50 values showed that a methyl group at the ortho position 
was detrimental for activity; HT64 was ineffective in inducing a two-fold 
ARE induction up to a upper limit concentration of 20 μM, while the IC50 
value for inhibiting NO release was increased by more than two times as 
compared to HLO4.  
Substitution of bulky alkyl groups at the para position of the 2’-phenyl 
group led to an enhancement in ARE-inducing and NO-inhibiting activities.  
HB311 bearing a para-ethyl substituent displayed greater activity (CD 7.00 
µM, IC50 7.99 µM) than HLO4, whereas a HT59 and HT65 respectively 
bearing para-isopropyl and para-n-butyl groups possessed activities 
comparable to HLO6 (HT59: CD 5.14 µM, IC50 5.97 µM; HT65: CD 3.28 
µM, IC50 5.92 µM). Notably, methoxy and methylthiol substitution at the meta 
and para position on the 2’-phenyl group yielded HB307 and HB313 
respectively, which did not result in any significant improvement and the 
activities were similar to HLO4.  
It was further observed that while a phenyl- or alkylphenyl-substitution 
at the 2’ position augmented the activity of the supercinnamaldehyde scaffold, 
substitution of electron-withdrawing groups on the 2’-phenyl group generally 
failed to potentiate activities of the analogs. Conjugation of para-chlorophenyl 
group at the 2’ position in HT72 exhibited marginal enhancement in activity 
compared to HLO4, while HT52, HT56, and HT58 containing para-, meta-, or 
ortho-trifluoromethyl substitutions on the 2’-phenyl group, as well as those of 




substituted phenyl groups at the 2’ position were less potent inducers than the 
parent supercinnamaldehyde HLO4. A meta-nitrile-substituted 2’-phenyl also 
rendered analog HT70 inferior to HLO4 (Table 6.1).    
The compounds HT76 and HT81 have a Z conformation, and showed 
weaker activities compared to their respective E isomers, HT72 and HLO6. 
All other compounds studied had an E conformation.  
Compounds with alkyl or benzyl substituents at the N-1 position were 
also investigated. It was noted that increasing chain lengths in SP3 (ethyl), 
SP6 (n-propyl), SP13 (isopropyl) and SP16 (n-butyl) did not cause significant 
changes to the potencies. A benzyl-substitution in SP22 also did not lead to an 
improvement in its activities as compared to HLO4.   
Based on the ARE activity and NO release assays, analogs HLO6, 
HT59 and HT65 were found to display the greatest activities. To select the 
lead compound for evaluation of chemopreventive potential, it was thought 
that the compound exhibiting least cytotoxicity together with potent 
cytoprotective and anti-inflammatory activities would be a suitable candidate. 
As a result, after considering its effects on ARE activity, NO release and cell 












Table 6.1 CD (ARE-dependent luciferase activity) and IC50 (NO release) values for 
supercinnamaldehydes. Mean CD and IC50 values (± SD) were calculated from three 
independent experiments.  




 Mean IC50  for 
inhibition of LPS-
induced NO release 
(μM) 
HLO4  10.95 (± 1.12)  14.09 (± 1.70) 
HLO6  2.98 (± 0.57)  5.01 (± 0.70) 
HB307  15.00 (± 2.17)  9.23 (± 1.42) 
HB309  7.61 (± 0.51)  7.85 (± 0.49) 
HB310  8.22 (± 2.09)  7.17 (± 0.43) 
HB311  7.00 (± 1.27)  7.99 (± 0.59) 
HB313  15.05 (± 3.05)  8.78 (± 0.63) 
HT52  18.53 (± 2.02)  14.14 (± 1.78) 
HT56  20.00 (± 2.14)  16.91 (± 2.03) 
HT58  19.10 (± 2.24)  17.19 (± 1.27) 
HT59  5.14 (± 1.07)  5.97 (± 0.44) 
HT63  14.91 (± 1.35)  16.04 (± 2.54) 
HT64  -  17.86 (± 1.77) 
HT65  3.28 (± 0.95)  5.92 (± 1.86) 
HT70  -  19.85 (± 3.07) 
HT71  19.69 (± 2.13)  17.15 (± 2.45) 
HT72  8.89 (± 0.98)  9.94 (± 0.86) 
HT76  18.63 (± 3.10)  16.54 (± 1.50) 
HT81  10.75 (± 2.12)  13.56 (± 2.57) 
SP3  13.92 (± 1.19)  10.35 (± 0.56) 
SP6  14.14 (± 3.34)  13.78 (± 3.89) 
SP13  15.2 (± 1.07)  11.13 (± 1.16) 
SP16  10.63 (± 0.90)  8.32 (± 0.62) 
































































































































































































































6.2.3 Investigation of the possible involvement of Keap1 in induction of 
Nrf2-mediated expression of phase 2 enzymes by supercinnamaldehyde 
analogs 
 Following the observation that supercinnamaldehyde analogs induced 
ARE activity, effects of the parent supercinnamaldehyde HLO4 and the lead 
compound HLO6 on Nrf2 levels were evaluated in HEK-293 cells and WT 
MEFs. As shown in Fig. 6.6a, for the two cell lines studied, a marked increase 
in Nrf2 levels was observed in samples treated with HLO6; the induction was 
generally comparable to that produced by known Nrf2 inducer tBHQ. On the 
other hand, HLO4 and CA produced a mild increase in Nrf2 levels that were 
lower than the levels induced by HLO6.  
 Expression of phase 2 enzymes such as HO-1, NQO1 and GSTA1 in 
WT MEFs following treatment with CA, HLO4 and HLO6 was next studied. 
Western blot analyses of the cell lysates depicted increased enzyme levels in 
cells treated with CA, HLO4 or HLO6. The positive control tBHQ also 
brought about upregulation of the phase 2 enzymes in WT MEFs (Fig. 6.6b).  
Electrophilic compounds including those bearing Michael acceptor 
moieties have been demonstrated to induce Nrf2 by targeting cysteine residues 
in Keap1. The possible involvement of Keap1 in the induction of phase 2 
family of proteins by supercinnamaldehyde compounds was therefore 
investigated. Keap1-/- MEFs were employed for this purpose and the cells 
were treated with test compounds HLO4 and HLO6 along with CA and tBHQ. 
It was noted that the compounds produced little induction in the levels of Nrf2 




in HO-1 levels was observed in Keap1-/- MEFs, which might be attributed to 
the presence of other promoter sequences regulating expression of this 
enzyme. Activation of HO-1 is majorly regulated by transcription factors such 
as AP-1 and NF-κB apart from Nrf2. The results presented indicate that 
induction of HO-1 is also mediated through other sequences, and thus use of 
HO-1 as a standalone biomarker might not have been appropriate to show 
induction of phase 2 enzymes through ARE. However, together with the ARE 
activation and increase in Nrf2 levels, it is likely that induction of HO-1 in the 
WT MEFs was at least partially mediated through Nrf2.Failure to induce the 
cytoprotective response in the knockout cells underscored the requirement of 






























Figure 6.6 Stabilization of Nrf2 and induction of phase 2 enzyme expression by 
supercinnamaldehydes. (a) HEK-293 cells or WT MEFs were treated with CA, HLO4 
or HLO6 for 3 h, and the cell lysates obtained were analyzed for levels of Nrf2 using 
western blot analyses. (b) WT MEFs treated with the test compounds for 16 h were 
lysed and the cell lysates were analyzed for levels of phase 2 enzymes such as HO-1, 
NQO1 and GSTA1 using western blot analysis (c) Keap1-/- MEFs were treated with 
CA, HLO4 or HLO6 for 3 h (for Nrf2) or 16 h (for phase 2 enzymes) followed by cell 
lysis. Lysates obtained were analyzed for levels of Nrf2 and phase 2 enzymes such as 





6.2.4 Suppression of the LPS-induced inflammatory response via 
inhibition of NF-κB pathway by supercinnamaldehyde analogs 
 Given that the supercinnamaldehydes effectively suppressed LPS-
induced NO production, expression of the inflammatory mediator iNOS was 
studied in RAW 264.7 cells. It was found that LPS treatment induced a 
marked elevation in the levels of iNOS, which was reduced in cells pre-treated 
with HLO4 or HLO6.  
 The effects of supercinnamaldehydes on the NF-κB signaling pathway, 
which participates in activation of the inflammatory response upon LPS 
treatment, were next investigated. Activation of NF-κB signaling in LPS-
treated cells was demonstrated by an enhanced phosphorylation of p65 and 
IKKα/β accompanied by a reduction in the levels of IκBα. The lead 
supercinnamaldehyde analog HLO6 effectively inhibited activation of the NF-
κB pathway and a dose-dependent decrease in the levels of phosphorylated 
p65 and IKKα/β was observed with no changes in total p65, IKKα, and IKKβ 
levels (Fig. 6.7). Degradation of IκBα was also inhibited, and its levels at 20 
µM HLO6 were similar to levels present in LPS-untreated cells. CA and 
HLO4 also inhibited activation of the NF-κB signaling, although the inhibitory 



















Figure 6.7 (a) Supression of LPS-induced expression of iNOS and (b) inhibition of 
NF-κB activation by supercinnamaldehydes. RAW 264.7 cells treated with CA, 
HLO4 or HLO6 for 1 h were stimulated with LPS. Cell lysates were collected at 30 
min post-LPS stimulation to study NF-κB signaling, or at 20 h for the levels of the 
downstream inflammatory mediator iNOS. Cell lysates were analyzed by western 
blotting using antibodies against iNOS and NF-κB signaling proteins such as p65, 
phospho-p65, IκBα, IKKα, IKKβ, and phospho-IKKα/β. 
 
 Having found that the supercinnamaldehyde analogs inhibited 
activation of the NF-κB pathway, their suppressive effects on the 
inflammatory activation of human monocytes were investigated. Isolated 
human monocytes (CD14-positive) were treated with HLO4 or HLO6 for 1h 
followed by stimulation with LPS for 20 h. Media of cells was collected and 
analyzed for levels of cytokines using ELISA. The cytokines tested included 
IL-1β, IL-6 and TNFα. It was found that LPS-treated monocytes exhibited a 
marked increase in cytokine secretion (Fig. 6.8). Dose-dependent reduction in 























Figure 6.8 Suppression of cytokine secretion in LPS-stimulated human monocytes by 
supercinnamaldehydes. Isolated human monocytes were treated with HLO4 or HLO6 
for 1 h prior to LPS challenge (100 ng/ml, 20 h). Media of the cells was analyzed for 
pro-inflammatory cytokines such as TNFα, IL-1β and IL-6 using ELISA (data points 
are means of 2 independent experiments, SD presented as error bars. * p < 0.05 





 The 3-substituted indolin-2-one compounds have been extensively 
studied for their chemotherapeutic effects and the arylideneindolin-2-one 
compound sunitinib, which acts as a tyrosine kinase inhibitor and prevents 
angiogenesis, is prescribed for treatment of renal cell carcinoma and 
gastrointestinal stromal tumor (Demetri et al., 2006; Motzer et al., 2006). In 
spite of the presence of a Michael acceptor group in the 3-arylideneindolin-2-
ones, few studies have attempted to investigate the chemopreventive 
properties of such compounds. This chapter involved investigation of the 
possible chemopreventive properties of a series of supercinnamaldehydes that 
are essentially 3-substituted indolin-2-ones.  
 Supercinnamaldehydes were found to induce the Nrf2-mediated phase 
2 enzyme expression and suppress inflammatory responses. For the latter 
effect, suppression was at least partly through inhibition of the NF-κB 
signaling pathway. Phytochemicals such as sulforaphane, curcumin, 
chalcones, triterpenoids and epigallocatechin-3-gallate have been previously 
reported to exert dual properties of Nrf2 induction and NF-κB inhibition. The 
Nrf2 and NF-κB pathways have been found to interlace at several levels; 
Keap1 targets IKKβ for degradation whereas NF-κB has been found to inhibit 
Nrf2 transcriptional activity (Lee et al., 2009; Liu et al., 2008). It has also been 
reported that downstream targets of NF-κB and Nrf2 modulate activities of the 
two pathways (Wakabayashi et al., 2010). Observed correlation between the 
two activities elicited by supercinnamaldehydes was therefore possibly due to 




The compound HLO6, with a phenyl substitution at the 2’-position 
exhibited greatest activity among the series. Generally, electron-donating 
groups on the phenyl ring at 2’-position elicited stronger activities than those 
observed for compounds containing electron-withdrawing groups. Increasing 
chain lengths of the alkyl group or a benzyl group at the N-1 position did not 
produce significant enhancement in activity as compared to the parent 
supercinnamaldehyde analog HLO4. It was also noted that the lead compound 
HLO6 displayed marked superiority to the naturally occurring CA, whereas 
the activity of HLO6 was comparable to BCA.     
Cysteine residues in Keap1 are susceptible to attack by electrophilic 
compounds such as Michael acceptors and it was thus surmised that 
supercinnamaldehydes may elicit their effects through Keap1. It was found 
that the phase 2 enzyme response was mitigated in the absence of Keap1, 
suggesting that this group of compounds may exert their cytoprotective 
activities at least in part through Keap1. Additional studies involving site-
directed mutagenesis experiments and mass spectrometric analysis are 
required to verify whether supercinnamaldehydes directly bind to Keap1 and 
to shed light on the amino acid residues in Keap1 that might be involved in 
this binding.  
Overproduction of cytokines such as TNFα, IL-1 and IL-6 by immune 
cells in inflamed or precancerous tissues has been implicated in the 
development of neoplasms (Miki et al., 2007). These cytokines operate by 
encouraging proliferation of the transformed cells, supporting angiogenesis, as 




secretion of TNFα, IL-1β and IL-6 was studied in LPS-stimulated human 
monocytes and it was found that HLO4 and HLO6 inhibited release of these 
cytokines.  
To summarize, as illustrated in Fig. 6.9, the supercinnamaldehyde 
group of compounds that carry a 3-oxoarylidene indoline-2-onyl-based 
structure not only enhanced Nrf2-regulated phase 2 enzyme expression, but 
also repressed LPS-mediated inflammatory responses. Induction of the phase 2 
cytoprotective response by the parent supercinnamaldehyde HLO4 and the 
lead analog HLO6 was abrogated in the absence of Keap1. HLO4 and HLO6 
also suppressed cytokine secretion by human monocytes, further highlighting 
their chemopreventive potential. Thus, based on the findings obtained, it was 
evident that the supercinnamaldehyde scaffold is a promising candidate to be 
developed further by structural modifications to yield more potent 





















Figure 6.9 Graphic representation of the cellular effects of supercinnamaldehydes that 
may protect against carcinogenesis. The compounds suppressed activation of the NF-
κB pathway thereby decreasing production of the pro-inflammatory mediators and 
induced Nrf2-mediated phase 2 enzyme expression. Together these effects might 







CHAPTER 7  
 




7.1 General discussion 
7.1.1 Antitumor properties of cinnamaldehydes 
 The aims of this project were to evaluate the anticancer and 
chemopreventive properties of cinnamoyl-based compounds and investigation 
of the molecular mechanisms and cellular events associated with these 
properties. Anticancer activities of cinnamaldehydes were first investigated 
and it was found that among the ortho-substituted CA analogs studied, PP1 
and GJ23 were found to be the most potent against HCT 116 and MCF-7 cells, 
closely followed by BCA. Investigation of the cellular events upon treatment 
with these compounds was suggestive of their multi-targeting nature. 
Treatment with pro-apoptotic doses of these compounds caused depletion of 
the cell cycle regulatory proteins cdk1 and cdc25C and induced tubulin 
aggregation. These effects contributed at least in part to the G2 phase arrest 
that led to apoptosis. In addition, mechanisms such as inhibition of thioredoxin 
reductase, AP-1 and proteasome have been previously proposed to evoke cell 
death in tumor cells (Chew et al., 2010; Hong et al., 2007; C. W. Lee et al., 
2007). The electrophilic nature of the Michael acceptor group has made it 
likely that the Michael acceptor-containing compounds possess the propensity 
to interact with nucleophilic components of biological macromolecules such 
as cysteine residues in multiple cellular proteins. This promiscuity makes it 
challenging to identify the precise target protein(s) to which the compounds 
bind first, and to determine the important targets that may contribute to their 
pro-apoptotic effects. However, the multi-targeting nature of these compounds 
may be beneficial in cancer. Carcinogenesis is a mutli-step process that 




typically harbor multiple mutations that evolve with time (Ruddon, 2007). 
Drugs blocking a specific target or signaling pathway are vulnerable to 
development of resistance due to further changes in the cancer genome and 
development of drug-resistance mutations. Promiscuous drugs hence may 
have an advantage over single-target drugs, and might be more efficient in 
suppressing growth of tumors.  
It would be of further interest to study the pharmacological and 
pharmacokinetic properties of the lead analogs PP1 and GJ23 in vivo to 
evaluate their potential as therapeutic agents. As concentrations required for 
their antiproliferative effects in vitro were in the micromolar range, there is a 
possibility that such high concentrations may limit their advancement in the 
drug discovery pipeline. However, structural derivatization of these 
compounds can be performed to yield analogs with higher potencies that may 
be developed as future cancer therapeutics.  
7.1.2 Chemopreventive potential of cinnamaldehydes and 
supercinnamaldehyes 
The CA analog BCA and the supercinnamaldehyde analog HLO6 
stabilized Nrf2 and increased the ARE-dependent expression of the 
downstream phase 2 enzymes. These compounds also suppressed LPS-
mediated induction of inflammatory responses in cells of the immune system 
through inhibition of NF-κB signaling.  
Tumorigenesis starts as single mutation in a cell, which undergoes 
abnormal proliferation and acquires more mutations as it advances to a 




suppress doxorubicin-inflicted DNA damage in non-cancerous HEK-293 cells, 
indicating its potential protective effect against carcinogen-induced 
genotoxicity in normal cells. In vivo validation of the cancer preventive 
potential of BCA is provided by a study employing an H-ras12V mutant 
mouse model. This mutation renders the mice more susceptible for 
development of hepatocellular carcinoma. It has been reported that the mutant 
mice receiving BCA treatment display protection against development of 
cancer (Lee et al., 2009). As reported in the work by Lee et. al. (2009), 
although the mechanism for protection was unclear, chemoprevention offered 
by BCA was evident from the reduction in number and volume of tumors.  
Investigation of the supercinnamaldehydes in this Ph.D. study 
established the potential chemopreventive effects of 3-oxoethylidene-indolin-
2-ones. Structural features that augmented or attenuated the activity of these 
compounds were also identified. It was observed that generally, substitution of 
non-polar, electron-donating groups on the phenyl ring at 2’-position of the 3-
oxoethylidene group augmented the activity. In contrast, compounds 
containing electron-withdrawing groups on the 2’-phenyl group displayed 
weaker activities. Indolinones have been predominantly studied for their 
antiproliferative effects mediated through inhibition of tyrosine kinases and 
few studies have reported their chemopreventive activities (Prakash & Raja, 
2012). The biorelevant Michael acceptor-bearing supercinnamaldehydes are 
thus an addition to the list of electrophilic compounds exhibiting phase 2 
enzyme induction through stabilization of Nrf2. 
Similar to cinnamaldehydes, the supercinnamaldehyde analogs were 




at higher concentrations (personal communication with Ms. Kamila Kaminska, 
Department of Pharmacy, National University of Singapore). We postulated 
that the observation of a protective response at low concentrations and a lethal 
effect at higher doses of cinnamaldehydes and supercinnamaldehydes was 
attributable to the differential affinities of cellular targets towards these 
compounds. At lower concentrations, these compounds perhaps interacted 
with the more reactive sulfhydryl groups such as those contained in Keap1 that 
resulted in induced expression of the phase 2 enzymes. At higher 
concentrations, the compounds were possibly able to interact with multiple 
protein targets such as tubulin that led to growth-inhibition and induction of 
apoptosis. However, further studies need to be conducted to verify this 
postulation. Due to the dissimilar effects elicited at different concentrations, in 
vivo application of these compounds will require careful dose-optimization 
such that the compounds selectively exhibit desired effects.       
7.2 Conclusion 
The findings of this Ph.D. study have improved the understanding of 
the antitumor and chemopreventive properties of cinnamoyl-based compounds 
including analogs of the natural compound CA, and derivatives of 3-
oxopropylidene-2-indolinones (supercinnamaldehydes). Appropriate chemical 
derivatization of the parent analogs gave rise to novel analogs with superior 
activities, thus highlighting that these compounds can be further tailored to 






7.3 Future work 
7.3.1 Determination of cysteine residues of Keap1 susceptible to attack by 
BCA and HLO6 
 It has been found that distinct classes of electrophiles interact with 
unique cysteine residue(s) in Keap1 protein that leads to induction of the Nrf2-
mediated phase 2 response. Although studies in Chapter 6 established that 
Keap1 was essential for induction of the phase 2 enzymes, identification of the 
precise cysteine residues that interact with HLO6 needs to be pursued. Mass 
spectrometric analysis can be carried out to determine cysteine residues 
involved in interaction with BCA and HLO6.  
Mass spectrometric analysis of tubulin had been attempted previously 
to determine the cysteine residues targeted by the cinnamaldehyde 
compounds. Initially, mass spectrometric analysis was performed using 
electrospray ionisation (ESI). However, as the protein tubulin has the property 
of forming polymers or aggregates, the molecular weight of the injected 
tubulin samples was beyond the working range of the mass spectrometer. 
Mass spectrometry was again attempted with MALDI-TOF. Unfortunately, 
there was significant interference with the matrix and results obtained 
remained inconclusive (discussed in Chapter 5). For the suggested Keap1 
mass spectrometric analysis, enzymatic digestion of the protein can be 
performed followed by liquid chromatographic (LC) separation of the digested 
peptides. The separated peptides can be subjected to N-terminal sequencing to 




peptides can be subjected to tandem mass spectrometry (MS/MS) and binding 
can be determined by de novo sequencing.     
7.3.2 Elucidation of the protein targets of supercinnamaldehydes 
 Due to their electrophilic nature, supercinnamaldehyde compounds 
have the propensity to interact with cellular proteins. A derivative of HLO4 
containing a biotin tag has been synthesized in Dr. Geoffrey Wells’ laboratory 
(Department of Pharmaceutical and Biological Chemistry, University College 
London School of Pharmacy, London, UK). An in vitro pull-down experiment 
can be performed using the biotinylated HLO4 and identity of the proteins 
pulled-down can be determined by subjecting the eluates to SDS-PAGE 
followed by mass spectrometric analysis.    
7.3.3 Investigation of phase I enzyme induction by supercinnamaldehydes 
Certain naturally occurring indole compounds are known inducers of 
phase I metabolic enzymes through activation of the arylhydrocarbon 
receptor-xenobiotic response element (Ahr-XRE) pathway.  Compounds 
activating both the Nrf2-ARE and the Ahr-XRE pathways are bifunctional 
inducers whereas monofunctional inducers selectively activate expression of 
the cytoprotective enzymes through the Nrf2-ARE system. For 
chemopreventive applications, monofunctional inducers activating solely the 
cytoprotective response through Nrf2-ARE are desirable than compounds 
showing bifunctional induction. It would therefore be of merit to determine 
whether the supercinnamaldehyde compounds act as mixed inducers or 
monofunctional inducers. To determine their possible involvement in 




with supercinnamaldehydes can be studied using XRE-dependent luciferase 
reporter gene assays and subsequent cell-based assays.  
7.3.4 Pharmacokinetic studies of lead analogs 
 Pharmacokinetic profiles of the cinnamoyl-based compounds such as 
BCA, PP1, GJ23 and HLO6 can be investigated in animal models. 
Determination of the pharmacokinetic parameters will aid in determining the 
doses for subsequent efficacy studies in vivo. 
7.3.5 In vivo evaluation of antitumor efficacy of PP1 and GJ23 in colon 
tumor xenografts 
 The compounds PP1 and GJ23 displayed the greatest anticancer 
activities among the series of CA analogs studied. PP1 and GJ23 induced 
apoptotic cell death in cancer cell lines, and also suppressed growth of cancer 
cells in anchorage-independent cultures. Hence, with regards to their cell-
based activities, PP1 and GJ23 deserve evaluation in tumor xenograft models. 
The in vitro cell-based studies for the CA analogs showed that the colon 
carcinoma cell line HCT 116 was more susceptible to the compounds and thus 
colon cancer can be chosen as a model system. Following dose-optimization, 
effect of these compounds on the growth of established tumors in nude mice 
can be determined.    
7.3.6 In vivo evaluation of the chemopreventive potential of BCA and 
HLO6 
BCA and HLO6 were found to exhibit cytoprotective and anti-




chemopreventive effects of these compounds can be evaluated in vivo by 
employing animal models such as Apc
Min/+
 mice. Prior to in vivo evaluation, 
dose-escalation studies can be performed and doses can be selected such that 
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Figure 1. Effect of supercinnamaldehyde analogs on viability of HEK-293 cells. 
HEK-293 cells were cultured in 96-well plates and treated with 5, 10, 20 and 30 μM 
of supercinnamaldehyde analogs for 24 h and cell viabilities were evaluated using 
MTT assay.  
